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 ABSTRACT
Haloperidol is a typical antipsychotic drug (APD) associated with an increased risk of extrapyramidal 
side-effects (EPS) and hyperprolactinemia relative to atypical APDs such as clozapine.  Both drugs 
are dopamine D2 receptor (D2R) antagonists, with contrasting kinetic profiles. Haloperidol displays 
fast association/slow dissociation at the D2R whereas clozapine exhibits relatively slow 
association/fast dissociation. Recently, we have provided evidence that slow dissociation from the 
D2R predicts hyperprolactinemia, whereas fast association predicts EPS. Unfortunately, clozapine 
can cause severe side-effects independent of its D2R action. Our results suggest an optimal kinetic 
profile for D2R antagonist APDs that avoids EPS. To begin exploring this hypothesis, we conducted 
a structure-kinetic relationship study of haloperidol and reveal that subtle structural modifications 
dramatically change binding kinetic rate constants, affording compounds with a clozapine-like kinetic 
profile. Thus, optimisation of these kinetic parameters may allow development of novel APDs based 
on the haloperidol scaffold with improved side-effect profiles.
 INTRODUCTION
Haloperidol (1, Figure 1) is an effective, typical antipsychotic drug (APD) used in the treatment of 
schizophrenia (SCZ). As for all current APDs, its mechanism of action is primarily through 
antagonism of dopamine (DA) D2 receptors (D2R) in the mesolimbic pathway, where excessive DA 
activity is thought to underlie the positive symptoms of schizophrenia.1-3 Unfortunately, 1 along with 
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2
other typical APDs, are associated with severe on-target side effects including EPS (e.g., Parkinsonian 
symptoms such as bradykinesia and tremor) and hyperprolactinemia.3,4 These symptoms are mediated 
by blockade of D2R signalling in the nigrostriatal and tuberoinfundibular DA pathways, 
respectively.2-7 Tardive dyskinesia is also associated with long-term exposure to typical APDs such 
as 1.8 
Atypical APDs display a diminished incidence of EPS and hyperprolactinemia relative to typical 
APSs.9-11 While the primary distinction between typicality and atypicality is based on such clinical 
observations, the mechanism(s) that might drive this distinction remain unclear. Clozapine (2, Figure 
1) is a prototypical atypical antipsychotic. It has a complex pharmacological profile with high affinity 
for other members of the biogenic amine receptor family and, in particular, a relatively high affinity 
for the serotonin 2A receptor (5-HT2AR).12 Many atypical APDs have similar pharmacology leading 
to the hypothesis that a relatively high affinity for the 5HT2AR as compared to the D2R confers 
atypicality.13-16 However, not all atypical APDs share this profile suggesting that this theory cannot 
account for all examples of atypicality.13,17 Unfortunately, this lack of selectivity across aminergic 
receptors is associated with off-target side-effects, including sedation, metabolic disorders, weight 
gain, urinary incontinence and constipation.18 2 can also cause acute agranulocytosis, a potentially 
life-threatening white blood cell disorder. 
O
N
OH
F
Haloperidol (1)
Cl
Cl
N
H
N
N
N
Clozapine (2)
Figure 1. Typical APD haloperidol (1) and atypical APD clozapine (2).
The relatively fast rate at which 2, and other related APDs, dissociate from the D2R has also been 
suggested to be the basis for an atypical profile.17 Rapid dissociation of an antagonist might allow a 
fraction of D2Rs to be occupied by transiently high concentrations of DA released into the synapse 
whereas  an antagonist with a slow dissociation rate would cause insurmountable antagonism. Central 
to this hypothesis was the consensus that APDs exhibit similar association rates (kon) for the D2R 
meaning that affinity is largely mediated by differences in dissociation rate (koff).19 Olanzapine, 
however, which has a similar high affinity for the D2R as many typical antipsychotics, displays an 
atypical profile.4
The incorporation of drug-receptor kinetic binding parameters into drug discovery programs is seen 
as increasingly important for the development of next generation therapeutics.20-28 Previous efforts to 
derive estimates of APD kinetic rate constants have used radiometric detection methods with limited 
Page 2 of 78
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
3
assay throughput.19,29,30 We have recently developed a competition association assay using TR-FRET 
to determine ligand kinetic parameters of unlabelled D2R agonists,31,32 and profiled an extensive 
series of APDs in order to explore the kinetic basis for on-target side effects.33 We found that the 
association rates of the APDs varied over three orders of magnitude and that association rates, rather 
than dissociation rates, correlated with EPS. These observations led us to propose a revised kinetic 
hypothesis whereby rapid association rate leads to drug rebinding at the D2R, maintaining a higher 
concentration of APD in the synaptic compartment. This causes increased competition with DA 
leading to EPS. In contrast, hyperprolactinaemia was correlated with APD dissociation rate.33 
Optimising D2R binding kinetics may permit the design of novel tools to test this kinetic hypothesis, 
as well as facilitate the generation of new APDs with an improved therapeutic profile. 
Although clozapine (2) appears to possess the desired slow on/fast off kinetic profile for reduced on-
target side effects (kon = 8.23 ± 1.42 × 107 M-1 min-1, koff =   1.67 ± 0.25 min-1),33 it displays affinity 
for many aminergic GPCRs, contributing to its off-target side effects. Haloperidol (1), in contrast, 
has a better off-target selectivity profile, but an undesirable fast on/slow off kinetic profile at the D2R 
(kon = 1.29 ± 0.21 × 109 M-1 min-1, koff = 0.61 ± 0.04 min-1) that contributes to its on-target side effects.
The aim of the current study was to optimise the kinetic binding parameters of the more selective 
scaffold of haloperidol towards a slow on/fast off profile. To this end, we herein describe the design 
and synthesis of 50 analogues of 1, focusing on structural modification of four key moieties (figure 
2) and use competition association kinetic binding methodology to determine their association and 
dissociation rates, and equilibrium affinities at the D2R. We reveal that both the association and 
dissociation kinetics of this scaffold can vary considerably with subtle structural modification. 
Interestingly, we have identified previous analogues of 1, among others, that may have been 
overlooked on the basis of affinity-driven scaffold optimisation, that possess favourable kinetic 
profiles. These data reveal the structure-kinetic relationships (SKR) of 1, as well identify novel tool 
compounds with which to interrogate the relationship between APD kinetic binding parameters and 
on-target side-effect profiles. Although the structure-activity relationships (SAR) surrounding the 
butyrophenone scaffold of APDs have been extensively studied in previous years,34-39 to our 
knowledge, these data represent the first reported SKR relating to analogues of 1.
 RESULTS AND DISCUSSION
Chemistry. To begin our structure-kinetic study, we focused on modifying four distinct regions of 
1, namely the para-fluorophenyl (red box), ketone and alkyl linker (green box), piperidinol (orange 
box), and para-chlorophenyl (blue box) moieties, as depicted in figure 2. For completeness, we 
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4
included both established and novel analogues of 1 in our approach, covering 50 compounds in 
totality. 
Figure 2. Structural regions of haloperidol (1) investigated as part of the SKR study.
Variation of para-chlorophenyl moiety of 1. In evaluating the positional effects of halogen 
substitution on the p-chlorophenyl moiety, we initially synthesised analogues bearing the chloro-
substituent in the ortho (8n) and meta (8a) positions, as well as incorporation of all possible dichloro 
substitution patterns (2,3-diCl (8b); 2,4-diCl (8c); 2,5-diCl (8d); 2,6-diCl (8e); 3,4-diCl (8f);40 and 
3,5-diCl (8g)). In addition, we wanted to assess the effects of halogen removal through the proteo 
analogue (8h),41 as well as alternative para-substituents, including methyl (8i),41 trifluoromethyl (8j), 
N,N-dimethylamino (8k) and fluoro (8l).41 The synthesis of these compounds is summarised in 
scheme 1. Firstly, the appropriately substituted bromobenzene (3a-l) underwent lithiation using n-
BuLi, followed by treatment with commercially available tert-butyl 4-oxopiperidine-1-carboxylate 
(4) to afford the corresponding N-Boc-protected phenylpiperidinols (5a-l). HCl-mediated N-Boc-
deprotection afforded the corresponding hydrochloride salts or free amines following basic work-up 
(6a-l). Finally, nucleophilic displacement of key intermediate 4-chloro-1-(4-fluorophenyl)butan-1-
one (7a) with the appropriate substituted phenylpiperidinol (6a-l) was achieved by refluxing in 
toluene in the presence of KI and NaHCO3, to afford the desired final analogues (8a-l). 
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Scheme 1. Synthesis of haloperidol (1) analogues with modification to para-chlorophenyl 
moietya
Br
R1
N O
O
O
(i)
R1
N
HO
O
O
+
R1
NH
HO
(ii)
(iii)O
N
OH
F
R1
3a-l 4 5a-l
6a, 6c, 6e-f, 6h-l (free base)
6b, 6d, 6g (HCl salt)
8a-l
   a  R1 = 3-Cl
   b  R1 = 2,3-Cl
   c  R1 = 2,4-Cl
   d  R1 = 2,5-Cl
   e  R1 = 2,6-Cl
f R1 = 3,4-Cl
g  R1 = 3,5-Cl
h  R1 = H
i   R1 = 4-Me
j   R1 = 4-CF3
k  R1 = 4-N(CH3)2
l   R1 = 4-F
O
F 7a
Cl
8
aReagents and conditions: (i) n-BuLi, THF, -78 ºC, 3-8 h, 50-88% (5a-l); (ii) HCl (4 M), 1,4-dioxane, 
1-3 h, 75-98% (6a, 6c, 6e-f, 6h-l (free base) 6b, 6d, 6g (HCl salt)); (iii) NaHCO3, KI, toluene, reflux, 
24 h, 45-70% (8a-l).
Though established, the employed lithiation chemistry proved to be problematic towards the synthesis 
of the o-chloro analogue (8n, scheme 2). Standard conditions failed to deliver the desired N-Boc-
protected piperidinol intermediate from 3m, instead producing the biphenyl piperidinol (5m). Whilst 
unintended, this molecule would still provide additional information to our study and was N-Boc 
deprotected to give 6m, followed by N-alkylation with 7a using conditions outlined previously, to 
furnish biphenyl analogue (8m). In contrast, the desired o-chloro analogue was accessed in three steps 
using an alternative approach (scheme 2). Grignard addition of 3m to 4 yielded o-chlorophenyl 
piperidinol intermediate 5n, which underwent N-Boc deprotection to give 6n. Final N-alkylation with 
7a, furnished 8n.
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Scheme 2. Synthesis of biphenyl side-product and ortho-Cl analogues of 1a
Br
Cl
NO
O
O
+
(i) or (ii)
N
OH
R2
O
O
(iii)
(iv) O R2
N
OH
F
3m 4 5m, 5n 6m, 6n
8m, 8n
7a Cl
Cl
HN
OH
R2
R2 = R2 =
5m, 6m, 8m 5n, 6n, 8n
aReagents and conditions: (i) n-BuLi, THF, -78 ºC, 6 h, 55% (5m); (ii) Mg, I2(cat.), Et2O, 0 ºC – 
reflux, 3 h, 54% (5n); (iii) HCl, 1,4-dioxane, rt, 2 h, 72-96% (6m, 6n); (iii) NaHCO3, KI, toluene, 
reflux, 24 h, 62-76% (8m, 8n).
Variation of the p-fluorophenyl moiety of 1. To investigate positional effects of fluorine substitution 
on the butyrophenone phenyl ring on the kinetics of 1, we generated analogues with all possible mono 
and di-fluoro substituents (2-F (14a);42 3-F (14b);42 2,3-diF (14c); 2,4-diF (14d); 2,5-diF (14e); 2,6-
diF (14f); 3,4-diF (14g);42 3,5-diF (14h), as well as two ortho-substituted analogues (2-Cl (14i) and 
2-Me (14j)), a para-substituted analogue (4-Cl (16k))43 and a des-fluoro variant (14l).41 As detailed 
in scheme 3, commercially available 3-butynol (9) was treated with SOCl2 and catalytic pyridine at 
reflux temperature, followed by distillation to afford 4-chlorobut-1-yne (10).42 The appropriate 
iodobenzene (11a-j) was then employed in a Pd-catalysed Sonogashira cross-coupling reaction42 with 
10, affording the corresponding internal aryl alkynes (12a-j). Next, we utilised a TfOH-catalysed 
metal-free regioselective Markovnikov-type hydration protocol44 with 2,2,2-trifluoroethanol as 
solvent in the presence of H2O, furnishing the corresponding aryl ketones (13a-j). Finally, N-
alkylation of commercially available key intermediate 7b with each synthesised alkyl chloride (13a-
b, 13d-e, 13g-j) furnished final analogues 14a-b, 14d-e, and 14g-j. Alternatively, 4-chloro-1-(4-
chlorophenyl)butan-1-one (13l) was accessed via Freidel-Crafts acylation, followed by N-alkylation 
of 7b to afford 14k. Finally, commercially available 4-chloro-1-phenylbutan-1-one (13l) was 
aminated with 7b to afford the des-fluoro analogue 14l. 
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Scheme 3. Synthesis of analogues of 1 with modification to p-fluorophenyl moietya
OH Cl(i) (ii)
R3
R3
O
Cl (iv) O
N
OH
Cl
R3
(iii)
9 10 12a-j
13a-j
HN
OH
Cl
7b
R3
I
11a-j
13k R3 = 4-Cl
13l R3 = H
14 a R3 = 2-F
     b R3 = 3-F
     c R3 = 2,3-F
     d R3 = 2,4-F
     e R3 = 2,5-F
f R3 = 2,6-F
g R3 = 3,4-F
h R3 = 3,5-F
i  R3 = 2-Cl
j  R3 = 2-Me
k R3 = 4-Cl
l  R3 = H
R3
O
Cl
Cl
aReagents and conditions: (i) SOCl2, pyridine, 0 ºC – reflux, 30 min, 82%; (ii) PdCl2(PPh3)2, CuI, 
Et3N, 1,4-dioxane, 50 ºC, 1-3 h, 45-85% (12a-j); (iii) TfOH, H2O, CF3CH2OH, 60 ºC, 3-8 h, 50-90% 
(13a-j); (iv) NaHCO3, KI, toluene, reflux, 24 h, 50-82% (14a-b, d-e, g-l); 14c and 14f were detected 
but unable to be isolated in appreciable yield.
The synthesis of analogues containing 2,3-difluorophenyl (14c) and 2,6-difluorophenyl (14f) 
substituents were problematic. When attempting to N-alkylate key intermediate 7b with the 
corresponding alkyl halides (13c, 13f) major side-products due to a competing SNAr reaction were 
observed, making purification of the target compounds by FCC and preparative HPLC extremely 
challenging. These side-products are believed to arise due to activation of the position ortho to the 
ketone moiety, when a fluoro-substituent is present. To circumvent the SNAr reaction, syntheses of 
the affected analogues were modified to incorporate ketal protection/deprotection of the ketone, 
permitting nucleophilic displacement of the alkyl halide only (scheme 4). Beginning with ketal 
protection of 13c, we employed a pTsOH-catalysed reaction with trimethyl orthoformate in MeOH 
at room temperature, to afford the corresponding dimethyl ketal (15c). Alternatively, 13f was reacted 
with 1,2-ethanediol in the presence of catalytic pTsOH in toluene under Dean-Stark conditions, to 
afford the corresponding 1,3-dioxolane (15f). These compounds were then subjected to nucleophilic 
displacement using 7b to furnish 16c and 16f, followed by acid-catalysed hydrolysis in acetone at 
reflux, affording final compounds 14c and 14f.
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Scheme 4. Synthesis of 2,3- and 2,6-difluoro analogues of 1 using various protection strategiesa
N
OH
Cl
OO
R4 R5 (iv)
O
Cl Cl
OO(i) or (ii) (iii)
R3
13c R3 = 2,3-diF
13f R3 = 2,6-diF
R4 R5
R3
R3
15c R3 = 2,3-F, R4 = Me, R5 = Me
15f R3 = 2,6-F, R4 = R5 = (CH2)2
N
OH
Cl
R3
O
16c R3 = 2,3-F, R4 = Me, R5 = Me
16f R3 = 2,6-F, R4 = R5 = (CH2)2
14c R3 = 2,3-F
14f R3 = 2,6-F
7b
aReagents and conditions: (i) trimethylorthoformate, p-TsOH.H2O, MeOH, rt, 12 h, 77% (15c); (ii) 
ethylene glycol, p-TsOH.H2O, toluene, reflux (Dean-Stark), 16 h, 83% (15f); (iii) NaHCO3, KI, 
toluene, reflux, 24 h, 71-77% (16c, 16f); (iv) p-TsOH.H2O, 15:1 acetone/H2O, reflux, 48 h, 76-82% 
(14c, 14f). 
Variation of ketone and linker moiety of 1. We focused on replacement of the ketone group of 1 with 
a range of moieties, including ether, thioether and the corresponding carbinol (racemic). The ether- 
and thioether-variants of 1 were accessed using a literature procedure in three steps45 (17a-b, Figure 
3, Supplementary Scheme 1), whilst the corresponding secondary alcohol was afforded in two-steps 
also through literature procedure (18, Figure 3)46 (Supplementary Scheme 2). 
X
F
N
OH
Cl
17a X = S
17b X = O
OH
N
OH
F
Cl
18
N
Cl
OH
O
F 42
O
N
OH
O
N
OH
Cl
F
53 54
N
N
F
Cl
O
43
O
N
O
N
F 47 48
Cl
Figure 3. Literature analogues of 1 synthesised using various methodologies. Ether- and thioether 
analogues45 (17a-b, respectively); racemic alcohol analogue46 (18) ; tropanyl analogue34 (42); 
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9
piperazinyl analogue34 (43); phenyl- and p-chlorophenylpiperidine analogues38,47 (47-48, 
respectively); reverse substitution analogue48 (53) ; des-halo analogue41 (54). 
Our subsequent focus was to further understand the effect and importance of geometry on the kinetics 
of conformationally restricted analogues of 1, via synthesis of both olefin geometric isomers. The 
trans-olefin 23 was accessed through a five step chemical synthesis as outlined in scheme 5, 
beginning with a one-pot base-mediated intramolecular enolate alkylation of key intermediate 7a, to 
furnish cyclopropyl(4-fluorophenyl)methanone (19) in quantitative yield. Subsequent reduction with 
NaBH4 afforded secondary alcohol 20, followed by a vanadyl acetylacetonate-catalysed 
stereoselective isomerisation in chlorobenzene to yield (E)-4-(4-fluorophenyl)but-3-en-1-ol (21) as 
the exclusive geometric isomer. Compound 21 was subsequently activated with methanesulfonyl 
chloride to give mesylate 22. This was followed by N-alkylation of 7b using standard conditions, 
affording final olefin analogue 23. 
Scheme 5. Synthesis of trans-olefin analogue of 1a
F
O
F
OH
(ii)
(E)
F
OH
F
O
Cl (i)
(iii)
(E)
F
OMs (iv)
(E)
F
Cl
N OH
(iii)
7a 19 20
21 22 23
7b
aReagents and conditions: (i) NaOH, MeOH, 60 ºC, 5 h, quantitative; (ii) NaBH4, MeOH, 0 ºC – rt, 
3 h, 99%; (iii) VO(acac)2, BHT, PhCl, 80 ºC, 48 h, 35%; (iv) MsCl, DCM, Et3N, rt, 3h, 88%; (v) 
NaHCO3, KI, toluene, reflux, 24 h, 82%.    
The cis-isomer 28, was accessed through a three-step synthesis as outlined in scheme 6. Initially, Ni-
catalysed stereoselective arylation of 2,3-dihydrofuran 24 with (4-fluorophenyl)magnesium bromide 
(25) at -30 ºC, successfully afforded the cis-olefin 2649 as the exclusive isomer. This compound was 
then mesylated using standard conditions to afford 27, followed by N-alkylation of 7b using 
conditions outlined previously, furnishing 28. As outlined in scheme 7, both trans and cis-isomers 
(21 and 26, respectively) were treated with diethylzinc and diiodomethane using Simmons-Smith50 
conditions to access the corresponding racemic trans- and cis-cyclopropanes (29 and 30, 
respectively). This was followed by mesylation to give 29a and 30a, and subsequent N-alkylation of 
7b to afford racemic 29b and 30b. 
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Scheme 6. Synthesis of cis-olefin analogue of 1a
O
F
MgBr
(Z)
F
OH
(i) (ii)
(Z)
F
OMs
(iii)
24 25 26 27
28
7b
(Z)
F
N
OH
Cl
aReagents and conditions: (i) Ni[COD]2, 1,3-bis-(2,6-diisopropylphenyl)imidazolinium chloride, 
LiCl, THF, -30 ºC, 8 h, 31%; (ii) MsCl, Et3N, DCM, rt, 24 h, 90%; (iii) NaHCO3, KI, toluene, reflux, 
24 h, 75%.
Scheme 7. Synthesis of both trans- and cis-cyclopropane enantiomers of 1a
(i)
F OH
(ii)
F OMs
(iii)
F
Cl
N
OH
29 = trans
30 = cis
29a = trans
30a = cis
29b = trans
30b = cis
(Z)
F
26 = cis
(E)
F
OH
21 = trans
OH
7b
aReagents and conditions: (i) Et2Zn, CH2I2, DCM, 0 ºC – rt, 24 h, 95-98% (29, 30); (ii) MsCl, Et3N, 
DCM, rt, 90-95% (29a, 30a); (iii) NaHCO3, KI, toluene, reflux, 24 h, 67-70% (29b, 30b).
Next, we focused on the synthesis of both propiophenone and valerophenone analogues of 1 that 
maintained the ketone functionality (scheme 8). Beginning with Friedel-Crafts acylation chemistry, 
the appropriate commercially available acyl chloride (31a, 31c) was reacted with fluorobenzene 32 
in the presence of stoichiometric AlCl3 to afford the corresponding phenones (33a,51 33c52). This was 
followed by N-alkylation of 7b to afford final analogues (34a, 34c53). In addition, we wanted to access 
the 1,3-propylene, 1,4-butylene and 1,5-pentylene analogues of 1 (scheme 8). To achieve this, 
phenones 33a, 7a, and 33c were treated with triethylsilane in TFA, followed by evaporation and direct 
chromatographic purification to furnish the corresponding reduced intermediates 35a-c. Lastly, N-
alkylation of key intermediate 7b furnished alkane analogues 36a-c. 
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Scheme 8. Synthesis of ketone and alkane analogues of 1a
Cl
F
Cl
O
Cl
O
Cl
F
(i)
(vi)
F
Cl
N
OH
n
n
(ii)
O
F
Cl
N
OH
(iii)
F
nn
n
31a n = 1
31c n = 3
33a n = 1
33c n = 3
34a n = 1
34c n = 3
35a n = 1
35b n = 2
35c n = 3
36a n = 1
36b n = 2
36c n = 3
32
O
F
(iii)
7a
Cl
7b
7b
aReagents and conditions: (i) AlCl3, DCM, 0 ºC – rt, 6 h, 85% (33a, 33c); (ii) NaHCO3, KI, toluene, 
reflux, 24 h, 75-90% (34a, 34c); (iii) triethylsilane, trifluoroacetic acid, 0 ºC, 2-3 h, 75-85% (35a-c); 
(iv) NaHCO3, KI, toluene, reflux, 24 h, 72-91% (36a-c).
To assess analogues of 1 incorporating internal aromatic alkynes (scheme 9), 1-fluoro-4-iodobenzene 
(37) was initially subjected to modified Sonagashira conditions54 using commercially available 
alcohols (38a, 38c), affording aryl alkynes (39a,55 39c). Next, the alcohols were converted to their 
corresponding mesylates (40a,56 40c), followed by N-alkylation of 7b with the appropriate mesylate 
to afford the corresponding final propynyl and pentynyl analogues (41a and 41c, respectively). The 
butynyl analogue 41b was accessed via the cross-coupling reaction between key intermediate 10 and 
1-fluoro-4-iodobenzene (37), providing aryl alkyne intermediate 40b, which underwent amination 
with 7b.
Scheme 9. Synthesis of internal alkyne analogues of 1a
F
OH
n
F
I
n
(i)
+
(ii)
F
OMs
n (iv)
HN
OH
Cl
F
n
N
OH
Cl
F
Cl
F
I
(iii) Cl
OH
37
37
10
7b
38a n = 1
38c n = 3
39a n = 1
39c n = 3
40a n = 1
40c n = 3
40b
41a n = 1
41b n = 2
41c n = 3
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aReagents and conditions: (i) Pd(PPh3)2Cl2, CuI, Et3N, MeCN, rt, 5 h, 94% (39a, 39c); (ii) 
methanesulfonyl chloride, Et3N, DCM, 24 h, 93% (40a, 40c); (iii) PdCl2(PPh3)2, Et3N, 1,4-dioxane, 
50 ºC, 3 h, 75% (40b); (iii) NaHCO3, KI, toluene, reflux, 24 h, 68-74% (41a-c). 
Variation of the piperidinol moiety of 1. Modification to the piperidinol moiety of 1 was another key 
interest in our SKR investigation. To observe the kinetic effect of introducing an ethylene bridge on 
the piperidinol, we synthesised tropanyl analogue 42 according to a literature procedure36 (Figure 3, 
Supplementary Scheme 3), utilising n-BuLi in place of Grignard chemistry. We then sought to modify 
the tertiary alcohol group, beginning with synthesis of piperazinyl analogue 43 (Figure 3). This 
compound was accessed in two steps via the construction of the piperazine ring and subsequent N-
alkylation with 7a34 (Supplementary Scheme 4). 
Removing the tertiary alcohol within 1 to generate the corresponding 3,6-dihydropyridine (45) was 
our next focus, as well as further elaboration of the olefin to yield the corresponding cycloalkane 
derivative (46) (scheme 10). Key piperidinol intermediate 7b was firstly dehydrated using neat 
concentrated HCl followed by an alkaline work-up to afford the 1,2,3,6-tetrahydropyridine (44). 
Displacement of 7a with 44 furnished olefin 45.57 This molecule was subsequently treated using 
Simmons-Smith50 conditions, as outlined previously, to afford the corresponding cyclopropane 
analogue 46. 
Scheme 10. Synthesis of dihydropyridyl and fused cyclopropane analogues of 1a
(i)
HN
OH
Cl
HN
Cl
(ii)
N
F
Cl
O
O
N
F
Cl
46
(iii)
7b 44 45
7a
Rac
Reagents and conditions: (i) HCl (conc.), reflux, 5 h, quantitative; (ii) NaHCO3, KI, toluene, reflux, 
24 h, 65% (45); (iii) Et2Zn, CH2I2, DCM, 0 ºC – rt, 24 h, 75% (46). 
In addition, we synthesised two analogues of 1 containing modified phenyl piperidine (47)47 and p-
chlorophenyl piperidine (48)38 cores (Figure 3), of which their synthesis is detailed in Supplementary 
Scheme 5. 
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Further emphasis was placed on the tertiary alcohol contained within 1, where we sought to assess 
the impact of O-methylation (scheme 11). N-Boc-protection of key intermediate 7b gave 49, followed 
by O-alkylation with methyl iodide to afford the corresponding methyl ether 50. This was followed 
by N-Boc-deprotection to give the secondary amine hydrochloride 51.Final N-alkylation with key 
intermediate 7a afforded compound 52.
Scheme 11. Synthesis of methyl ether analogue of 1a
HN
OH
Cl
N
OH
Cl
O
O
N
O
Cl
O
O
H2N
O
ClCl N
F
O Cl
O
(i) (ii)
(iii) (iv)
7b 49 50
51 52
7a
aReagents and conditions: (i) Boc2O, Et3N, DCM, rt, 4 h, 85%; (ii) NaH, MeI, DMF, rt, 24 h, 80%; 
(iii) HCl, 1,4-dioxane, rt, 2 h, 95%; (iv) NaHCO3, KI, toluene, reflux, 24 h, 70%.
Dual modification to halo-aryl moieties of 1. Recent molecular dynamics (MD) simulations by 
Thomas et al.58 were used to understand the ligand binding pathways of 1 and 2 at the D2R/D3R. The 
final stable pose of 1 was shown to occupy the same space as predicted in a number of molecular 
docking studies;59-61 however, the molecular orientation was contradictory to these data by 180º, with 
the butyrophenone moiety buried most deeply in the receptor. Therefore, and due to confounding 
studies regarding the orientation of 1 at the D2R, it was of interest to investigate the kinetic effects of 
modifying both phenyl moieties of 1 simultaneously. Accordingly, we synthesised a further two 
structural analogues of 1 (Figure 3). These modifications included swapping both aromatic termini 
(53), as well as removal of these aromatic substituents (54). 53 was synthesised according to a 
literature procedure following Friedel-Crafts acylation and N-alkylation (Figure 3, Supplementary 
Scheme 6).43 Compound 54 was similarly accessed through literature methods (Figure 3, 
Supplementary Scheme 7).41 
Pharmacology. Characterisation of PPHT-red binding. Specific equilibrium binding of the agonist 
PPHT-red (Cisbio Bioassays) to human D2L receptor (hD2LR) was saturable and best described by the 
interaction of PPHT-red with a single population of binding sites (Supplementary Figure 1A). From 
these studies, the equilibrium dissociation constant (Kd) of the fluorescent ligand was determined to 
be 43.2 ± 0.37 nM. The binding kinetics of PPHT-red were characterised by monitoring the observed 
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association rates at six different ligand concentrations (Supplementary Figure 1B). The observed rate 
of association was related to PPHT-red concentration in a linear fashion (Supplementary Figure 1C). 
Kinetic rate parameters for PPHT-red were calculated by globally fitting the association time courses, 
resulting in a kon of 9.21 ± 0.24 × 106 M-1 min-1 and koff of 0.35 ± 0.01 min-1. The resulting Kd (koff/kon) 
of 46.3 ± 0.15 nM was comparable to that obtained from equilibrium studies. 
Characterisation of kinetic binding parameters of unlabelled analogues of 1 at the D2R. The 
competition association binding method allows the characterisation of the kinetic rate parameters of 
unlabelled compounds (kon, koff) and the subsequent calculation of a kinetically derived (kon/koff) 
equilibrium dissociation constant (Kd). The binding affinity of the various ligands for the hD2LR were 
measured at equilibrium at 37 ºC in a buffer containing 5′-guanylyl imidodiphosphate (GppNHp) (0.1 
mM) to ensure that antagonist and tracer binding only occurred to the G protein-uncoupled form of 
the receptor. Ki values for compound 1, and the 50 structural analogues studied are summarised in 
Tables 1-5, and representative competition curves are presented in Figure 4A. In these tables we have 
separated the analogues into five groups, those that have been modified at the para-chlorophenyl, 
para-fluorophenyl, piperidinol, ketone/alkyl linker, and concurrent phenyl ring moiety modification, 
as indicated in Figure 2. Representative kinetic competition curves for selected analogues are in 
Figures 4B-D. Association curves for PPHT-red alone and in the presence of competitor were globally 
fitted to Eq. 3 enabling the calculation of both kon (k3) and koff (k4) for each of the ligands, as reported 
in Tables 1-5. To validate the rate constants, we compared the kinetically derived dissociation 
constant (Kd) values (kon/koff) with the dissociation constant (Ki) obtained from equilibrium 
competition binding experiments (Figure 5). There was a good correlation between these two values 
for all compounds tested (two-tailed Pearson’s correlation r2 = 0.99, p < 0.0001), indicating that the 
parameters determined in the kinetic assay were in agreement with those determined at equilibrium.
Characterisation of the kinetic profile of 1 at the hD2LR. The equilibrium affinities and kinetic rate 
constants of 1 and 2 have recently been determined using the aforementioned TR-FRET assay.33 Prior 
to initiating an investigation into 1, we also assessed its parameters and determined similar estimates 
in agreement with literature33 (koff = 0.61 ± 0.04 min-1, kon = 1.29 ± 0.21 × 109 M-1 min-1, pKd = 9.31 
± 0.05, Table 1), validating our experimental conditions and further demonstrating that 1 is indeed a 
high affinity, fast kon/slow koff compound at the hD2LR. Kinetic estimates for 1 are outlined in Tables 
1-5 and all experimental structure-kinetic data will make specific reference to these data as a 
comparison. Furthermore, compounds with fast koff values approaching >1.0 min-1 were reassessed 
using a modified injection protocol, whereby the hD2LR membrane homogenates were introduced 
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using an online injector whilst simultaneously measuring TR-FRET binding. This is to avoid any 
delay between membrane addition and initial TR-FRET measurement, improving the quality of the 
non-linear fit for compounds with rapid equilibration kinetics and thus increasing our confidence in 
the rate parameter estimate. Characterisation of 1 using this methodology returned comparable 
estimates to the offline injection protocol. Additional data acquired for selected compounds using this 
methodology are located in Tables 2 and 3.
Figure 4. Equilibrium and competition association binding. (A) Competition between PPHT-red 
(12.5 nM) and increasing concentrations of 1 and representative analogues (8b, 8d, 8g, 8l, 14j, 14k, 
45, 46, 48, 52, 53) at the hD2LR. PPHT-red competition association curves in the presence of (B) 30b; 
(C) 34c; (D) 42. All binding reactions were performed at 37 ºC in the presence of GppNHp (100 µM) 
with non-specific binding levels determined by inclusion of haloperidol (10 µM). Kinetic and 
equilibrium data were fitted to the equations described in “Methods” section to calculate Ki, Kd, and 
kon and koff values for the unlabelled ligands: these are summarised in tables 1-5. Data are presented 
as singlet values from a representative of four. 
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Figure 5. Correlating equilibrium and kinetically derived parameters for haloperidol (1) and 
51 structural analogues at the dopamine D2 receptor. Correlation between pKi and kinetically 
derived pKd for the 51 test ligands including haloperidol. pKi values were taken from PPHT-red 
competition binding experiments at equilibrium as exemplified in Figure 4A. The values composing 
the kinetically derived pKd (koff/kon) were taken from competition kinetic association experiments as 
exemplified in Figures 4B-D. All data used in these plots are detailed in Tables 1-5. Data are presented 
as mean ± S.E.M. from four separate experiments.
Measurement of the functional activity of analogues of 1.  1 is a hD2LR antagonist. It is possible, 
however, that modification of this structure may yield agonists. We measured the activity of all 
analogues in an assay measuring inhibition of intracellular cAMP production stimulated by forskolin 
using a bioluminescence resonance energy transfer (BRET) biosensor. This is a measurement of Gi/o 
G protein activation by the hD2LR. We performed two types of measurement. In the first, we tested 
the ability of a 10 µM concentration of each analogue alone to activate the hD2LR and in the second 
we measured the ability of each analogue to antagonise the action of an EC80 (30 nM) concentration 
of the agonist dopamine. The results of these experiments revealed that none of the compounds 
displayed agonist activity apart from 47 which displayed 20% of the maximal effect of dopamine at 
a concentration of 10 µM (Supplementary Table 1). All compounds antagonised the effect of 
dopamine to a basal (unstimulated) level except for 47 which reduced the effect of dopamine to a 
level consistent with the intrinsic activity determined in the agonist assay protocol (Supplementary 
Table 1). 
Kinetic effects of variation of the para-chlorophenyl moiety of 1.  Initially focusing on modification 
of the para-chlorophenyl moiety of 1, we sought to assess the kinetic effect of all possible mono (8a, 
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8n) and di-chlorophenyl substituents (8b-g), as well as variation of the para- substituent (8h-m) 
through the synthesis of 14 structural analogues (Table 1). These compounds exhibited a 17-fold 
variation in affinity, which was driven by interesting changes in kinetic parameters, spanning a >10-
fold variation in association rate (kon = 1.22 ± 0.20 × 108 M-1 min-1 to 2.95 ± 0.30 × 109 M-1 min-1), 
and a ~4-fold variation in dissociation rate (koff = 0.30 ± 0.01 min-1 to koff = 1.25 ± 0.09 min-1). 
The data show that analogues lacking an electron withdrawing group (EWG) (chloro) substituent at 
the meta- and para-positions have reduced binding affinity, and this loss is mirrored by a decrease in 
kon and an increase in koff relative to 1. For example, the ortho-Cl analogue (8n) displayed an ~8-fold 
reduction in affinity resulting from a decreased kon and increased koff (kon = 3.54 ± 0.16 × 108 M-1 
min-1, koff = 1.16 ± 0.11 min-1). This was also evident for the 2,6-diCl analogue (8e) losing ~6-fold 
affinity, also mediated by a slowed association and increased dissociation rate (kon = 5.07 ± 0.47 × 
108 M-1 min-1, koff = 1.05 ± 0.05 min-1). This trend continued with the des-Cl analogue 8h, as it also 
revealed a similar change in rate constants (kon = 1.22 ± 0.20 × 108 M-1 min-1, koff = 1.02 ± 0.10 min-
1). 
Addition of a strong electron donating group (EDG) (N,N-dimethylamino, 8k) results in a >10-fold 
decrease in affinity (pKd = 8.12 ± 0.04) and again appears to be driven by a decrease in kon and an 
increase in koff (kon = 1.64 ± 0.12 × 108 M-1 min-1, koff = 1.25 ± 0.09 min-1). Furthermore, other 
analogues bearing weakly electron donating substituents (e.g. para-tolyl analogue 8i) saw a smaller 
decrease in affinity (~3-fold), similarly mediated by a change in both rate constants towards a slow 
on, fast off profile (kon = 1.00 ± 0.06 × 109 M-1 min-1, koff = 0.98 ± 0.02 min-1).
Conversely, insertion of a meta-Cl substituent (exemplified by 8a), despite decreasing affinity ~8-
fold, acts only to decrease the kon whilst having no effect on koff (kon = 3.62 ± 0.94 × 108 M-1 min-1, 
koff = 0.64 ± 0.10 min-1), and this similarly applies to para-Cl substituents. The trend continued with 
2,4-dichloro (8c) and 2,5-dichloro (8d) analogues, losing ~7-fold and 3-fold affinity, respectively. 
Again, this loss was largely mediated by a decreased association rate (8c: kon = 2.87 ± 0.56 × 108 M-
1 min-1, koff = 0.70 ± 0.16 min-1; 8d: kon = 5.29 ± 0.36 × 108 M-1 min-1, koff = 0.56 ± 0.06 min-1), relative 
to 1. Interestingly, when the ortho- and meta-chloro substituents are combined (2,3-diCl analogue 
(8b)), affinity increases ~5-fold, and this is now predominantly mediated by both a ~2-fold increase 
in association rate and ~2-fold decrease in dissociation rate (pKd = 9.84 ± 0.08, kon = 2.20 ± 0.30 × 
109 M-1 min-1, koff = 0.30 ± 0.01 min-1). Substitution with a strongly electron withdrawing para-CF3 
substituent (8j) maintained affinity, with no effect on the kinetic profile of the analogue relative to 1 
(kon = 1.36 ± 0.07 × 109 M-1 min-1, koff = 0.62 ± 0.02 min-1). Furthermore, replacing the para-chloro 
substituent for a para-fluoro (8l) predominantly decreased kon. 
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All compounds bearing an ortho-substituent (8n, 8c, 8d, 8e, 8m), with the exception of 8b, displayed 
a reduced on-rate, indicating potential sensitivity to steric bulk at this position through resulting 
rotation of the phenyl group relative to the piperidinol. Interestingly, the 2,3-diCl analogue (8b), 
contains the privileged 2,3-dichlorophenylpiperidine pharmacophore known to confer high affinity 
in other molecules at both the D2-like and 5HT receptors. This particular substitution pattern may 
therefore support a different binding mode. Both increased lipophilicity and steric bulk are preferred 
at the meta- and para–positions of the ring, with the 4-position being optimal, which is supported by 
8h (4-fluoro) and 8l (4-H) being less favoured. For the off rate, the substituent effect is reversed in 
terms of increasing koff (o>m>p). This parameter appears to be less impacted by steric factors, and 
instead the electronics may play a greater role (8k, 8i, 8h). In summary, these initial data provide 
insight into how structural modifications of haloperidol (1) impact upon individual kinetic 
parameters, demonstrating the potential for differential modification of rate constants towards a slow 
on, fast off profile, depending on the position and nature of the aryl substituents of the 4-
phenylpiperidin-4-ol moiety.
Table 1. Kinetic binding parameters for haloperidol (1) and unlabelled analogues of 1 for 
human D2L receptors estimated using TR-FRET assay.
O
N
OH
F
R2
Haloperidol (1), 8a-8n
R2 kon (M-1 min-1)a koff (min-1) a t1/2 (min) a pKd a pKi b
1 Cl 1.29 ± 0.21 × 109 0.61 ± 0.04 1.15 ± 0.08 9.31 ± 0.05 9.33 ± 0.09
8a
Cl
6.32 ± 0.94 × 108 0.64 ± 0.10 1.19 ± 0.22 9.00 ± 0.05 9.00 ± 0.03
8n
Cl
3.54 ± 0.16 × 108 1.16 ± 0.11 0.61 ± 0.05 8.49 ± 0.03 8.67 ± 0.09
8b
ClCl
2.20 ± 0.30 × 109 0.30 ± 0.01 2.28 ± 0.04 9.84 ± 0.08 9.92 ± 0.03
8c
Cl
Cl 2.87 ± 0.56 × 108 0.70 ± 0.16 1.15 ± 0.24 8.62 ± 0.02 8.58 ± 0.01
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8d
Cl
Cl
5.29 ± 0.36 × 108 0.56 ± 0.06 1.27 ± 0.11 8.98 ± 0.02 8.99 ± 0.01
8e
Cl
Cl
5.07 ± 0.47 × 108 1.05 ± 0.05 0.67 ± 0.05 8.68 ± 0.04 8.83 ± 0.08
8f
Cl
Cl 2.95 ± 0.30 × 109 0.42 ± 0.02 1.67 ± 0.11 9.84 ± 0.03 9.81 ± 0.04
8g
Cl
Cl
6.58 ± 0.67 × 108 0.43 ± 0.02 1.94 ± 0.30 9.27 ± 0.06 9.35 ± 0.04
8h 1.22 ± 0.20 × 108 1.02 ± 0.10 0.71 ± 0.08 8.07 ± 0.04 8.12 ± 0.02
8i 1.00 ± 0.06 × 109 0.98 ± 0.11 0.73 ± 0.07 9.02 ± 0.03 9.14 ± 0.08
8j CF3 1.36 ± 0.07 × 109 0.62 ± 0.02 1.12 ± 0.04 9.34 ± 0.04 9.49 ± 0.10
8k N 1.64 ± 0.12 × 108 1.25 ± 0.09 0.56 ± 0.03 8.12 ± 0.04 8.28 ± 0.09
8l
F 2.61 ± 0.24 × 108 0.78 ± 0.08 0.92 ± 0.11 8.52 ± 0.02 8.48 ± 0.01
8m
Cl
3.25 ± 0.77 × 108 0.82 ± 0.11 0.89 ± 0.12 8.57 ± 0.05 8.61 ± 0.03
aThe rate constants koff, kon, the half-life (t1/2), and the kinetically derived pKd were obtained from competition 
kinetic association experiments using PPHT-red. bpKi values were taken from PPHT-red competition binding 
experiments at equilibrium. Data are presented as mean ± S.E.M. from four experiments performed in singlet. 
*Completed using online injection protocol. 
Kinetic effects of variation of the para-fluorophenyl moiety of 1. We examined the effect of fluoro 
substituents at both ortho-(14a) and meta-(14b) positions of the phenone moiety, as well as all 
possible di-fluorophenyl substituents (14c-h), together with three additional ortho-analogues (o-Cl 
(14i), o-CH3 (14j) o-Cl (14k)), and an unsubstituted analogue (14l). Modification to this moiety 
caused large decreases in affinity relative to 1, spanning over 100-fold from pKd = 6.67 ± 0.01 (14h) 
to pKd = 8.75 ± 0.02 (14l), and is associated with a wide range of association and dissociation rate 
constants. These losses in affinity are mediated through concurrent changes in both kon and koff. This 
applies to all but the para-Cl analogue (14k), as it lost affinity 10-fold relative to 1, but this was 
largely mediated by a decreased rate of association (kon = 1.38 ± 0.05 × 108, koff = 0.70 ± 0.03 min-1). 
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The des-fluoro analogue (14l) maintained the highest affinity, and similar to the previous series, this 
was facilitated by a shift in both rate constants (pKd = 8.75 ± 0.02, kon = 6.33 ± 1.06 × 108 M-1 min-1, 
koff = 1.12 ± 0.18 min-1). Of the three ortho-substituted analogues (14a (m-F), 14i (m-Cl)), 14j (m-
CH3)), the fluoro substituent was the least favourable in terms of affinity, decreasing ~13-fold relative 
to 1, whereas the ortho-tolyl substituent only reduces affinity by 6-fold. However, these changes are 
likewise mediated by a decreased association rate and increased rate of dissociation. Notably, the m-
Cl (14i) and m-CH3 (14j) substituents have similar Van der Waals radii, but very different electronic 
effects, thus highlighting a steric factor as being important. The meta-fluoro substituted analogue 
(14b) also dramatically reduced the affinity and was similarly driven by a decreased kon and increased 
koff (kon = 2.55 ± 0.27 × 107 M-1 min-1, koff = 1.08 ± 0.21 min-1). 
Di-fluoro substitution of the phenyl ring revealed no clear SKR and commonly caused substantial 
losses in binding affinity. However, unlike the previous chloro series, greater increases in the rate of 
dissociation were observed. Interestingly, using our online injection protocol, we identified 
compounds with even slower kon values relative to 2, coupled with equal to or faster koff values, despite 
their affinities being lower than 2. For example, the 2,3-(14c), 2,4-(14d) and 2,5-difluoro (14e) 
analogues of 1 (pKd = 7.28 ± 0.04, 6.92 ± 0.05 and 6.85 ± 0.04, respectively) showed dissociation 
rates faster than any compound identified in the previous series (koff = 1.70 ± 0.09 min-1, koff = 1.36 ± 
0.21 min-1 and koff = 1.49 ± 0.36 min-1, respectively). In conclusion, these preliminary data suggest 
that different fluorine substitution patterns dramatically reduce binding affinities, mediated through 
changes in both kinetic parameters. However, the relationship between the nature of substituents, the 
substitution pattern and the corresponding kinetic profile is unclear.
Table 2. Kinetic binding parameters of unlabelled analogues of 1 with modification to the 
para-fluorophenyl moiety for human D2L receptors estimated using TR-FRET assay. 
 
R6
O
N
OH
Cl
Haloperidol (1), 14a-l
R6 kon (M-1 min-1) koff (min-1) t1/2 (min) pKd pKi
1
F
1.29 ± 0.21 × 109 0.61 ± 0.04 1.15 ± 0.08 9.31 ± 0.05 9.33 ± 0.09
14a
F
9.93 ± 1.44 × 107 1.04 ± 0.11 0.69 ± 0.02 7.99 ± 0.05 8.10 ± 0.15
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14b
F
2.55 ± 0.27 × 107 0.96 ± 0.13 0.76 ± 0.09 7.43 ± 0.03 7.44 ± 0.03
14b*
F
2.64 ± 0.49 × 107 1.08 ± 0.21 0.70 ± 0.12 7.39 ± 0.01 7.42 ± 0.02
14c
F
F
3.01 ± 0.47 × 107 1.29 ± 0.26 0.60 ± 0.10 7.38 ± 0.02 7.39 ± 0.04
14c*
F
F
3.24 ± 0.34 × 107 1.70 ± 0.09 0.41 ± 0.10 7.28 ± 0.04 7.33 ± 0.04
14d
FF
1.07 ± 0.02 × 107 1.36 ± 0.21 0.51 ± 0.07 6.92 ± 0.05 7.08 ± 0.10
14e
F
F
1.15 ± 0.20 × 107 1.14 ± 0.15 0.63 ± 0.08 7.00 ± 0.04 7.12 ± 0.12
14e*
F
F
1.13 ± 0.38 × 107 1.49 ± 0.36 0.58 ± 0.16 6.85 ± 0.04 6.95 ± 0.12
14f
F
F
1.84 ± 0.26 × 107 1.09 ± 0.12 0.66 ± 0.09 7.22 ± 0.05 7.20 ± 0.04
14g
F
F
1.36 ± 0.21 × 108 1.03 ± 0.20 0.75 ± 0.14 8.13 ± 0.03 8.11 ± 0.03
14h
F
F
4.25 ± 0.52 × 106 0.92 ± 0.13 0.79 ± 0.09 6.67 ± 0.01 6.77 ± 0.08
14i
Cl
3.16 ± 0.54 × 108 1.11 ± 0.25 0.76 ± 0.22 8.47 ± 0.03 8.45 ± 0.01
14j 3.66 ± 0.91 × 108 0.83 ± 0.21 1.01 ± 0.25 8.71 ± 0.25 8.82 ± 0.02
14k
Cl
1.38 ± 0.05 × 108 0.70 ± 0.03 1.00 ± 0.04 8.30 ± 0.02 8.30 ± 0.02
14l 6.33 ± 1.06 × 108 1.12 ± 0.18 0.67 ± 0.11 8.75 ± 0.02 8.75 ± 0.05
aThe rate constants koff, kon, the half-life (t1/2), and the kinetically derived pKd were obtained from competition 
kinetic association experiments using PPHT-red. bpKi values were taken from PPHT-red competition binding 
experiments at equilibrium. Data are presented as mean ± S.E.M. from four experiments performed in singlet. 
*Completed using online injection protocol. 
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Kinetic effects of variation of ketone and linker moieties of 1. We next examined the effect of 
modification to the linker and ketone moieties of 1 through synthesis of a further 15 analogues. 
Specific linker-modified compounds included propiophenone (34a) and valerophenone (34c) 
analogues of 1, alongside 3-5 carbon alkyl (36a-c) and alkyne analogues (41a-c). In addition, a 
thorough analysis of modification to the ketone moiety was undertaken via synthesis of geometric 
olefin isomers (23, 26) and their corresponding cyclopropane derivatives (29b, 30b), through to 
isosteric replacement with sulfur (17a) or oxygen (17b), as well as conversion of the ketone to the 
corresponding secondary alcohol (18).
All compounds in this series lost binding affinity relative to 1 and, for the most part, this was mediated 
through a decrease in kon and an increase in koff. Converting the ketone to its corresponding secondary 
alcohol (18) (racemic), whilst engendering a 13-fold reduction in affinity compared to 1, was 
exclusively caused by a slowed kon (pKd = 7.04 ± 0.01, kon = 6.19 ± 0.41 × 106 M-1 min-1). Replacement 
of the carbonyl moiety with sulfur (17a) or oxygen (17b) modulated both kinetic binding parameters, 
though their respective association rates varied ~6-fold (kon = 4.99 ± 0.59 × 108 M-1 min-1 and kon = 
1.22 ± 0.35 × 109 M-1 min-1, respectively). This difference may be due to a number factors, including 
the electronegativity and size difference between the sulfur and oxygen atoms, the relatively longer 
S-C bond length compared to that of the O-C bond and the orbital arrangement around each 
heteroatom (resulting in considerably smaller bond angles in the thioether compared to the ether).  
The trans alkene (23) lost ~10-fold affinity relative to 1, and this was again predominantly due to a 
decreased kon (kon = 6.39 ± 0.88 × 107 M-1 min-1). Interestingly, the cis- isomer (26) saw a further 5-
fold reduction in affinity (pKd = 7.49 ± 0.12); however, this was predominantly due to a change in 
association rate, displaying a kon almost 20-fold slower and a koff 2-fold faster than 1 (kon = 3.35 ± 
0.72 × 107 M-1 min-1, koff = 1.25 ± 0.16 min-1). Analysis of the racemic cycloalkane diastereomers was 
also interesting; introduction of the trans-cyclopropane (29b) resulted in a ~10-fold increase in affinity 
relative to the parent trans-olefin 23, which was predominantly due to a ~10-fold increase in 
association rate (kon = 6.07 ± 0.87 × 108 M-1 min-1). Conversely, introduction of the cis-cyclopropane 
(30b) had no effects on affinity relative to the parent cis-olefin 28; however, this substituent 
marginally decreased kon whilst increasing the koff (kon = 4.47 ± 0.47 × 107 M-1 min-1, koff = 1.37 ± 
0.09 min-1). These data indicate that cis-geometry is preferred as opposed to trans- with respect to 
this sub-set of compounds in reference to tuning the kinetic profile towards "slow on, fast off” 
characteristics, and demonstrates the importance of geometry in the corresponding pharmacological 
profile of APDs. Analysis of the propiophenone and valerophenone analogues of 1 returned further 
intriguing results. Decreasing the linker length by just one carbon (34a) relative to 1 resulted in 
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dramatic changes in both association and dissociation rate constants (kon = 1.33 ± 0.17 × 107 M-1 
min-1, koff = 1.95 ± 0.32 min-1), resulting in a loss of affinity at the D2R by >20-fold (pKd = 6.84 ± 
0.05). 
Perhaps the most exciting compound to arise from our study was the valerophenone analogue (34c). 
Despite losing affinity by >10-fold relative to 1, this compound displayed a ~10-fold slower kon and 
a >3.5-fold faster koff than 1. Both the kinetic profile and affinity are similar to that of 2, which our 
previous studies predict would confer a low propensity to cause extrapyramidal side effects.33 The 
alkane analogues of 1 (36a-c) exhibited a 10-fold variation in affinity with respect to one another, 
with the butylene analogue (36b) found to be optimal in terms of affinity conservation relative to 1 
(pKd = 8.17 ± 0.03), despite all having >10-fold losses in affinity relative to 1. Despite having a >20-
fold lower affinity compared to 1, the propylene analogue (36a) was found to have a “slow on, fast 
off” kinetic profile (pKd = 7.18 ± 0.06, kon = 2.29 ± 0.15 × 107 M-1 min-1, koff = 1.54 ± 0.07 min-1). 
Finally, analysis of the 3-5-carbon alkyne analogues (41a-c) saw a 10-fold variation in affinity, with 
the pentyne analogue (41c) being optimal (pKd = 7.75 ± 0.03), as well as displaying the largest change 
in both rate constants towards a slow on, fast off profile (kon = 6.41 ± 0.80 × 107, koff = 1.15 ± 0.15 
min-1). 
Table 3. Kinetic binding parameters of unlabelled analogues of 1 with modifications to the 
ketone and linker moieties for human D2L receptors estimated using TR-FRET assay.
 
O
N
OH
F
Cl
Haloperidol (1), 17a-b, 18, 23, 26,
29b, 30b, 34a,c, 36a-c, 41a-c
Structure kon (M-1 min-1) koff (min-1) t1/2 (min) pKd pKi
1
O
1.29 ± 0.21 × 109 0.61 ± 0.04 1.15 ± 0.08 9.31 ± 0.05 9.33 ± 0.09
17a S 4.99 ± 0.59 × 108 0.99 ± 0.15 0.74 ± 0.10 8.71 ± 0.04 8.68 ± 0.04 
17b O 1.22 ± 0.35 × 109 0.91 ± 0.12 0.81 ± 0.11 9.10 ± 0.08 8.97 ± 0.04
18
OH
6.19 ± 0.41 × 106 0.57 ± 0.05 1.25 ± 0.13 7.04 ± 0.01 7.04 ± 0.02
23
(E)
6.39 ± 0.88 × 107 0.76 ± 0.13 0.74 ± 0.10 7.94 ± 0.03 7.95 ± 0.03
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(Z)
3.35 ± 0.72 × 107 1.25 ± 0.16 0.58 ± 0.09 7.49 ± 0.12 7.53 ± 0.06
29b
(±)-trans
6.07 ± 0.87 × 108 0.92 ± 0.14 0.82 ± 0.14 8.82 ± 0.04 8.82 ± 0.04
30b
(±)-cis
4.47 ± 0.47 × 107 1.37 ± 0.09 0.51 ± 0.03 7.51 ± 0.03 7.53 ± 0.03
34a
O
1.03 ± 0.18 × 107 1.27 ± 0.15 0.57 ± 0.07 6.89 ± 0.05 6.92 ± 0.02
34a*
O
1.33 ± 0.17 × 107 1.95 ± 0.32 0.43 ± 0.04 6.84 ± 0.05 6.88 ± 0.02
34c
O
1.42 ± 0.24 × 108 1.65 ± 0.30 0.48 ± 0.10 7.94 ± 0.04 7.97 ± 0.02
34c*
O
1.80 ± 0.15 × 108 2.35 ± 0.19 0.30 ± 0.03 7.89 ± 0.01 7.92 ± 0.02
36a 2.45 ± 0.26 × 107 1.33 ± 0.22 0.57 ± 0.10 7.28 ± 0.06 7.25 ± 0.03
36a* 2.29 ± 0.15 × 107 1.54 ± 0.07 0.46 ± 0.10 7.18 ± 0.06 7.21 ± 0.03
36b 1.57 ± 0.13 × 108 1.11 ± 0.05 0.63 ± 0.02 8.17 ± 0.03 8.27 ± 0.09
36c 5.51 ± 0.69 × 107 1.22 ± 0.15 0.60 ± 0.08 7.66 ± 0.03 7.66 ± 0.02
41a 3.37 ± 0.62 × 106 0.96 ± 0.14 0.77 ± 0.11 6.54 ± 0.01 6.55 ± 0.01
41b 1.61 ± 0.24 × 107 1.10 ± 0.21 0.69 ± 0.11 7.15 ± 0.05 7.13 ± 0.06
41c 6.41 ± 0.80 × 107 1.15 ± 0.15 0.65 ± 0.11 7.75 ± 0.03 7.72 ± 0.04
aThe rate constants koff, kon, the half-life (t1/2), and the kinetically derived pKd were obtained from competition 
kinetic association experiments using PPHT-red. bpKi values were taken from PPHT-red competition binding 
experiments at equilibrium. Data are presented as mean ± S.E.M. from four experiments performed in singlet. 
*Completed using online injection protocol. 
Kinetic effects of variation of the piperidinol moiety of 1. The kinetic effect of structural modifications 
to the 4-phenylpiperidin-4-ol moiety of 1 was explored through the synthesis of eight additional 
analogues. We observed the effects of introducing an ethylene bridge (42), as well as modification 
primarily to the tertiary alcohol through methyl ether formation (52) and its subsequent removal, 
generating a variety of compounds containing piperazinyl (43), dihydropyridinyl (45), cyclopropyl 
(46), and piperidinyl (47, 48) functionalities. We observed a wide range of affinities that spanned a 
~30-fold difference, and unlike the previous chemical series, modification to the piperidinol moiety 
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for the most part had relatively negligible effects on the koff, with the majority maintaining similar 
values to that of 1 (Table 3). Instead, a decrease in affinity relative to 1 was largely facilitated by a 
decreased kon. Notably, of the two analogues with higher affinities relative to 1, these were instead 
largely mediated by an increase in kon and decrease in koff. For example, introducing the tropanyl 
moiety (42) conferred a ~10-fold increase in affinity which was equally driven by an increase in kon 
and decrease in koff (pKd = 10.26 ± 0.06, kon = 3.68 ± 0.64 × 109 M-1 min-1, koff = 0.19 ± 0.02 min-1). 
The cyclopropane variants (46) 5-fold improved affinity relative to 1 was also mediated by an 
increased kon and decreased koff (pKd = 9.84 ± 0.02, kon = 2.03 ± 0.09 × 109 M-1 min-1, koff = 0.30 ± 
0.01 min-1). The improved affinities and decreased dissociation rates of 42 and 46 (tropanyl and 
cyclopropane analogues, respectively) can perhaps be rationalised through a major conformational 
difference induced by these substituents, resulting in a more entropically favourable binding event.  
From these preliminary data, it appears that modification to the piperidinol moiety is not particularly 
amenable to significant increases in the corresponding compounds rate of dissociation.
Table 4. Kinetic binding parameters of unlabelled analogues of 1 with modifications to the 
piperidinol moiety for human D2L receptors estimated using TR-FRET assay.
 
O
R7
F
Haloperidol (1), 42-43, 45-48, 52
# R7 kon (M-1 min-1) koff (min-1) t1/2 (min) pKd pKi
1
N
OH
Cl
1.29 ± 0.21 × 109 0.61 ± 0.04 1.15 ± 0.08 9.31 ± 0.05 9.33 ± 0.09
42
N
Cl
OH
3.68 ± 0.64 × 109 0.19 ± 0.02 3.59 ± 0.39
10.26 ± 
0.06
10.28 ± 0.08 
43 N
N
Cl
2.86 ± 0.33 × 107 0.80 ± 0.07 0.89 ± 0.09 7.55 ± 0.04 7.53 ± 0.04
45
N
Cl
6.52 ± 0.46 × 107 0.65 ± 0.05 1.09 ± 0.09 8.00 ± 0.02 8.00 ± 0.02
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46
N
Cl
2.03 ± 0.09 × 109 0.30 ± 0.01 2.35 ± 0.10 9.84 ± 0.02 9.80 ± 0.02
47
N
8.99 ± 0.37 × 107 0.71 ± 0.05 0.99 ± 0.07 8.10 ± 0.02 8.11 ± 0.03
48
N
Cl
4.31 ± 0.37 × 108 0.84 ± 0.09 0.86 ± 0.09 8.72 ± 0.03 8.76 ± 0.06
52
N
O
Cl
3.60 ± 0.22 × 108 0.68 ± 0.03 1.03 ± 0.05 8.72 ± 0.01 8.72 ± 0.01
aThe rate constants koff, kon, the half-life (t1/2), and the kinetically derived pKd were obtained from competition 
kinetic association experiments using PPHT-red. bpKi values were taken from PPHT-red competition binding 
experiments at equilibrium. Data are presented as mean ± S.E.M. from four experiments performed in singlet. 
Dual modifications to both phenyl moieties of 1. Finally, we assessed the effect of swapping the 
halogen substituents on each end of haloperidol (1) through compound (53), as well as their 
simultaneous removal as exemplified by the des-halo analogue 54 (Table 5). These structural changes 
all decreased affinity, which was reflected by decreases in the corresponding kon, with only minor 
effects on koff relative to 1. Swapping the halogen atoms on each ring (53) caused a 16-fold loss in 
affinity (pKd = 7.73 ± 0.02), which was predominantly driven by a 16-fold decrease in kon (kon = 4.17 
± 0.28 × 107 M-1 min-1). Finally, removal of both halogen atoms (54) simultaneously caused a ~18-
fold loss in affinity (pKd = 7.51 ± 0.01), driven by a sole ~18-fold decrease in kon relative to 1 (kon = 
2.28 ± 0.13 × 107 M-1 min-1). This effect is unlike that of previous analogues bearing a para-halo 
substituent on only one of the two phenyl rings (8h and 14l), whereby both kon and koff are altered 
(tables 1 and 2, respectively).  
Table 5. Kinetic binding parameters of unlabelled bi-functionalised analogues of 1 for human 
D2L receptors estimated using TR-FRET assay.
 
R6
O
N
OH
R2
Haloperidol (1), 53, 54
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# R6 R2 kon (M-1 min-1) koff (min-1)
t1/2 
(min)
pKd pKi
1
F
Cl 1.29 ± 0.21 × 109 0.61 ± 0.04 
1.15 ± 
0.08
9.31 ± 0.05 9.33 ± 0.09
53
Cl
F 4.17 ± 0.28 × 107 0.77 ± 0.05
0.91 ± 
0.06
7.73 ± 0.02 7.75 ± 0.01
54 2.28 ± 0.13 × 107 0.71 ± 0.05
0.98 ± 
0.07
7.51 ± 0.01 7.49 ± 0.01
aThe rate constants koff, kon, the half-life (t1/2), and the kinetically derived pKd were obtained from competition 
kinetic association experiments using PPHT-red. bpKi values were taken from PPHT-red competition binding 
experiments at equilibrium. Data are presented as mean ± S.E.M. from four experiments performed in singlet. 
*Completed using online injection protocol. 
Our studies show that modifying the scaffold of 1 produces compounds with a wide range of both 
association rates (spanning ~3 orders of magnitude, from kon = 3.37 ± 0.62 × 106 M-1 min-1 to 3.68 ± 
0.64 × 109 M-1 min-1) and dissociation rates (spanning >10-fold, from koff = 0.19 ± 0.02 min-1 to 2.35 
± 0.19 min-1), which constituted large variations in hD2LR affinities (spanning over three orders of 
magnitude from Kd = 288 nM to 0.0549 nM). To further understand the relationship between kinetic 
rate constants and the affinity of D2R ligands, we have correlated the kinetic binding data of these 50 
compounds (kon, koff) with the derived equilibrium affinity estimates (pKd) (Figure 6A). Our data 
confirms that pKd is robustly correlated with association rate (see Figure 6A, Spearman’s r2 = 0.96, p 
> 0.0001), whereas pKd is, to a much lesser extent, correlated with dissociation rate (Figure 6B). 
These data are in contrast to previous studies claiming the differences in APD affinities are 
determined entirely by how fast they dissociate from the D2R.19 This is due to the fact that association 
rates have widely been assumed to be diffusion limited. Indeed, studies conducted at other systems, 
namely the M3 muscarinic acetylcholine and A2A adenosine receptors, have found correlations 
between koff values and affinity.62-64 However, the association rate constants of a series of 
metabotropic glutamate receptor 2 positive allosteric modulators were found to be strongly correlated 
to affinity, whereas dissociation rate constants were not.22 This correlation has also been observed at 
the orexin OX2 receptor and β2-adrenoreceptors for ligands with distinct chemotypes.65,66  
It is evident that modification to the scaffold of 1 and the corresponding changes in affinity are 
principally mediated by a change in the rate of association (Figure 6A). Though, our study highlights 
that particular structural moieties of 1 are more appropriate for the modification of both kinetic 
parameters towards a “slow on, fast off” profile. For example, when modification to the piperidinol 
moiety caused a loss in binding affinity relative to 1, this was predominantly kon mediated, whilst 
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having negligible effects on koff. However, modification of the p-fluorophenyl or linker moieties and 
subsequent losses in affinity saw greater changes in both kinetic rate constants, highlighting these 
areas as a focal point for future SKR investigations. In addition, we were able to derive preliminary 
SKR for the p-chlorophenyl moiety of 1. From our kinetic data obtained from a limited amount of 
compound structural/chemical diversity, we determined that both the electronic nature and position 
of substituents on the aromatic ring dictate the corresponding kinetic profile. We found that meta- 
and para-EWG groups (depending on compound affinity), can either slow the kon whilst having no 
effect on koff (8a, 8c, 8d), or equally, slow the kon whilst increasing koff (8b, 8f, 8g). Conversely, 
compounds bearing ortho-Cl substituents and that are not meta- or para-substituted, act to slow the 
kon but increase the koff (8e, 8n). This is also true for para-EDG substituents at these positions (8h, 8i, 
8k). It may be possible to use such molecules as templates in an attempt to further increase affinity 
via decoration of the aromatic termini, whilst maintaining an ‘attractive’ or slow on, fast off kinetic 
profile.
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Figure 6. Correlating kinetically derived equilibrium dissociation constants vs. kinetic rate 
constants of haloperidol (1) and 51 structural analogues at the dopamine D2 receptor.  (A) A 
plot of log kon vs. pKd demonstrates a statistically significant correlation (two-tailed Pearson’s 
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correlation r2 = 0.96, p = < 0.0001) between these two variables. (B) Conversely, a plot of pKd vs. log 
koff demonstrates a much poorer correlation (two-tailed Pearson’s correlation r2 = 0.34, p = < 0.0001) 
despite the traditional scientific consensus that APD affinity is solely driven by changes in koff. (C) 
The observed association rate (log kon) and calculated partition coefficient (cLogP) show no 
correlation (two-tailed Pearson’s correlation r2 = 0.007, p = 0.562). The central line corresponds to 
the linear regression of the data, the dotted lines represent the 95% confidence intervals for the 
regression. (D) Representing the diversity in affinity and corresponding kinetic profiles for analogues 
of 1. A plot of log koff vs. log kon represents a spectrum of compounds with various kinetic profiles 
(~10-fold difference in koff, ~30-fold difference in kon) identified from this study. Clozapine33 (2) and 
typical APD chlorpromazine33 are also included as reference points. These data identify several 
compounds with interesting ‘slow on, fast off’ kinetic profiles (14c, 30b, 34c, 36a). Combinations of 
kon and koff that result in identical affinity (Kd) values are represented by diagonal dotted lines. All 
data used in these plots apart from chlorpromazine are detailed in Tables 1-5. Data are presented as 
mean from at least four separate experiments.
The derived association rate of all compounds was further assessed for any potential correlation with 
physicochemical parameters such as clogP (Figure 6C) and topological polar surface area (tPSA) 
(Supplementary Figure 2), to which there was found to be no relationship. This is unsurprising as this 
study places particular emphasis on the kinetics of not only positional isomers between subsets of 
compounds, but close structural analogues which display very similar properties of size, lipophilicity 
and polarity. This further provides evidence that the observed changes to affinity and kinetic profile 
are not simply due to modification of physicochemical properties. These data are in contrast to 
previous observations at the D2R reporting that compounds with fast dissociation rates are less 
lipophilic and have lower molecular weights.67 This is notable as additional micro-
pharmacokinetic/pharmacodynamic mechanisms, such as ligand binding to the cell membrane, are 
known to play a role in target binding kinetics.68 Although it is widely accepted that increasing 
lipophilicity results in increased affinity, this study shows that for this subset of compounds this is 
not the case, highlighting that careful analysis of kinetic parameters is essential and also likely to be 
context/target dependent. 
Our recent proposal to expand the kinetic hypothesis for APD side effects considers not only the 
dissociation rate (and therefore the propensity to display insurmountable antagonism), but the 
association rate and subsequent potential for receptor rebinding.33 Based on this hypothesis, we 
proposed three broad classes of APDs in an attempt to explain how different kinetic characteristics 
have the potential to influence on-target side effects. Class 1: fast on/slow off compounds exemplified 
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by haloperidol (1), Class 2: fast on/fast off compounds, namely chlorpromazine, an early typical APD 
and Class 3: slow on/fast off compounds exemplified by clozapine (2). A fast association rate will 
result in a higher D2R rebinding potential in the striatum and consequently high EPS potential. In 
contrast, slow dissociation from D2Rs expressed on pituitary lactotrophs results in insurmountable 
antagonism leading to increased prolactin release (e.g. 1). These data suggest that the profile of 1, i.e. 
slow kon/fast koff kinetics as exhibited by 2, is optimal for APDs targeting D2Rs. Using the scaffold of 
1, we have shown that single structural modifications to one of four moieties produces structurally 
similar molecules with a spectrum of association and dissociation kinetic rate constants (Figure 6D), 
and several molecules have been identified (14c, 30b, 34c, 36a) that display interesting profiles 
resembling that of 2. Of the known literature compounds that were tested (8f, 8h-i. 8l, 14a-b, 14g, 
14k-l, 17a-b, 18, 42, 43, 47, 48, 53, 54), information regarding their EPS and hyperprolactinemia 
liabilities is absent. Our data highlights the importance of employing kinetic analyses in conjunction 
with other parameters toward the optimisation of APD drug leads. 
The identification of substituents and structural drivers that modulate kinetic profiles for the 
butyrophenone scaffold through a concurrent increase in kon and decrease in koff, such as EDGs on 
the p-chlorophenyl moiety, difluoro-substituents on the p-fluorophenyl moiety, replacing the ketone 
for a cis-cyclopropane, or the simple alteration of the alkyl linker length, may be used to ‘fine tune’ 
the design of novel compounds structurally similar to 1 with optimized kinetic parameters similar to 
that of atypical APD 2. Collectively, these data represent the first reported kinetic characterisation of 
analogues of 1 and clearly demonstrate that incorporation of kinetic binding parameter analyses into 
APD discovery programs may facilitate the identification of D2R antagonist APDs with an improved 
therapeutic window.
Structural basis for structure-kinetic relationships. Given the focused nature of our SKR study, with 
modifications grouped by different moieties present on 1 (Figure 2), it is possible to conduct a global 
analysis of the kinetic binding parameters obtained, in relation to these modifications. Such analysis 
might be a useful indicator in determining whether specific regions of the haloperidol scaffold are 
more sensitive to structural modification in terms of kon, koff and Ki (Figure 7). 
Page 30 of 78
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
31
O
N
OH
F
Cl
 kon ~ 304-fold
 koff ~ 2.8-fold
 Ki ~ 363-fold
 kon ~ 24-fold
 koff ~ 4.2-fold
 Ki ~ 63-fold
 kon ~ 383-fold
 koff ~ 4.1-fold
 Ki ~ 603-fold
 kon ~ 129-fold
 koff ~ 4.4-fold
 Ki ~ 562-fold
Figure 7. Summary of the range of kinetic binding parameters obtained for each region of 
structural modification to haloperidol (1). Values describe the fold-difference between the largest 
and smallest value for each parameter and grouped by the moiety of 1 that was modified.
It is interesting to note that modification of the p-fluorophenyl and butyrophenone moieties result in 
a broader range of kon values compared to those observed with the piperidinol and chlorophenyl 
moiety analogues. This may indicate that these regions play an important role in guiding ligand entry 
to the binding site. In contrast, the chlorophenyl moiety seems to be a relatively less important 
determinant of kon  and affinity.
The recently published structure of the D2R69 offers insight into the observed binding pose of the 
atypical APD risperidone at a thermostabilised D2R. Co-crystal structures offer a wealth of structural 
information about the interaction between the co-crystallised ligand and receptor under specific 
experimental conditions and are useful in correlating pharmacologically determined measurements 
of affinity with such interactions. Furthermore, ligand docking studies into such structures can 
identify receptor-ligand interactions that in part might determine kinetic parameters (particularly, 
koff).
However, co-crystal structures only offer a static snapshot of a low energy ligand-bound 
conformation of the receptor, which may not represent the conformation stabilised by a structurally 
distinct ligand scaffold. In contrast, entry and egress is a complex process that involves the interaction 
of both a flexible receptor and the ligand, and the journey of that ligand from the extracellular milieu 
to the binding site. Recent MD simulations have revealed that residues in the extracellular loop 
regions of GPCRs play an important role in this process.58,70,71 This is a highly dynamic region of the 
receptor and the static conformation observed in a crystal structure cannot provide the complete 
picture of the role of this region, thus future studies using long timescale MD simulations are needed 
to allow us to reconcile our present findings with this structural data.
Recently, MD simulations have been carried out, attempting to explore the ligand binding journeys 
of both haloperidol (1) and clozapine (2) at the D2R/D3R.58 Interestingly, the binding of 1 at the D2R 
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has been proposed to arise via a “handover” mechanism, whereby an initial key π-stacking interaction 
with Tyr7.35 (Ballesteros-Weinstein numbering scheme)72 allows this residue to act as a pivot point 
from which the ligand can explore the extracellular vestibule, followed by formation of a salt-bridge 
with Asp3.32.58 This mechanism appears to be reliant upon an optimal intramolecular distance between 
the p-fluorophenyl moiety of 1 and the protonated piperidinyl amine, thus changes in this distance 
through linker extension might be expected to influence orthosteric binding and the corresponding 
kinetic profile of the ligand (particularly kon). Our findings correlate with this observation, as 
homologues of 1 bearing either a propiophenone (34a) or valerophenone (34c) moiety, both exhibit 
relatively lower kon values (1.03 ± 0.18 × 107 M-1 min-1 and 1.42 ± 0.24 × 108 M-1 min-1 respectively). 
This is further reflected in the corresponding alkyl linker analogues (36a-c), whereby 36b (bearing a 
butylene linker – the corresponding de-oxo analogue of 1) retained the highest kon value compared to 
its homologues (36a and 36c, table 3).
However, whilst these simulations were unbiased, only two of those reported resulted in a complete 
binding trajectory (determined by the presence of an ionic interaction between Asp3.32 on each 
receptor and the protonated nitrogen atom of each ligand), which occurred at the D3R only. The D2R 
structure was not available at the time of this study, and a D3R crystal structure73 was used as the 
basis for both simulations, with generation of a D2R homology model for the D2R simulations. 
Notably, comparison of the D2R and D3R crystal structures reveals a considerably different 
arrangement of the extracellular domains.69
In order to further our understanding about the SKR reported in our study, our future work will focus 
on conducting advanced MD simulations using the recently reported D2R structure, with a view to 
correlating how subtle structural changes in the haloperidol analogues (imbuing distinct kinetic 
profiles) described above might influence interaction with specific residues which line the entry to 
and exit from the ligand binding site.
 CONCLUSIONS
In this study, we report the chemical synthesis and extensive kinetic profiling of 50 analogues of 
haloperidol (1) at the hD2LR, using a TR-FRET competition association kinetic binding assay, 
permitting the derivation of multiple equilibrium and kinetic parameters (pKi, pKd, kon and koff). All 
analogues retained the hD2LR antagonist action of 1 apart from 47 that gave a partial response relative 
to dopamine at a concentration of 10 µM. The kinetic profile was assessed with respect to 
predominantly single modification of one of four structural moieties of 1, namely the p-fluorophenyl, 
ketone and alkyl linker, piperidinol, and p-chlorophenyl moieties. Specifically, we observed the effect 
of both mono and di-halogen substituents on individual phenyl rings, as well as ketone and linker 
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modified variants, incorporating cis- and trans-olefins and their corresponding cyclopropanes, 
together with numerous alkanes and alkynes. In addition, we investigated the effect of modification 
to the tertiary alcohol, as well as incorporation of piperazinyl, tetrahydropyridinyl and other 
piperidinyl moieties. Importantly, we show that there is no correlation between kon and the 
physicochemical parameters clogP and TPSA, meaning that differences in kinetic profiles and 
corresponding compound affinities are not simply due to non-specific effects such as cell membrane 
binding. Moreover, we reveal that kon is significantly correlated with pKd, and is contrary to previous 
reports at the D2R. Thus, we found that a loss in binding affinity is generally associated with a 
decrease in kon. However, preliminary SKR derived for the p-chlorophenyl moiety of 1, demonstrates 
that particular substitution patterns and the nature of aromatic substituents are more likely to 
concurrently decrease kon whilst increasing koff. For example, chloro substituents at the ortho-position 
modulate the kinetic parameters toward a slow kon/fast koff profile, whereas meta and/or para-chloro 
substituents can either decrease the kon, whilst having no effect on koff, or, equally, they may also 
simultaneously decrease kon/koff. The p-fluorophenyl and ketone/alkyl linker structural moieties of 1 
were found to be important for mediating changes in both kinetic rate parameters, particularly the koff, 
whilst the piperidinol moiety was more linked to changes in kon only. For example, converting the 
aryl ketone to a cis-cyclopropane group or increasing/decreasing the linker length, significantly 
modulates both rate constants, whereas most modifications to the piperidinol ring simply modulate 
the kon. We show that with minimal variation this scaffold can be converted to the slow on, fast off 
kinetic profile that we hypothesise is characteristic of APDs with reduced on-target side effect profiles 
(e.g. 14c, 30b, 34c, 36a). These compounds may be used as tools to further explore the influence of 
kinetic rate parameters and their role in the corresponding clinical profile of APDs toward the 
development of novel efficacious treatments devoid of EPS and hyperprolactinemia. 
 EXPERIMENTAL SECTION
General Chemistry. Chemicals and solvents of analytical and HPLC grade were purchased from 
commercial suppliers and used without further purification. Reactions were monitored by thin-layer 
chromatography on commercially available silica pre-coated aluminium-backed plates (Merck 
Kieselgel 60 F254). Visualisation was under UV light (254 nm and 366 nm), followed by staining 
with ninhydrin or KMnO4 dips. Flash column chromatography was performed using silica gel 60, 
230-400 mesh particle size (Sigma Aldrich). NMR spectra were recorded on a Bruker-AV 400. 1H 
spectra were recorded at 400.13 Hz and 13C NMR spectra at 101.62 Hz. All 13C NMR are 1H 
broadband decoupled. Solvents used for NMR analysis (reference peaks listed) were CDCl3 supplied 
by Cambridge Isotope Laboratories Inc., (δH = 7.26 ppm, δC = 77.16) and CD3OD supplied by VWR 
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(δH = 3.31 ppm and δC = 49.00). Chemical shifts (δ) are recorded in parts per million (ppm) and 
coupling constants are recorded in Hz. The following abbreviations are used to described signal 
shapes and multiplicities; singlet (s), doublet (d), triplet (t), quadruplet (q), broad (br), dd (doublet of 
doublets), ddd (double doublet of doublets), dtd (double triplet of doublets) and multiplet (m). Spectra 
were assigned using appropriate COSY and HSQC experiments. Processing of the NMR data was 
carried out using the NMR software Topspin 3.0. RP-HPLC-MS spectra were recorded on a 
Shimadzu UFLCXR system coupled to an Applied Biosystems API2000 and visualised at 254 nm 
(channel 1) and 220 nm (channel 2). RP-HPLC-MS was carried out using a Phenomenex Gemini® 
NX-C18 110 Å, column (50 mm × 2 mm x 3 μm) at a flow rate 0.5 mL/min over a 5-min period 
(Method A). The retention time (tR) of the final product is reported using a gradient method of 5-95% 
solvent B in solvent A over 12 minutes. (Solvent A = 0.01% trifluoroacetic acid in H2O, solvent B = 
0.01% trifluoroacetic acid in CH3CN (Method B). All screening compounds were one single peak 
and determined to be >95% purity at both 254 nm and 220 nm using Method B.  All high-resolution 
mass spectra (HRMS) were recorded on a Bruker microTOF mass spectrometer using MS 
electrospray ionization operating in positive ion mode. Preparative RP-HPLC was performed on a 
Waters 515 LC system and monitored using a Waters 996 photodiode array detector at wavelengths 
between 190 and 800 nm. Spectra were analysed using Millenium 32 software. Preparative RP-HPLC 
was performed using a Gemini® NX-C18 110 Å column (250 mm × 21.2 mm × 5 μm) at a flow rate 
of 20.0 mL/min using a gradient method of 5-95% B over 15 minutes (Solvent A = 0.01% 
trifluoroacetic acid in H2O, solvent B = 0.01% trifluoroacetic in CH3CN (Method C)). Predicted 
partition coefficient (cLogP) values were calculated using Data Warrior 4.7.2, Actelion 
Pharmaceutical Ltd.
General Procedure A. n-Butyllithium mediated addition of aryllithiums to ketones for the 
preparation of 5a-m. To a stirred solution of substituted bromobenzene (3a-l) (1.35 equiv.) in THF 
at -78 C was added n-butyllithium (1.30 equiv.) and the reaction maintained at -78 C for 30 min. 
After this, a solution of ketone (1 equiv.) in THF was slowly introduced into the reaction and stirred 
at -78 C for 2 h. The reaction was quenched with the addition of a saturated solution of NH4Cl and 
transferred to a separating funnel and extracted with DCM (3  40 mL). The organic extracts were 
dried (anhydrous Na2SO4) and the residue purified by column chromatography using PE/EtOAc in a 
ratio as indicated to afford the desired compound. 
General procedure B. N-Boc deprotection for the preparation of 6a-n. The N-Boc protected 
amine was taken up in 4 M HCl in 1,4-dioxane (20 mL) and stirred at r.t. for 2 h. The solvents were 
evaporated in vacuo to afford the corresponding amine hydrochloride. Alternatively, the residue could 
be taken up in H2O (20 mL) and added to a separating funnel. The aqueous solution was washed with 
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Et2O (3  30 mL), and the aqueous phase made alkaline with the addition of 2 M NaOH solution. 
This phase was then extracted with DCM (3  30 mL) and the organic extracts collected, dried over 
anhydrous Na2SO4 and evaporated in vacuo to afford the corresponding amine free base.
General Procedure C. N-Alkylation for the preparation of 8a-n, 14a-l, 17a-b, 18, 23, 26, 29b, 
30b, 34a, 34c, 36a-c, 41a-c, 42-43, 45-48, 52, 53, 54. To a round-bottom flask or sealed microwave 
vessel was added the amine (1.1 equiv.), alkyl halide or mesylate (1 equiv.), KI (0.1 equiv.) and 
NaHCO3 (2 equiv.) followed by toluene. This suspension was then heated at reflux temperature for 
24 h. The reaction was filtered and evaporated to dryness followed by direct chromatographic 
purification using an appropriate eluent as indicated.
General Procedure D. Sonogashira cross-coupling of aryl iodides for the preparation of 12a-j, 
40b. PdCl2(PPh3)2 (1 mol %) and copper(I) iodide (2 mol %) were placed in a 50 mL round-bottomed 
flask equipped with a magnetic bar and then non-dried 1,4-dioxane (10 mL), the corresponding iodide 
(1.0 equiv.), 4-chloro-1-butyne (1.2 equiv.), and triethylamine (5.0 equiv.) were added. The flask was 
capped with a rubber septum, and the resulting mixture was magnetically stirred at 50 °C for 2-6 h. 
The reaction was diluted with Et2O (100 mL) after cooling, removing the solids by filtration. The 
resulting solution was purified by column chromatography (petroleum ether) to yield the 
corresponding alkyne product.
General Procedure E. Sonogashira cross-coupling of aryl iodides for the preparation of 39a, 
39c. To a N2-degassed solution of CH3CN and triethylamine (2.0 equiv.) were added alkyne (1.1 
equiv.), the appropriate iodobenzene (1.0 equiv.), Pd(PPh3)2Cl2 (2% mol) and CuI (2% mol), and the 
mixture was stirred at room temperature for 5 hr. The reaction was diluted with Et2O, filtered, 
concentrated, and purified on silica gel (n-hexanes). 
General Procedure F. Triflic acid-catalysed Markovnikov-type hydration of internal alkynes 
for the preparation of 13a-j. The purified alkyne was treated with triflic acid (0.5 equiv.) and H2O 
(2 equiv) in 2,2,2-trifluoroethanol in a sealed vial equipped with a magnetic stirring bar, and stirred 
at 60 C for 6 h. The reaction mixture was concentrated under reduced pressure and the corresponding 
ketone directly purified by FCC with an appropriate eluent as indicated. 
General procedure G. Alcohol mesylation for the preparation of 22, 27, 29a, 30a, 40a, 40c). To 
a solution of alcohol (1 equiv.), Et3N (2.5 equiv.), in DCM was added at room temperature MsCl (1.3 
equiv.). The mixture was stirred at room temperature for 1.5-24 h until complete consumption of 
starting material was evident. The mixture was diluted with EtOAc, washed with H2O, brine, and the 
organic fraction dried (Na2SO4). The solvents were removed in vacuo and the residue 
chromatographed on silica eluting with the appropriate solvent as indicated. Similarly, and in many 
cases, the residue could be used for the next reaction without the need for purification. 
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tert-Butyl 4-(4-chlorophenyl)-4-hydroxypiperidine-1-carboxylate (5a). General procedure A. 
Purification by FCC (eluent: EtOAc/hexane 0-40%) gave 7.64 g of a white foam (74%). LCMS (m/z): 
312.1 [M+H]+, tR 2.95 min. 1H NMR (CDCl3) δ 7.43 – 7.38 (m, 2H), 7.34 – 7.30 (m, 2H), 4.08 – 3.91 
(m, 2H), 3.21 (td, J = 13.0, 2.7 Hz, 2H), 1.94 (td, J = 13.3, 4.9 Hz, 2H), 1.75 (s, 1H), 1.69 (dq, J = 
14.2, 2.8 Hz, 2H), 1.47 (s, 9H). 13C NMR (CDCl3) δ 154.9, 146.7, 133.2, 128.7, 126.2, 79.8, 71.5, 
39.9, 38.2, 28.6.
tert-Butyl 4-(3-chlorophenyl)-4-hydroxypiperidine-1-carboxylate (5b). General procedure A. 
Purification by FCC (eluent: EtOAc/hexane 0-40%) gave 1.25 g of a white solid (69.1%). LCMS 
(m/z): 312.1 [M+H]+, tR 2.95 min. 1H NMR (CDCl3) δ 7.51 (t, J = 1.8 Hz, 1H), 7.35 (dt, J = 7.6, 1.6 
Hz, 1H), 7.30 (t, J = 7.6 Hz, 1H), 7.25 (dt, J = 7.7, 1.7 Hz, 1H), 4.03 (ddt, J = 13.4, 4.2, 1.7 Hz, 2H), 
3.23 (td, J = 13.0, 2.7 Hz, 2H), 2.03 (s, 1H), 1.96 (td, J = 13.3, 4.9 Hz, 2H), 1.77 – 1.66 (m, 2H), 1.49 
(s, 9H). 13C NMR (CDCl3) δ 154.9, 150.4, 134.5, 129.8, 127.4, 125.2, 122.9, 79.8, 71.5, 39.9, 38.1, 
28.6. 
tert-Butyl 4-(2,3-dichlorophenyl)-4-hydroxypiperidine-1-carboxylate (5c). General procedure A. 
Purification by FCC (eluent: EtOAc/hexane 0-40%) gave 1.87 g of a white solid (65.9%). LCMS 
(m/z): 346.1 [M+H]+, tR 3.05 min. 1H NMR (CDCl3) δ 7.55 (dd, J = 8.0, 1.6 Hz, 1H), 7.49 (dd, J = 
8.0, 1.6 Hz, 1H), 7.35 – 7.26 (m, 1H), 4.15 – 4.05 (m, 2H), 3.33 (td, J = 13.0, 2.7 Hz, 2H), 2.38 – 
2.27 (m, 2H), 2.07 – 1.98 (m, 2H), 1.54 (s, 9H), 1.51 (s, 1H). 13C NMR (CDCl3) δ 155.0, 145.7, 135.2, 
130.2, 129.9, 127.7, 125.4, 79.7, 72.9, 39.9, 35.3, 28.6.
tert-Butyl 4-(2,4-dichlorophenyl)-4-hydroxypiperidine-1-carboxylate (5d). General procedure A. 
Purification by FCC (eluent: EtOAc/hexane 0-40%) gave 1.30 g of a transparent oil (71%). LCMS 
(m/z): 346.1 [M+H]+, tR 3.02 min. 1H NMR (CDCl3) δ 7.27 (d, J = 8.0 Hz, 2H), 7.03 (t, J = 8.0 Hz, 
1H), 4.01 (s, 2H), 3.42 (s, 1H), 3.23 (s, 2H), 2.76 (td, J = 13.2, 5.0 Hz, 2H), 1.90 (d, J = 12.9 Hz, 2H), 
1.44 (s, 9H). 13C NMR (CDCl3) δ 155.0, 145.2, 133.4, 133.0, 129.9, 128.7, 127.7, 79.8, 72.4, 35.0, 
28.6.
tert-Butyl 4-(2,5-dichlorophenyl)-4-hydroxypiperidine-1-carboxylate (5e). General procedure A. 
Purification by FCC (eluent: EtOAc/hexane 0-40%) gave 1.48 g of a white solid (68%). LCMS (m/z): 
346.3 [M+H]+, tR 3.02 min.1H NMR (CDCl3) δ 7.59 (d, J = 2.5 Hz, 1H), 7.29 (d, J = 8.5 Hz, 1H), 
7.18 (dd, J = 8.4, 2.5 Hz, 1H), 4.09 – 4.00 (m, 2H), 3.28 – 3.21 (m, 2H), 2.83 (d, J = 1.0 Hz, 1H), 
2.32 (td, J = 13.3, 4.9 Hz, 2H), 1.84 (d, J = 13.4 Hz, 2H), 1.47 (s, 9H). 13C NMR (CDCl3) δ 155.0, 
145.2, 133.4, 133.0, 129.9, 128.7, 127.7, 79.8, 72.4, 35.0, 28.6.
tert-Butyl 4-(2,6-dichlorophenyl)-4-hydroxypiperidine-1-carboxylate (5f). General procedure A. 
Purification by FCC (eluent: EtOAc/hexane 0-40%) gave 1.72 g of a transparent oil (76%). LCMS 
(m/z): 346.1 [M+H]+, tR 3.03 min. 1H NMR (CDCl3) δ 7.32 (d, J = 8.0 Hz, 2H), 7.12 – 7.03 (m, 1H), 
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4.02 (dd, J = 13.2, 4.8 Hz, 2H), 3.26 (td, J = 12.9, 2.8 Hz, 2H), 2.81 (td, J = 13.2, 5.0 Hz, 2H), 2.01 
– 1.89 (m, 2H), 1.48 (s, 9H). 13C NMR (CDCl3) δ 155.1, 140.1, 133.8, 132.1, 128.4, 79.6, 76.1, 39.9, 
35.7, 28.6.
tert-Butyl 4-(3,4-dichlorophenyl)-4-hydroxypiperidine-1-carboxylate (5g). General procedure A. 
Purification by FCC (eluent: EtOAc/hexane 0-40%) gave 1.25 g of a white foam (73.4%). LCMS 
(m/z): 346.2 [M+H]+, tR 3.06 min. 1H NMR (CDCl3) δ 7.59 (d, J = 2.2 Hz, 1H), 7.38 (d, J = 8.4 Hz, 
1H), 7.26 (dd, J = 8.4, 2.2 Hz, 1H), 3.97 (dt, J = 12.9, 3.3 Hz, 2H), 3.19 (t, J = 12.9 Hz, 2H), 1.86 (td, 
J = 13.2, 4.8 Hz, 2H), 1.71 – 1.65 (m, 2H), 1.46 (s, 1H), 1.44 (s, 9H). 13C NMR (CDCl3) δ 154.9, 
148.9, 132.4, 130.9, 130.3, 127.2, 124.3, 79.8, 70.9, 42.9, 36.6, 28.5.
tert-Butyl 4-(3,5-dichlorophenyl)-4-hydroxypiperidine-1-carboxylate (5h). General procedure A. 
Purification by FCC (eluent: EtOAc/hexane 0-40%) gave 2.22 g of a white solid (78.2%). LCMS 
(m/z): 345.9 [M+H]+, tR 3.09 min. 1H NMR (CDCl3) δ 7.35 (d, J = 1.9 Hz, 2H), 7.24 (t, J = 1.9 Hz, 
1H), 4.01 (ddt, J = 13.5, 4.7, 1.8 Hz, 21H), 3.18 (td, J = 13.1, 2.7 Hz, 2H), 2.22 (s, 1H), 1.90 (td, J = 
13.3, 4.9 Hz, 2H), 1.71 – 1.62 (m, 2H), 1.45 (s, 9H).  13C NMR (CDCl3) δ 154.9, 151.9, 135.2, 127.3, 
123.7, 79.9, 71.5, 39.8, 38.1, 28.6.
tert-Butyl 4-hydroxy-4-phenylpiperidine-1-carboxylate (5i). General procedure A. Purification by 
FCC (eluent: EtOAc/hexane 0-40%) gave 1.49 g of a white foam (76%). LCMS (m/z): 278.1 [M+H]+, 
tR 2.83 min. 1H NMR (CDCl3) δ 7.53 – 7.45 (m, 2H), 7.43 – 7.33 (m, 2H), 7.34 – 7.24 (m, 1H), 4.03 
(ddt, J = 13.3, 4.4, 1.8 Hz, 2H), 3.26 (td, J = 13.1, 2.7 Hz, 2H), 2.01 (td, J = 13.4, 4.9 Hz, 2H), 1.84 
(s, 1H), 1.50 (s, 9H). 13C NMR (CDCl3) δ 154.9, 148.1, 128.5, 127.2, 124.5, 79.5, 71.5, 39.9, 38.1, 
28.5.
tert-Butyl 4-hydroxy-4-(p-tolyl)piperidine-1-carboxylate (5j). General procedure A. Purification 
by FCC (eluent: EtOAc/hexane 0-40%) gave 1.29 g of white foam (68%). LCMS (m/z): 292.2 
[M+H]+, tR 2.93 min. 1H NMR (CDCl3) δ 7.37 – 7.33 (m, 2H), 7.17 (dt, J = 7.9, 0.7 Hz, 2H), 3.99 
(dt, J = 13.1, 2.6 Hz, 2H), 3.23 (td, J = 13.1, 2.7 Hz, 2H), 2.34 (s, 3H), 1.96 (td, J = 13.4, 4.9 Hz, 2H), 
1.84 – 1.78 (m, 1H), 1.76 – 1.66 (m, 2H), 1.47 (s, 9H). 13C NMR (CDCl3) δ 155.0, 145.3, 136.9, 
129.2, 124.5, 79.6, 71.4, 40.0, 38.3, 28.6, 21.1.
tert-Butyl 4-hydroxy-4-(4-(trifluoromethyl)phenyl)piperidine-1-carboxylate (5k). General 
procedure A. Purification by FCC (eluent: EtOAc/hexane 0-40%) gave 1.43 g of a white foam (84%). 
LCMS (m/z): 346.2 [M+H]+, tR 3.00 min. 1H NMR (CDCl3) δ 7.60 (m, 4H), 4.04 (ddt, J = 13.7, 4.6, 
1.8 Hz, 2H), 3.22 (td, J = 13.0, 2.6 Hz, 2H), 1.98 (td, J = 13.3, 4.9 Hz, 2H), 1.75 – 1.66 (m, 2H), 1.47 
(s, 9H), 1.35 – 1.27 (m, 1H). 13C NMR (CDCl3) δ 154.9, 152.2 (d, J = 1.5 Hz), 129.6 (q, J = 32.5 Hz), 
125.5 (q, J = 3.8 Hz), 125.1, 124.2 (q, J = 272.1 Hz), 79.9, 71.7, 39.8, 38.1, 28.6.
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tert-Butyl 4-(4-(dimethylamino)phenyl)-4-hydroxypiperidine-1-carboxylate (5l). General 
procedure A. Purification by FCC (eluent: EtOAc/hexane 0-40%) gave 1.22 g of white solid (69%). 
LCMS (m/z): 321.0 [M+H]+, tR 2.51 min. 1H NMR (CDCl3) δ 7.34 (d, J = 8.9 Hz, 2H), 6.73 (d, J = 
8.5 Hz, 2H), 3.96 (s, 2H), 3.25 (t, J = 11.6 Hz, 2H), 2.94 (s, 6H), 2.03 – 1.88 (m, 2H), 1.79 – 1.71 (m, 
2H), 1.47 (s, 9H). 13C NMR (CDCl3) δ 155.1, 129.2, 128.3, 125.7, 112.6, 79.5, 71.1, 40.8, 28.6, 28.6.
tert-Butyl 4-(4-fluorophenyl)-4-hydroxypiperidine-1-carboxylate (5m). General procedure A. 
Purification by FCC (eluent: EtOAc/hexane 0-40%) gave 1.24 g of transparent oil (71%). 1H NMR 
(CDCl3) δ 7.42 – 7.35 (m, 2H), 6.94 (t, J = 8.7 Hz, 2H), 3.88 (dd, J = 12.8, 4.4 Hz, 2H), 3.22 – 3.09 
(m, 2H), 3.07 (s, 1H), 1.83 (td, J = 13.2, 4.7 Hz, 2H), 1.64 (dd, J = 14.1, 2.5 Hz, 2H), 1.39 (s, 9H). 
13C NMR (CDCl3) δ 161.8 (d, J = 245.3 Hz), 154.9, 144.3 (d, J = 3.1 Hz), 126.4 (d, J = 7.9 Hz), 114.9 
(d, J = 21.2 Hz), 79.6, 70.9, 38.1, 28.4.
tert-Butyl 4-(2'-chloro-[1,1'-biphenyl]-2-yl)-4-hydroxypiperidine-1-carboxylate (5m). General 
procedure A. Purification by FCC (eluent: EtOAc/hexane 0-40%) gave 700 mg of a white solid 
(55%). Reaction by-product from the attempted synthesis of TF-01-62. LCMS (m/z): 388.1 [M+H]+, 
tR 3.12 min. 1H NMR (CDCl3) δ 7.51 (dd, J = 8.0, 1.3 Hz, 1H), 7.49 – 7.41 (m, 1H), 7.40 (td, J = 7.7, 
1.6 Hz, 1H), 7.29 (dtd, J = 10.5, 6.2, 5.6, 2.9 Hz, 4H), 7.01 (dd, J = 7.5, 1.5 Hz, 1H), 3.89 (dddd, J = 
15.5, 13.2, 5.0, 2.6 Hz, 2H), 3.06 (qd, J = 12.4, 2.7 Hz, 2H), 2.09 – 1.98 (m, 1H), 1.96 – 1.85 (m, 
1H), 1.74 (ddd, J = 13.8, 11.4, 2.7 Hz, 2H), 1.44 (s, 9H). 13C NMR (CDCl3) δ 154.9, 145.0, 142.9, 
137.3, 133.5, 132.3, 131.0, 129.5 128.8, 128.2, 126.9, 126.4, 126.3, 79.5, 73.6, 38.6, 38.2, 28.6.
tert-Butyl 4-(2-chlorophenyl)-4-hydroxypiperidine-1-carboxylate (5n). To a stirred solution of 1-
bromo-2-chloro-benzene (609 L, 5.22 mmol) in Et2O was added magnesium turnings (150 mg, 6.17 
mmol), followed by catalytic iodide and the reaction stirred at room temperature for 2 h. This mixture 
was then cooled to 0°C, and treated with 4-oxopiperidine-1-carboxylic acid tert-butyl ester (946 mg, 
4.75 mmol) dissolved in Et2O (10 mL) and added to the reaction mixture slowly. The reaction was 
heated at reflux temperature for 3 h. The reaction was quenched with a saturated solution NH4Cl and 
the aqueous phase extracted with EtOAc. The organic extracts were combined and dried over MgSO4, 
filtered and evaporated in vacuo. The residue was purified by FCC (eluent: EtOAc/n-hexanes 0-40%) 
and gave 800 mg of a white foam (54%). LCMS (m/z): 312.2 [M+H]+, tR 2.97 min. 1H NMR (CDCl3) 
δ 7.56 (dd, J = 7.9, 1.8 Hz, 1H), 7.30 (dd, J = 7.8, 1.5 Hz, 1H), 7.21 (td, J = 7.6, 1.5 Hz, 1H), 7.15 
(td, J = 7.5, 1.7 Hz, 1H), 3.96 (dd, J = 13.4, 4.8 Hz, 2H), 3.22 (t, J = 12.9 Hz, 2H), 3.05 (s, 1H), 2.29 
(td, J = 13.2, 4.9 Hz, 2H), 1.87 – 1.78 (m, 2H), 1.43 (s, 9H). 13C NMR (CDCl3) δ 154.9, 143.5, 131.7, 
131.5, 128.6, 127.2, 127.1, 79.5, 72.2, 39.8, 34.9, 28.5.
4-(3-Chlorophenyl)piperidin-4-ol (6a). General procedure B. Alkaline work-up afforded 660 mg of 
a white solid (97%). LCMS (m/z): 212.0 [M+H]+, tR 0.74 min. 1H NMR (CDCl3) δ 7.52 (t, J = 1.9 
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Hz, 1H), 7.37 (dt, J = 7.7, 1.5 Hz, 1H), 7.29 (t, J = 7.8 Hz, 1H), 7.24 (dt, J = 7.9, 1.7 Hz, 1H), 3.10 
(td, J = 12.3, 2.6 Hz, 2H), 2.99 – 2.90 (m, 2H), 2.42 (d, J = 9.1 Hz, 2H), 1.97 (td, J = 13.2, 4.6 Hz, 
2H), 1.70 (dd, J = 14.1, 2.5 Hz, 2H). 13C NMR (CDCl3) δ 151.2, 134.4, 129.8, 127.1, 125.2, 122.9, 
71.4, 42.2, 39.1.
4-(2,3-Dichlorophenyl)-4-hydroxypiperidin-1-ium chloride (6b). General procedure B. 
Concentration in vacuo gave 685 mg of a beige solid (94%). LCMS (m/z): 246.0 [M+H]+, tR 2.53 
min. 1H NMR (DMSO-d6) δ 9.19 (d, J = 55.0 Hz, 2H), 7.75 (dd, J = 8.1, 1.7 Hz, 1H), 7.60 (dd, J = 
8.0, 1.6 Hz, 1H), 7.40 (t, J = 8.0 Hz, 1H), 5.88 (s, 1H), 3.20 (s, 4H), 2.74 (dt, J = 14.1, 8.9 Hz, 2H), 
1.80 (dd, J = 14.3, 2.4 Hz, 2H). 13C NMR (DMSO-d6) δ 146.4, 133.4, 129.7, 128.8, 128.0, 126.8, 
69.8, 30.5.
4-(2,4-Dichlorophenyl)piperidin-4-ol (6c). General procedure B. Alkaline work-up afforded 325 
mg of a white solid (65 %). LCMS (m/z): 246.0 [M+H]+, tR 2.65 min. 1H NMR (CDCl3) δ 7.27 (dd, 
J = 8.0, 1.9 Hz, 2H), 7.01 (td, J = 8.0, 2.1 Hz, 1H), 3.20 – 3.09 (m, 2H), 2.96 – 2.84 (m, 2H), 2.80 – 
2.66 (m, 3H), 1.91 (dt, J = 14.0, 2.4 Hz, 2H). 13C NMR (CDCl3) δ 140.9, 133.9, 131.9, 131.9, 127.9, 
76.0, 42.1, 36.6.
4-(2,5-Dichlorophenyl)-4-hydroxypiperidin-1-ium chloride (6d). General procedure B. 
Concentration in vacuo gave 180 mg of a white solid (98%). LCMS (m/z): 246.2 [M+H]+, tR 1.34 
min.1H NMR (DMSO-d6) δ 9.42 – 8.91 (m, 2H), 7.79 (d, J = 2.6 Hz, 1H), 7.45 (d, J = 8.4 Hz, 1H), 
7.39 (dd, J = 8.5, 2.6 Hz, 1H), 5.98 (s, 1H), 3.23 – 3.11 (m, 4H), 2.77 (dt, J = 14.1, 9.0 Hz, 2H), 1.70 
(d, J = 13.9 Hz, 2H).13C NMR (DMSO-d6) δ 146.1, 133.2, 132.1, 129.1, 128.8, 128.0, 69.4, 39.2, 
30.3.
4-(2,6-Dichlorophenyl)piperidin-4-ol (6e). General procedure B. Alkaline work-up afforded 682 
mg of a white solid (96%). LCMS (m/z): 246.0 [M+H]+, tR 0.88 min. 1H NMR (DMSO-d6) δ 8.93 (d, 
J = 60.3 Hz, 2H), 7.45 (d, J = 7.9 Hz, 2H), 7.28 (dd, J = 8.4, 7.5 Hz, 1H), 5.67 (s, 1H), 3.21 (s, 4H), 
2.90 – 2.76 (m, 2H), 2.16 (d, J = 13.7 Hz, 2H). 13C NMR (DMSO-d6) δ 139.9, 133.6, 132.0, 129.2, 
72.0, 32.1.
4-(3,4-Dichlorophenyl)piperidin-4-ol (6f). General procedure B. Alkaline work-up afforded 702 mg 
of a white solid (98%). LCMS (m/z): 246.0 [M+H]+, tR 1.86 min. 1H NMR (CDCl3) δ 7.61 (d, J = 2.2 
Hz, 1H), 7.40 (d, J = 8.4 Hz, 1H), 7.30 (dd, J = 8.4, 2.2 Hz, 1H), 3.07 (td, J = 12.3, 2.7 Hz, 2H), 2.97 
– 2.90 (m, 2H), 2.21 (s, 2H), 1.94 (ddd, J = 13.6, 12.2, 4.8 Hz, 2H), 1.70 – 1.63 (m, 2H). 13C NMR 
(CDCl3) δ 149.3, 132.4, 130.8, 127.1, 124.2, 71.2, 42.1, 38.9.
4-(3,5-Dichlorophenyl)-4-hydroxypiperidin-1-ium chloride (6g). General procedure B. 
Concentration in vacuo gave 755 mg of a white solid (93%). LCMS (m/z): 246.0 [M+H]+, tR 2.62 
min. 1H NMR (DMSO-d6) δ 9.03 (s, 2H), 7.52 (t, J = 1.9 Hz, 1H), 7.45 (d, J = 1.9 Hz, 2H), 5.79 (s, 
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1H), 3.17 (dtd, J = 22.5, 12.8, 11.9, 7.0 Hz, 4H), 2.26 (td, J = 13.5, 5.0 Hz, 2H), 1.74 (dd, J = 13.9, 
2.3 Hz, 2H). 13C NMR (DMSO-d6) δ 152.7, 134.0, 126.5, 123.7, 68.5, 33.9.
4-Phenylpiperidin-4-ol (6h). General procedure B. Alkaline work-up afforded 622 mg of a white 
solid (97%). LCMS (m/z): 178.2 [M+H]+, tR 0.42 min. 1H NMR (CDCl3) δ 7.55 – 7.48 (m, 2H), 7.41 
– 7.32 (m, 2H), 7.31 – 7.22 (m, 1H), 3.10 (dd, J = 12.2, 2.6 Hz, 2H), 2.98 – 2.89 (m, 2H), 2.22 (s, 
2H), 2.00 (ddd, J = 13.5, 12.2, 4.6 Hz, 2H), 1.75 – 1.69 (m, 2H). 13C NMR (CDCl3) δ 149.1, 128.4, 
126.9, 124.6, 71.5, 42.4, 39.3.
4-(p-Tolyl)piperidin-4-ol (6i). General procedure B. Alkaline work-up afforded 621 mg of a white 
solid (95%). LCMS (m/z): 192.1 [M+H]+, tR 0.62 min. 1H NMR (CDCl3) δ 7.37 (d, J = 8.3 Hz, 2H), 
7.15 (d, J = 8.0 Hz, 2H), 3.07 (dd, J = 12.2, 2.7 Hz, 2H), 2.92 – 2.86 (m, 2H), 2.42 – 2.26 (m, 5H), 
1.96 (td, J = 13.0, 4.6 Hz, 2H), 1.69 (dd, J = 14.1, 2.6 Hz, 2H). 13C NMR (CDCl3) δ 146.2, 136.5, 
129.1, 124.6, 71.2, 42.4, 39.3, 21.0.
4-(4-(Trifluoromethyl)phenyl)piperidin-4-ol (6j). General procedure B. Alkaline work-up afforded 
702 mg of a light yellow solid (92%). LCMS (m/z): 246.1 [M+H]+, tR 1.41-1.82 min. 1H NMR 
(CDCl3) δ 7.66 – 7.56 (m, 4H), 3.11 (td, J = 12.3, 2.6 Hz, 2H), 3.01 – 2.92 (m, 2H), 2.20 – 2.07 (m, 
2H), 2.01 (ddd, J = 13.5, 12.3, 4.8 Hz, 2H), 1.74 – 1.65 (m, 2H). 13C NMR (CDCl3) δ 152.9, 129.3 
(q, J = 32.4 Hz), 125.4 (q, J = 3.7 Hz), 125.1, 71.7, 42.3, 39.2.
4-(4-(Dimethylamino)phenyl)piperidin-4-ol (6k). General procedure B. Alkaline work-up afforded 
675 mg of a light orange solid (98%). LCMS (m/z): 221.2 [M+H]+, tR 0.31 min. 1H NMR (CDCl3) δ 
7.40 – 7.31 (m, 2H), 6.76 – 6.68 (m, 2H), 3.09 (td, J = 12.1, 2.7 Hz, 2H), 2.93 (s, 6H), 2.90 (dt, J = 
11.9, 3.5 Hz, 2H), 2.07 (s, 2H), 1.96 (ddd, J = 13.3, 11.9, 4.5 Hz, 2H), 1.77 – 1.68 (m, 2H). 13C NMR 
(CDCl3) δ 149.6, 136.9, 125.4, 112.4, 70.9, 42.5, 40.7, 39.3.
4-(4-Fluorophenyl)piperidin-4-ol (6l). General procedure B. Alkaline work-up afforded 600 mg of 
a light yellow solid (92%). LCMS (m/z): 196.2 [M+H]+, tR 0.42 min.1H NMR (CDCl3) δ 7.47 – 7.42 
(m, 2H), 7.01 (t, J = 8.7 Hz, 2H), 3.07 (td, J = 12.2, 2.6 Hz, 2H), 2.91 (ddd, J = 12.6, 4.2, 2.1 Hz, 
2H), 1.95 (td, J = 13.0, 4.7 Hz, 2H), 1.69 (dd, J = 14.1, 2.6 Hz, 2H). 13C NMR (CDCl3) δ 161.9 (d, J 
= 245.2 Hz), 144.9 (d, J = 3.0 Hz), 126.4 (d, J = 8.0 Hz), 115.1 (d, J = 21.1 Hz), 71.4, 42.5, 39.5.
4-(2'-Chloro-[1,1'-biphenyl]-2-yl)piperidin-4-ol (6m). General procedure B. Alkaline work-up 
afforded 200 mg of a white solid (95%). LCMS (m/z): 288.0 [M+H]+, tR 2.06 min. 1H NMR (CDCl3) 
δ 7.61 (dd, J = 8.1, 1.3 Hz, 1H), 7.49 – 7.41 (m, 1H), 7.44 – 7.37 (m, 1H), 7.35 – 7.25 (m, 4H), 7.02 
(dd, J = 7.6, 1.5 Hz, 1H), 3.05 – 2.95 (m, 2H), 2.90 – 2.81 (m, 2H), 2.37 (s, 2H), 2.09 (ddd, J = 13.9, 
12.2, 4.6 Hz, 1H), 1.98 (ddd, J = 13.7, 12.2, 4.7 Hz, 1H), 1.78 (ddt, J = 13.5, 10.5, 2.7 Hz, 2H). 13C 
NMR (CDCl3) δ 145.6, 143.1, 137.2, 133.4, 132.2, 131.1, 129.4, 128.6, 128.2, 126.7, 126.5, 126.2, 
73.5, 39.2, 38.8.
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4-(2-Chlorophenyl)piperidin-4-ol (6n). General procedure B. Alkaline work-up afforded 285 mg of 
a white solid (72 %). LCMS (m/z): 2121 [M+H]+, tR 0.48 min. 1H NMR (CDCl3) δ 7.57 (dd, J = 7.9, 
1.8 Hz, 1H), 7.34 (dd, J = 7.8, 1.5 Hz, 1H), 7.25 (td, J = 7.6, 1.5 Hz, 1H), 7.18 (td, J = 7.6, 1.8 Hz, 
1H), 3.15 (td, J = 12.4, 2.7 Hz, 2H), 2.99 – 2.89 (m, 2H), 2.63 (s, 1H), 2.29 (ddd, J = 13.4, 12.3, 4.7 
Hz, 2H), 1.96 – 1.86 (m, 2H). 13C NMR (CDCl3) δ 144.2, 131.9, 131.8, 128.5, 127.3, 127.2, 72.4, 
42.2, 36.3.
4-(4-Chlorophenyl)piperidin-4-ol (7b). General procedure B. Alkaline work-up afforded 1.62 g of 
a beige solid (96%). LCMS (m/z): 311.1 [M+H]+, tR 0.76 min. 1H NMR (CDCl3) δ 7.43 – 7.38 (m, 
2H), 7.32 – 7.27 (m, 2H), 3.05 (td, J = 12.3, 2.7 Hz, 2H), 2.91 – 2.84 (m, 2H), 2.18 (s, 2H, broad), 
1.91 (ddd, J = 13.4, 12.2, 4.7 Hz, 2H), 1.71 – 1.60 (m, 2H). 13C NMR (CDCl3) δ 147.7, 132.7, 128.5, 
126.2, 71.3, 42.3, 39.3.
4-(4-(3-Chlorophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one (8a). General 
procedure C. Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 91 mg of the title 
compound as a white solid (68%). LCMS (m/z): 376.2 [M+H]+, tR 3.37 min. HRMS (m/z): 
C21H23ClFNO2: requires 376.1505 [M+H]+; found 376.1546. 1H NMR (CDCl3) δ 8.02 (t, J = 6.7 Hz, 
2H), 7.44 (s, 1H), 7.35 – 7.18 (m, 3H), 7.14 (t, J = 8.4 Hz, 2H), 2.98 (t, J = 7.0 Hz, 2H), 2.78 (d, J = 
11.4 Hz, 2H), 2.55 – 2.35 (m, 4H), 2.06 – 1.90 (m, 5H), 1.67 (d, J = 13.6 Hz, 2H). 13C NMR (CDCl3) 
δ 198.5, 165.7 (d, J = 254.5 Hz), 150.7, 134.4, 133.8 (d, J = 3.1 Hz), 130.8 (d, J = 9.2 Hz), 129.7, 
127.2, 125.2, 122.9, 115.8 (d, J = 21.7 Hz), 71.3, 57.9, 49.4, 38.5, 36.4, 22.1.
4-(4-(2,3-Dichlorophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one (8b). 
General procedure C. Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 82 mg of 
the title compound as a white solid (68%). LCMS (m/z): 410.3 [M+H]+, tR 3.58 min. HRMS (m/z): 
C21H22Cl2FNO2: requires 410.1118 [M+H]+; found 410.1151. 1H NMR (CDCl3) δ 7.99 (dd, J = 8.6, 
5.6 Hz, 2H), 7.41 (ddd, J = 16.5, 8.0, 1.5 Hz, 2H), 7.18 (t, J = 8.0 Hz, 1H), 7.11 (t, J = 8.6 Hz, 2H), 
2.98 (t, J = 7.1 Hz, 3H), 2.94 (s, 1H), 2.81 (dt, J = 11.9, 3.2 Hz, 2H), 2.58 – 2.45 (m, 4H), 2.26 (td, J 
= 13.0, 4.4 Hz, 2H), 2.04 – 1.93 (m, 4H). 13C NMR (CDCl3) δ 198.5, 165.7 (d, J = 254.4 Hz), 145.9, 
134.9, 133.7 (d, J = 3.0 Hz), 130.8 (d, J = 9.2 Hz), 129.7, 127.5, 125.5, 115.7 (d, J = 21.8 Hz), 72.4, 
57.7, 49.1, 36.3, 35.4, 21.8.
4-(2,4-Dichlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-4-hydroxypiperidin-1-ium 2,2,2-
trifluoroacetate (8c). General procedure C. Purification by preparative HPLC (Method C) afforded 
the title compound as a white solid (44 mg, 60%). LCMS (m/z): 410.3 [M+H]+, tR 3.47 min. HRMS 
(m/z): C21H22Cl2FNO2: requires 410.1012 [M+H]+; found 410.1094. 1H NMR (CDCl3) δ 12.05 (s, 
1H), 8.00 – 7.92 (m, 2H), 7.33 (d, J = 8.0 Hz, 2H), 7.12 (td, J = 8.2, 4.1 Hz, 2H), 5.59 (s, 1H), 3.58 
(d, J = 11.3 Hz, 2H), 3.36 (q, J = 11.2 Hz, 2H), 3.28 – 3.10 (m, 6H), 2.35 (d, J = 14.1 Hz, 2H), 2.22 
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(p, J = 6.8 Hz, 2H). 13C NMR (CDCl3) δ 196.78, 166.1 (d, J = 255.6 Hz), 137.8, 133.8, 132.7 (d, J = 
3.1 Hz), 132.2, 130.8 (d, J = 9.5 Hz), 129.2, 116.0 (d, J = 21.9 Hz), 73.3, 56.7, 48.5, 35.1, 33.7, 18.2.
4-(4-(2,5-Dichlorophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one (8d). 
General procedure C. Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 91 mg of 
the title compound as a white solid (70%). LCMS (m/z): 410.3 [M+H]+, tR 3.65 min. HRMS (m/z): 
C21H22Cl2FNO2: requires 410.1012 [M+H]+; found 410.1093. 1H NMR (CDCl3) δ 8.04 – 7.94 (m, 
2H), 7.53 (d, J = 2.5 Hz, 1H), 7.25 (d, J = 8.5 Hz, 1H), 7.17 – 7.07 (m, 3H), 2.97 (t, J = 7.0 Hz, 2H), 
2.77 (dt, J = 10.8, 2.8 Hz, 3H), 2.51 – 2.42 (m, 4H), 2.28 (td, J = 13.0, 4.4 Hz, 2H), 1.96 (p, J = 7.1 
Hz, 2H), 1.86 (dd, J = 13.7, 2.6 Hz, 2H). 13C NMR (CDCl3) δ 198.7, 165.7 (d, J = 254.4 Hz), 145.6, 
133.8 (d, J = 3.1 Hz), 133.2, 132.8, 130.8 (d, J = 9.1 Hz), 130.1, 128.4, 127.7, 115.7 (d, J = 21.8 Hz), 
72.0, 57.7, 49.1, 36.3, 35.2, 21.9.
4-(4-(2,6-Dichlorophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one (8e). 
General procedure C. Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 69 mg of 
the title compound as a white solid (73%). LCMS (m/z): 410.72 [M+H]+, tR 3.50 min. HRMS (m/z): 
C21H22Cl2FNO2: requires 410.1111 [M+H]+; found 410.1066. 1H NMR (CDCl3) δ 8.01 (dd, J = 8.7, 
5.6 Hz, 2H), 7.29 (d, J = 7.9 Hz, 2H), 7.12 (t, J = 8.6 Hz, 2H), 7.04 (t, J = 8.0 Hz, 1H), 3.24 (s, 1H), 
2.98 (t, J = 7.1 Hz, 2H), 2.81 – 2.69 (m, 4H), 2.54 – 2.48 (m, 2H), 2.45 (t, J = 7.1 Hz, 2H), 2.06 (d, J 
= 13.6 Hz, 2H), 1.97 (p, J = 7.1 Hz, 2H). 13C NMR (CDCl3) δ 198.8, 165.7 (d, J = 254.1 Hz), 140.7, 
134.0, 133.8 (d, J = 3.0 Hz), 132.0, 130.8 (d, J = 9.2 Hz), 128.2, 115.7 (d, J = 21.7 Hz), 75.8, 57.8, 
49.2, 36.4, 36.2, 22.1.
4-(4-(3,4-Dichlorophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one (8f). 
General procedure C. Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 84 mg of 
the title compound as a white solid (70%). LCMS (m/z): 410.2 [M+H]+, tR 3.69 min. HRMS (m/z): 
C21H22Cl2FNO2: requires 410.1111 [M+H]+; found 410.1066. 1H NMR (CDCl3) δ 8.03 (dd, J = 8.7, 
5.5 Hz, 2H), 7.55 (d, J = 2.1 Hz, 1H), 7.40 (d, J = 8.5 Hz, 1H), 7.31 – 7.23 (m, 1H), 7.16 (t, J = 8.6 
Hz, 2H), 2.99 (t, J = 7.0 Hz, 2H), 2.80 (dt, J = 11.4, 2.9 Hz, 2H), 2.54 – 2.37 (m, 4H), 2.08 – 1.91 (m, 
4H), 1.66 (dd, J = 14.1, 2.6 Hz, 2H). 13C NMR (CDCl3) δ 198.4, 167.0, 164.5, 148.9, 133.8, 133.8, 
132.5, 130.9, 130.8, 130.7, 130.3, 127.2, 124.3, 115.9, 115.7, 77.5, 77.2, 76.8, 71.1, 57.9, 49.3, 38.4, 
36.3, 22.0.
4-(4-(3,5-Dichlorophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one (8g). 
General procedure C. Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 92 mg of 
the title compound as a white solid (62%). LCMS (m/z): 410.7 [M+H]+, tR 3.59 min. HRMS (m/z): 
C21H22Cl2FNO2: requires 410.1084 [M+H]+; found 410.1097. 1H NMR (DMSO-d6) δ 8.08 (dd, J = 
8.5, 5.6 Hz, 2H), 7.41 (t, J = 1.9 Hz, 1H), 7.35 (t, J = 8.7 Hz, 2H), 7.28 (d, J = 1.9 Hz, 2H), 5.04 (s, 
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1H), 2.95 (t, J = 6.6 Hz, 2H), 2.57 (d, J = 10.9 Hz, 2H), 2.35 (t, J = 6.8 Hz, 2H), 2.29 (t, J = 11.4 Hz, 
2H), 1.85 (t, J = 6.7 Hz, 2H), 1.58 (dt, J = 12.9, 6.4 Hz, 2H), 1.42 (d, J = 12.9 Hz, 2H). 13C NMR 
(DMSO-d6) δ 198.2, 164.7 (d, J = 251.1 Hz), 154.7, 134.1 (d, J = 2.9 Hz), 133.7, 130.8 (d, J = 9.4 
Hz), 125.8, 123.8, 115.6 (d, J = 21.7 Hz), 69.9, 57.2, 48.7, 37.5, 35.6, 22.2.
1-(4-Fluorophenyl)-4-(4-hydroxy-4-phenylpiperidin-1-yl)butan-1-one (8h). General procedure 
C. Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 101 mg of the title 
compound as a white solid (88%). LCMS (m/z): 342.3 [M+H]+, tR 2.92 min. HRMS (m/z): 
C21H24FNO2: requires 342.1864 [M+H]+; found 342.1873. 1H NMR (CDCl3) δ 8.08 – 7.99 (m, 2H), 
7.48 (dd, J = 7.6, 1.7 Hz, 2H), 7.36 (t, J = 7.7 Hz, 2H), 7.31 – 7.22 (m, 1H), 7.15 (t, J = 8.6 Hz, 2H), 
3.00 (t, J = 7.1 Hz, 2H), 2.81 (dt, J = 11.7, 3.1 Hz, 2H), 2.56 – 2.42 (m, 4H), 2.05 (ddd, J = 28.3, 
13.9, 5.8 Hz, 4H), 1.89 (s, 1H), 1.73 (dd, J = 14.2, 2.6 Hz, 2H).13C NMR (CDCl3) δ 198.5, 165.7 (d, 
J = 254.3 Hz), 148.5, 133.8 (d, J = 3.0 Hz), 130.8 (d, J = 9.3 Hz), 128.4, 127.1, 124.6, 115.7 (d, J = 
21.7 Hz), 71.4, 57.9, 49.5, 38.5, 36.4, 22.0.
1-(4-Fluorophenyl)-4-(4-hydroxy-4-(p-tolyl)piperidin-1-yl)butan-1-one (8i). General procedure 
C. Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 84 mg of the title compound 
as a white solid (80%). LCMS (m/z): 356.2 [M+H]+, tR 3.22 min. HRMS (m/z): C22H26FNO2: requires 
356.2067 [M+H]+; found 356.2068. 1H NMR (CDCl3) δ 8.01 (dd, J = 8.7, 5.6 Hz, 2H), 7.34 (d, J = 
8.0 Hz, 2H), 7.18 – 7.08 (m, 4H), 2.98 (t, J = 7.1 Hz, 2H), 2.78 (dt, J = 12.1, 3.3 Hz, 2H), 2.52 – 2.40 
(m, 4H), 2.33 (s, 3H), 2.09 – 1.94 (m, 5H), 1.70 (dd, J = 14.2, 2.6 Hz, 2H). 13C NMR (CDCl3) δ 198.5, 
165.7 (d, J = 254.3 Hz), 145.6, 136.7, 133.8 (d, J = 3.1 Hz), 130.8 (d, J = 9.3 Hz), 129.1, 124.6, 115.7 
(d, J = 21.8 Hz), 71.1, 57.9, 49.6, 38.5, 36.4, 21.9, 21.1. CDCl3
1-(4-Fluorophenyl)-4-(4-hydroxy-4-(4-(trifluoromethyl)phenyl)piperidin-1-yl)butan-1-one 
(8j). General procedure C. Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 65 
mg of the title compound as a white solid (69%). LCMS (m/z): 410.2 [M+H]+, tR 3.59 min. HRMS 
(m/z): C22H23F4NO2: requires 410.1756 [M+H]+; found 410.1778. 1H NMR (CDCl3) δ 8.00 (dd, J = 
8.6, 5.5 Hz, 2H), 7.57 (s, 4H), 7.13 (t, J = 8.6 Hz, 2H), 2.99 (t, J = 7.0 Hz, 2H), 2.85 (d, J = 11.2 Hz, 
2H), 2.57 – 2.45 (m, 4H), 2.17 – 1.90 (m, 5H), 1.79 – 1.63 (m, 2H). 13C NMR (CDCl3) δ 198.4, 165.8 
(d, J = 254.7 Hz), 152.3, 133.7 (d, J = 3.1 Hz), 129.4 (d, J = 32.4 Hz), 125.4 (q, J = 3.7 Hz), 125.2, 
124.3 (q, J = 272.9 Hz), 115.8 (d, J = 21.9 Hz), 71.3, 57.9, 49.3, 38.2, 36.3, 21.7.
4-(4-(4-(Dimethylamino)phenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one (8k). 
General procedure C. Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 60 mg of 
the title compound as a light orange solid (62%). LCMS (m/z): 385.4 [M+H]+, tR 1.41 min. HRMS 
(m/z): C23H29FN2O2: requires 385.2310 [M+H]+; found 385.2274. 1H NMR (CDCl3) δ 7.99 (dd, J = 
8.7, 5.6 Hz, 2H), 7.32 (d, J = 8.8 Hz, 2H), 7.12 (t, J = 8.6 Hz, 2H), 6.70 (d, J = 8.9 Hz, 2H), 3.01 (t, 
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J = 7.0 Hz, 2H), 2.92 (s, 6H), 2.93 – 2.86 (m, 2H), 2.60 (dt, J = 14.8, 8.4 Hz, 4H), 2.14 (td, J = 13.3, 
4.3 Hz, 2H), 2.02 (p, J = 7.3 Hz, 2H), 1.94 (s, 1H), 1.77 (dd, J = 14.3, 2.7 Hz, 2H). 13C NMR (CDCl3) 
δ 198.2, 165.8 (d, J = 254.4 Hz), 149.8, 135.8, 133. (d, J = 3.0 Hz), 130.8 (d, J = 9.2 Hz), 125.5, 115.7 
(d, J = 21.8 Hz), 112.5, 70.4, 57.5, 49.4, 40.7, 37.7, 36.3, 21.2.
1-(4-Fluorophenyl)-4-(4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl)butan-1-one (8l). General 
procedure C. Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 80 mg of the title 
compound as a white solid (74%). LCMS (m/z): 360.3 [M+H]+, tR 3.09 min. HRMS (m/z): 
C21H23F2NO2: requires 360.1697 [M+H]+; found 360.1777. 1H NMR (CDCl3) δ 8.12 – 7.96 (m, 2H), 
7.44 – 7.36 (m, 2H), 7.13 (t, J = 8.6 Hz, 2H), 7.00 (t, J = 8.7 Hz, 2H), 2.98 (t, J = 7.0 Hz, 2H), 2.80 
(dt, J = 11.7, 3.0 Hz, 2H), 2.55 – 2.41 (m, 4H), 2.02 (dt, J = 14.3, 10.2 Hz, 5H), 1.70 (dd, J = 14.2, 
2.6 Hz, 2H). 13C NMR (CDCl3) δ 198.5, 165.8 (d, J = 254.4 Hz), 161.9 (d, J = 245.3 Hz), 144.2 (d, J 
= 2.6 Hz), 133.8 (d, J = 3.3 Hz), 130.8 (d, J = 9.2 Hz), 126.4 (d, J = 8.0 Hz), 115.7 (d, J = 21.8 Hz), 
115.1 (d, J = 21.1 Hz), 71.1, 57.9, 49.5, 38.5, 36.4, 21.9.
4-(2'-Chloro-[1,1'-biphenyl]-2-yl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-4-hydroxypiperidin-1-
ium 2,2,2-trifluoroacetate (8m). General procedure C. Purification by preparative HPLC (Method 
C) afforded 95 mg of the title compound as a transparent oil (76%). LCMS (m/z): 452.2 [M+H]+, tR 
4.00 min. HRMS (m/z): C27H27ClFNO2: requires 452.1787 [M+H]+; found 452.1811. 1H NMR 
(CDCl3) δ 12.19 (s, 1H), 7.94 (dd, J = 8.6, 5.3 Hz, 2H), 7.53 (d, J = 8.0 Hz, 1H), 7.49 – 7.38 (m, 2H), 
7.33 (ddd, J = 7.5, 5.1, 2.7 Hz, 2H), 7.25 (d, J = 7.6 Hz, 2H), 7.12 (t, J = 8.5 Hz, 2H), 7.02 (d, J = 7.5 
Hz, 1H), 3.44 (dd, J = 26.7, 11.6 Hz, 2H), 3.22 – 2.99 (m, 6H), 2.71 – 2.58 (m, 1H), 2.46 (td, J = 
14.0, 4.1 Hz, 1H), 2.35 (s, 1H), 2.15 (t, J = 7.2 Hz, 2H), 2.01 (dd, J = 30.5, 14.6 Hz, 2H). 13C NMR 
(CDCl3) δ 196.7, 166.1 (d, J = 255.6 Hz), 142.3, 142.1, 137.1, 133.4, 132.8 (d, J = 3.0 Hz), 132.4, 
130.9, 130.8 (d, J = 9.5 Hz), 129.6, 129.2, 128.8, 127.8, 126.7, 126.4, 116.0 (d, J = 21.9 Hz), 71.4, 
56.6, 48.6, 35.9, 35.6, 35.1, 18.2.
4-(2-Chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-4-hydroxypiperidin-1-ium 2,2,2-
trifluoroacetate  (8n). General procedure C. Purification by preparative HPLC (Method C) afforded 
88 mg of the title compound as a white solid (62%). LCMS (m/z): 376.2 [M+H]+, tR 3.37 min. HRMS 
(m/z): C21H23ClFNO: requires 376.1474 [M+H]+; found 376.1479. 1H NMR (CDCl3) δ 12.14 (s, 1H), 
8.01 – 7.92 (m, 2H), 7.46 (dd, J = 7.7, 1.9 Hz, 1H), 7.37 (dd, J = 7.5, 1.8 Hz, 1H), 7.32 – 7.19 (m, 
2H), 7.13 (t, J = 8.5 Hz, 2H), 4.05 (s, 1H), 3.58 (d, J = 11.5 Hz, 2H), 3.36 (q, J = 11.2 Hz, 2H), 3.15 
(q, J = 6.5, 5.2 Hz, 4H), 2.67 (td, J = 13.9, 4.1 Hz, 2H), 2.31 (d, J = 14.1 Hz, 2H), 2.22 (p, J = 6.6 Hz, 
2H). 13C NMR (CDCl3) δ 196.6, 166.0 (d, J = 255.5 Hz), 140.6, 132.6 (d, J = 3.0 Hz), 131.9, 131.5, 
130.7 (d, J = 9.4 Hz), 129.5, 127.7, 127.1, 115.9 (d, J = 22.0 Hz), 69.8, 56.6, 48.4, 35.0, 32.9, 18.1.
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4-Chlorobut-1-yne (9). 3-Butynol (25.0 mL, 330 mmol) and pyridine (2.66 mL, 33 mmol) were 
placed in a 100 mL roundbottomed flask, and the mixture was cooled in an ice bath. Then, thionyl 
chloride (24.4 mL, 334 mmol) was added dropwise for 10 min. The flask was shaken occasionally 
during the addition, and after the thionyl chloride was added, the mixture was heated under reflux for 
30 min. Fractional distillation of the products gave 4-chloro-1-butyne as a light-yellow liquid (24 mL, 
82%). 1H NMR (CDCl3) δ 3.58 (t, J = 7.1 Hz, 2H), 2.63 (td, J = 7.1, 2.6 Hz, 2H), 2.07 (t, J = 2.7 Hz, 
1H). 13C NMR (CDCl3) δ 80.2, 70.5, 41.9, 22.8.
1-(4-Chlorobut-1-yn-1-yl)-2-fluorobenzene (12a). General procedure D. Purification by FCC (n-
hexanes) gave 1.24 g of a yellow oil (72%). LCMS (m/z): 183.1 [M+H]+, tR 3.05 min. 1H NMR 
(CDCl3) δ 7.47 – 7.40 (m, 1H), 7.34 – 7.26 (m, 1H), 7.15 – 7.03 (m, 2H), 3.73 (t, J = 7.2 Hz, 2H), 
2.95 (t, J = 7.2 Hz, 2H). 13C NMR (CDCl3) δ 162.9 (d, J = 251.0 Hz), 133.8 (d, J = 1.5 Hz), 129.9 (d, 
J = 7.9 Hz), 124.0 (d, J = 3.8 Hz), 115.6 (d, J = 21.0 Hz), 111.7 (d, J = 15.7 Hz), 91.2 (d, J = 3.3 Hz), 
75.9 (d, J = 1.1 Hz), 42.1, 24.1.
1-(4-Chlorobut-1-yn-1-yl)-3-fluorobenzene (12b). General procedure D. Purification by FCC (n-
hexanes) gave 1.55 g of a yellow oil (90%). LCMS (m/z): 183.0 [M+H]+, tR 3.02 min. 1H NMR 
(CDCl3) δ 7.32 – 7.25 (m, 1H), 7.22 (dt, J = 7.7, 1.3 Hz, 1H), 7.14 (ddd, J = 9.5, 2.6, 1.4 Hz, 1H), 
7.03 (tdd, J = 8.4, 2.7, 1.2 Hz, 1H), 3.71 (t, J = 7.2 Hz, 2H), 2.91 (t, J = 7.2 Hz, 2H). 13C NMR 
(CDCl3) δ 162.6 (d, J = 246.3 Hz), 129.9 (d, J = 8.5 Hz), 127.7 (d, J = 3.1 Hz), 125.1 (d, J = 9.5 Hz), 
118.6 (d, J = 22.7 Hz), 115.6 (d, J = 21.2 Hz), 86.9, 81.5 (d, J = 3.4 Hz), 42.1, 23.9.
1-(4-Chlorobut-1-yn-1-yl)-2,3-difluorobenzene (12c). General procedure D. Purification by FCC 
(n-hexanes) gave 1.65 g of a yellow oil (87%). LCMS (m/z): 201.1 [M+H]+, tR 3.02 min. 1H NMR 
(CDCl3) δ 7.20 – 7.11 (m, 1H), 7.15 – 7.05 (m, 1H), 7.00 (dddd, J = 8.3, 7.8, 4.9, 1.6 Hz, 1H), 3.70 
(t, J = 7.2 Hz, 2H), 2.93 (td, J = 7.2, 0.7 Hz, 2H). 13C NMR (CDCl3) δ 151.3 (dd, J = 252.7, 13.4 Hz), 
150.7 (dd, J = 248.3, 12.2 Hz), 128.5 (d, J = 3.4 Hz), 123.9 (dd, J = 7.3, 4.9 Hz), 117.4 (d, J = 17.5 
Hz), 113.9 (dd, J = 12.3, 1.8 Hz), 92.6 (d, J = 3.8 Hz), 74.9 (dd, J = 4.6, 1.3 Hz), 41.9, 24.1.
1-(4-Chlorobut-1-yn-1-yl)-2,4-difluorobenzene (12d). General procedure D. Purification by FCC 
(n-hexanes) gave 1.72 g of a yellow oil (82.3%). LCMS (m/z): 201.1 [M+H]+, tR 2.99 min. 1H NMR 
(CDCl3) δ 7.42 – 7.35 (m, 1H), 6.86 – 6.78 (m, 2H), 3.69 (t, J = 7.2 Hz, 2,H), 2.91 (t, J = 7.2 Hz, 2H). 
13C NMR (CDCl3) δ 163.3 (dd, J = 253.7, 12.2 Hz), 162.6 (dd, J = 251.7, 11.3 Hz), 134.6 (dd, J = 
9.7, 2.8 Hz), 111.6 (dd, J = 21.9, 3.8 Hz), 108.1 (dd, J = 16.0, 4.1 Hz), 104.3 (dd, J = 24.9, 0.2 Hz), 
90.9 (dd, J = 3.4, 1.8 Hz), 75.0 (d, J = 1.4 Hz), 42.04, 24.1.
2-(4-Chlorobut-1-yn-1-yl)-1,4-difluorobenzene (12e). General procedure D. Purification by FCC 
(n-hexanes) gave 1.45 g of a yellow oil (70%). LCMS (m/z): 201.1 [M+H]+, tR 3.00 min. 1H NMR 
(CDCl3) δ 7.10 (ddd, J = 8.5, 5.4, 2.9 Hz, 1H), 7.04 – 6.93 (m, 2H), 3.69 (t, J = 7.2 Hz, 2H), 2.92 (t, 
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J = 7.2 Hz, 2H). 13C NMR (CDCl3) δ 159.3 (d, J = 249.6 Hz), 158.2 (d, J = 242.8 Hz), 128.8 (d, J = 
81.5 Hz), 119.8 (dd, J = 25.2, 1.9 Hz), 116.7 (dd, J = 10.6, 8.6 Hz), 116.5 (dd, J = 10.5, 8.5 Hz), 92.3 
(d, J = 3.4 Hz), 75.1 (d, J = 2.6 Hz), 41.9, 24.1.
2-(4-Chlorobut-1-yn-1-yl)-1,3-difluorobenzene (12f). General procedure D. Purification by FCC 
(n-hexanes) gave 992 mg of a pink oil (53%). LCMS (m/z): 200.9 [M+H]+, tR 2.97 min. 1H NMR 
(CDCl3) δ 7.32 – 7.20 (m, 1H), 6.96 – 6.86 (m, 2H), 3.74 (t, J = 7.3 Hz, 2H), 2.99 (t, J = 7.3 Hz, 2H). 
13C NMR (CDCl3) δ 163.5 (d, J = 253.2 Hz), 163.4 (d, J = 253.3 Hz), 129.6 (t, J = 10.0 Hz), 111.4 
(dd, J = 4.5, 0.3 Hz), 111.2 (dd, J = 4.5, 1.2 Hz), 102.2 (t, J = 19.8 Hz), 96.2 (t, J = 3.1 Hz), 69.6 (t, 
J = 1.4 Hz), 41.8, 24.3.
4-(4-Chlorobut-1-yn-1-yl)-1,2-difluorobenzene (12g). General procedure D. Purification by FCC 
(n-hexanes) gave 1.53g of a yellow oil (81%). LCMS (m/z): 200.9 [M+H]+, tR 3.03 min. 1H NMR 
(CDCl3) δ 7.21 (ddd, J = 10.9, 7.5, 2.0 Hz, 1H), 7.13 (dd, J = 4.6, 1.6 Hz, 1H), 7.08 (dt, J = 10.2, 8.2 
Hz, 1H), 3.67 (t, J = 7.1 Hz, 2H), 2.86 (t, J = 7.1 Hz, 2H). 13C NMR (CDCl3) δ 150.6 (dd, J = 250.9, 
12.5 Hz), 150.0 (dd, J = 248.7, 13.0 Hz), 128.4 (dd, J = 6.4, 3.6 Hz), 120.8 (d, J = 18.3 Hz), 117.5 (d, 
J = 17.8 Hz), 86.5 (d, J = 1.9 Hz), 80.6 (t, J = 2.3 Hz), 42.1, 23.8.
1-(4-Chlorobut-1-yn-1-yl)-3,5-difluorobenzene (12h). General procedure D. Purification by FCC 
(n-hexanes) gave 1.61 g of a yellow oil (85%). LCMS (m/z): 200.9 [M+H]+, tR 3.03 min. 1H NMR 
(CDCl3) δ 6.98 – 6.91 (m, 2H), 6.79 (tt, J = 9.0, 2.4 Hz, 1H), 3.70 (t, J = 7.1 Hz, 2H), 2.90 (t, J = 7.1 
Hz, 2H). 13C NMR (CDCl3) δ 162.8 (d, J = 248.5 Hz), 162.7 (d, J = 248.6 Hz), 125.9 (t, J = 11.8 Hz), 
114.9 (d, J = 7.4 Hz), 114.7 (d, J = 7.4 Hz), 104.5 (t, J = 25.4 Hz), 88.2, 80.6 (t, J = 3.9 Hz), 41.94, 
23.8.
1-Chloro-2-(4-chlorobut-1-yn-1-yl)benzene (12i). General procedure E. Purification by FCC (n-
hexanes) gave 1.12 g of a light-yellow liquid (88%). LCMS (m/z): 200.4 [M+H]+, tR 3.02 min.1H 
NMR (CDCl3) δ 7.45 (dd, J = 7.5, 1.9 Hz, 1H), 7.38 (dd, J = 7.9, 1.5 Hz, 1H), 7.21 (dtd, J = 16.1, 
7.4, 1.6 Hz, 2H), 3.72 (t, J = 7.3 Hz, 2H), 2.95 (t, J = 7.3 Hz, 2H). 13C NMR (CDCl3) δ 136.0, 133.5, 
129.3, 129.2, 126.5, 123.1, 91.3, 79.5, 42.1, 24.1.
1-(4-Chlorobut-1-yn-1-yl)-2-methylbenzene (12j). General procedure E. Purification by FCC (n-
hexanes) gave 1.32 g of a transparent liquid (92%). LCMS (m/z): 179.1 [M+H]+, tR 3.03 min. 1H 
NMR (CDCl3) δ 7.39 (dd, J = 7.4, 1.3 Hz, 1H), 7.23 – 7.17 (m, 2H), 7.17 – 7.07 (m, 1H), 3.71 (t, J = 
7.2 Hz, 2H), 2.93 (t, J = 7.2 Hz, 2H), 2.44 (s, 3H). 13C NMR (CDCl3) δ 140.4, 132.0, 129.5, 128.2, 
125.6, 123.0, 89.7, 81.5, 42.5, 24.1, 20.8.
4-Chloro-1-(2-fluorophenyl)butan-1-one (13a). General procedure F. Purification by FCC (n-
hexanes/EtOAc 10:0.1) gave 1.12 g of a yellow oil (82%). LCMS: tR 2.91 min.  1H NMR (CDCl3) δ 
7.87 (td, J = 7.6, 1.9 Hz, 1H), 7.52 (dddd, J = 8.3, 7.1, 5.0, 1.9 Hz, 1H), 7.23 (ddd, J = 7.8, 7.3, 1.1 
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Hz, 1H), 7.14 (ddd, J = 11.3, 8.3, 1.1 Hz, 1H), 3.66 (t, J = 6.4 Hz, 2H), 3.18 (td, J = 6.9, 3.1 Hz, 2H), 
2.27 – 2.17 (m, 2H). 13C NMR (CDCl3) δ 197.4 (d, J = 4.0 Hz), 162.2 (d, J = 254.6 Hz), 134.8 (d, J 
= 9.1 Hz), 130.7 (d, J = 2.7 Hz), 125.6 (d, J = 13.0 Hz), 124.6 (d, J = 3.4 Hz), 116.9 (d, J = 24.0 Hz), 
44.6, 40.5 (d, J = 7.8 Hz), 26.8 (d, J = 2.1 Hz).
4-Chloro-1-(3-fluorophenyl)butan-1-one (13b). General procedure F. Purification by FCC (n-
hexanes/EtOAc 10:0.1) gave 449 mg of a dark red oil (41%). LCMS (m/z): 201.1 [M+H]+, tR 2.91 
min. 1H NMR (CDCl3) δ 7.77 (ddd, J = 7.8, 1.6, 1.0 Hz, 1H), 7.66 (ddd, J = 9.5, 2.6, 1.5 Hz, 1H), 
7.46 (td, J = 8.0, 5.5 Hz, 1H), 7.28 (tdd, J = 8.3, 2.7, 1.0 Hz, 1H), 3.69 (t, J = 6.2 Hz, 2H), 3.17 (t, J 
= 6.9 Hz, 2H), 2.27 – 2.20 (m, 2H). 13C NMR (CDCl3) δ 197.7 (d, J = 2.0 Hz), 162.9 (d, J = 248.0 
Hz), 138.9 (d, J = 6.0 Hz), 130.4 (d, J = 7.6 Hz), 123.9 (d, J = 3.0 Hz), 120.3 (d, J = 21.4 Hz), 114.8 
(d, J = 22.3 Hz), 44.6, 35.5, 26.7. 
4-Chloro-1-(2,3-difluorophenyl)butan-1-one (13c). General procedure F. Purification by FCC (n-
hexanes/EtOAc 10:0.1) gave 745 mg of a yellow oil (81%). LCMS: tR 2.94 min.  1H NMR (CDCl3) 
δ 7.61 (ddt, J = 7.8, 6.0, 1.7 Hz, 1H), 7.36 (dddd, J = 9.8, 8.2, 7.4, 1.8 Hz, 1H), 7.17 (tdd, J = 8.1, 4.6, 
1.5 Hz, 1H), 3.66 (t, J = 6.3 Hz, 2H), 3.18 (td, J = 6.9, 3.1 Hz, 2H), 2.22 (dddd, J = 13.3, 6.9, 6.2, 0.8 
Hz, 32H). 13C NMR (CDCl3) δ 196.2 (dd, J = 3.8, 2.6 Hz), 151.1 (dd, J = 250.1, 14.0 Hz), 150.5 (dd, 
J = 256.7, 13.7 Hz), 127.5 (d, J = 9.9 Hz), 125.1 (dd, J = 3.6, 1.6 Hz), 124.5 (dd, J = 6.6, 4.5 Hz), 
121.6 (dd, J = 17.5, 1.4 Hz), 44.4, 40.5 (d, J = 7.0 Hz), 26.6 (d, J = 2.0 Hz).
4-Chloro-1-(2,4-difluorophenyl)butan-1-one (13d). General procedure F. Purification by FCC (n-
hexanes/EtOAc 10:0.1) gave 294 mg of a yellow oil (58%). LCMS: tR 2.91 min. 1H NMR (CDCl3) δ 
7.94 (td, J = 8.6, 6.6 Hz, 1H), 7.01 – 6.91 (m, 1H), 6.87 (ddd, J = 11.1, 8.6, 2.4 Hz, 1H), 3.65 (t, J = 
6.3 Hz, 2H), 3.14 (td, J = 6.9, 3.3 Hz, 2H), 2.20 (dddd, J = 13.3, 6.9, 6.2, 0.8 Hz, 2H). 13C NMR (101 
MHz, CDCl3) δ 195.7 (d, J = 4.8 Hz), 165.9 (dd, J = 257.2, 12.4 Hz), 162.9 (dd, J = 257.5, 12.6 Hz), 
132.7 (dd, J = 10.5, 4.3 Hz), 122.0 (dd, J = 13.2, 3.6 Hz), 112.4 (dd, J = 21.4, 3.4 Hz), 104.9 (dd, J = 
27.9, 25.4 Hz), 44.5 (s), 40.3 (d, J = 7.8 Hz), 26.7 (d, J = 2.2 Hz).
4-Chloro-1-(2,5-difluorophenyl)butan-1-one (13e). General procedure F. Purification by FCC (n-
hexanes/EtOAc 10:0.1) gave 384 mg of a clear oil (82%). LCMS: tR 2.90 min. 1H NMR (CDCl3) δ 
7.50 (ddd, J = 8.7, 5.5, 3.3 Hz, 1H), 7.18 (ddt, J = 9.0, 7.0, 3.6 Hz, 1H), 7.10 (ddd, J = 10.1, 9.0, 4.2 
Hz, 1H), 3.62 (t, J = 6.3 Hz, 2H), 3.13 (td, J = 6.9, 3.2 Hz, 2H), 2.17 (pd, J = 6.6, 0.8 Hz, 2H). 13C 
NMR (CDCl3) δ 195.8 (dd, J = 4.8, 1.3 Hz), 158.7 (dd, J = 244.6, 2.2 Hz), 158.1 (dd, J = 250.8, 2.4 
Hz), 126.4 (dd, J = 15.8, 6.2 Hz), 121.4 (dd, J = 24.6, 9.4 Hz), 118.3 (dd, J = 27.4, 7.9 Hz), 116.4 
(dd, J = 25.0, 3.3 Hz), 44.4, 40.3 (d, J = 8.2 Hz), 26.6 (d, J = 2.3 Hz).
4-Chloro-1-(2,6-difluorophenyl)butan-1-one (13f). General procedure F. Purification by FCC (n-
hexanes/EtOAc 10:0.1) gave 408 mg of a clear oil (79%). LCMS (m/z): 219.1 [M+H]+, tR 2.90 min. 
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1H NMR (CDCl3) δ 7.39 (tt, J = 8.4, 6.3 Hz, 1H), 6.94 (t, J = 8.2 Hz, 2H), 3.63 (t, J = 6.3 Hz, 2H), 
3.06 (t, J = 7.0 Hz, 2H), 2.20 (p, J = 6.7 Hz, 2H). 13C NMR (CDCl3) δ 196.6, 159.9 (d, J = 253.5 Hz), 
159.9 (d, J = 253.7 Hz), 132.6 (t, J = 10.5 Hz), 112.4 – 112.3 (m), 112.21 – 112.06 (m), 44.2, 41.9 (t, 
J = 2.3 Hz), 26.5.
4-Chloro-1-(3,4-difluorophenyl)butan-1-one  (13g). General procedure F. Purification by FCC (n-
hexanes/EtOAc 10:0.1) gave 1.27 g of a yellow oil (78%). LCMS (m/z): 219.5 [M+H]+, tR 2.94 min.  
1H NMR (CDCl3) δ 7.87 – 7.78 (m, 1H), 7.78 (dtd, J = 6.5, 2.1, 1.0 Hz, 1H), 7.34 – 7.22 (m, 1H), 
3.71 – 3.67 (m, 2H), 3.16 (t, J = 6.9 Hz, 2H), 2.30 – 2.20 (m, 2H). 13C NMR (CDCl3) δ 196.5, 153.8 
(dd, J = 257.1, 13.0 Hz), 150.6 (dd, J = 251.0, 13.0 Hz), 133.9 (t, J = 3.8 Hz), 125.1 (dd, J = 7.5, 3.6 
Hz), 117.7 (d, J = 17.8 Hz), 117.4 (dd, J = 17.9, 1.9 Hz), 44.6, 35.3, 26.7.
4-Chloro-1-(3,5-difluorophenyl)butan-1-one (13h). General procedure F. Purification by FCC (n-
hexanes/EtOAc 10:0.1) gave 309 mg of a red oil (72%). LCMS: tR 2.96 min. 1H NMR (CDCl3) δ 7.53 
– 7.42 (m, 2H), 7.02 (tt, J = 8.4, 2.4 Hz, 1H), 3.67 (t, J = 6.2 Hz, 2H), 3.13 (t, J = 6.9 Hz, 2H), 2.22 
(tt, J = 6.8, 6.0 Hz, 2H). 13C NMR (CDCl3) δ 196.47 (t, J = 2.4 Hz), 163.20 (dd, J = 251.1, 11.7 Hz), 
139.71 (t, J = 7.4 Hz), 111.07 (dd, J = 18.9, 7.3 Hz), 108.63 (t, J = 25.4 Hz), 44.46, 35.61, 26.57.
4-Chloro-1-(2-chlorophenyl)butan-1-one (13i). General procedure F. Purification by FCC (n-
hexanes/EtOAc 10:0.1) gave 1.12 g of a yellow oil (80%). LCMS (m/z): 217.1 [M+H]+, tR 2.90 min. 
1H NMR (CDCl3) δ 7.48 (dd, J = 7.5, 1.7 Hz, 1H), 7.44 – 7.36 (m, 2H), 7.32 (td, J = 7.2, 1.8 Hz, 1H), 
3.65 (t, J = 6.3 Hz, 2H), 3.14 (t, J = 7.0 Hz, 2H), 2.21 (p, J = 6.7 Hz, 2H). 13C NMR (CDCl3) δ 202.2, 
139.3, 131.9, 130.9, 130.7, 128.9, 127.1, 44.4, 39.9, 26.9.
4-Chloro-1-(o-tolyl)butan-1-one (13j). General procedure F. Purification by FCC (n-
hexanes/EtOAc 10:0.1) gave 900 mg of a yellow oil (74%). LCMS (m/z): 197.3 [M+H]+, tR 2.90 min. 
1H NMR (CDCl3) δ 7.68 (dd, J = 7.8, 1.4 Hz, 1H), 7.38 (td, J = 7.5, 1.4 Hz, 1H), 7.30 – 7.23 (m, 2H), 
3.67 (t, J = 6.3 Hz, 2H), 3.10 (t, J = 6.9 Hz, 2H), 2.50 (s, 3H), 2.20 (p, J = 6.6 Hz, 2H). 13C NMR 
(CDCl3) δ 203.1, 138.2, 137.8, 132.1, 131.5, 128.6, 125.9, 44.7, 38.3, 27.0, 21.5.
4-(4-Chlorophenyl)-1-(4-(2-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridin-1-ium 2,2,2-
trifluoroacetateone (14a). General procedure C. Purification by preparative HPLC (Method C) 
afforded 49 mg of white solid (45%). LCMS (m/z): 376.3 [M+H]+, tR 3.34 min. HRMS (m/z): 
C21H23ClFNO2: requires 376.1401 [M+H]+; found 376.1483. 1H NMR (CDCl3) δ 11.71 (s, 1H), 7.87 
(td, J = 7.6, 1.8 Hz, 1H), 7.57 (tdd, J = 7.3, 5.0, 1.8 Hz, 1H), 7.41 (d, J = 8.5 Hz, 2H), 7.33 (d, J = 8.4 
Hz, 2H), 7.29 – 7.22 (m, 1H), 7.17 (dd, J = 11.4, 8.3 Hz, 1H), 3.88 (s, 1H), 3.55 (d, J = 11.6 Hz, 2H), 
3.34 (q, J = 11.2 Hz, 2H), 3.14 (tt, J = 6.6, 3.3 Hz, 4H), 2.53 (td, J = 14.1, 4.1 Hz, 2H), 2.26 – 2.14 
(m, 2H), 1.94 (d, J = 14.4 Hz, 2H).
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4-(4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)-1-(3-fluorophenyl)butan-1-one (14b). General 
procedure C. Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 55 mg of a white 
solid (39%). LCMS (m/z): 376.1 [M+H]+, tR 3.21 min. HRMS (m/z): C21H23ClFNO2: requires 
376.1474 [M+H]+; found 376.1480. 1H NMR (Methanol-d4) δ 7.89 (dt, J = 7.8, 1.2 Hz, 1H), 7.75 
(ddd, J = 9.7, 2.7, 1.6 Hz, 1H), 7.63 – 7.51 (m, 3H), 7.45 – 7.35 (m, 3H), 3.61 (d, J = 11.9 Hz, 2H), 
3.49 (td, J = 12.7, 2.8 Hz, 2H), 3.34 – 3.24 (m, 4H), 2.43 (td, J = 14.5, 4.4 Hz, 2H), 2.31 – 2.18 (m, 
2H), 2.01 (dq, J = 15.3, 2.9 Hz, 2H). 13C NMR (Methanol-d4) δ 198.9 (d, J = 2.3 Hz), 164.3 (d, J = 
246.3 Hz), 147.0, 140.1 (d, J = 6.2 Hz), 134.23, 131.8 (d, J = 7.7 Hz), 129.5, 127.5, 125.2 (d, J = 3.0 
Hz), 121.3 (d, J = 21.7 Hz), 115.5 (d, J = 22.8 Hz), 69.3, 50.3, 49.6, 36.4, 36.3, 19.6.
4-(4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)-1-(2,3-difluorophenyl)butan-1-one (14c). A 
solution of 4-(4-chlorophenyl)-1-(4-(2,3-difluorophenyl)-4,4-dimethoxybutyl)piperidin-4-ol (110 
mg, 250 mol) in 15 mL of 15:1 acetone:H2O was treated with pTsOH (61.8 mg, 326 mol), and the 
mixture was heated at reflux for 48 h. The mixture was concentrated under reduced pressure. The 
residue was dissolved in EtOAC (20 mL) and poured into saturated NaHCO3 (20 mL). The aqueous 
phase was extracted with EtOAc (2 × 20 mL) and the combined extracts were dried (Na2SO4), and 
concentrated under reduced pressure. The residue was purified by FCC (SiO2, 98:1 EtOAc:MeOH), 
affording the title compound as a beige solid (75 mg, 76%). LCMS (m/z): 394.2 [M+H]+, tR 3.37 min. 
HRMS (m/z): C21H22ClF2NO2: requires 394.1380 [M+H]+; found 394.1390. 1H NMR (CDCl3) δ 7.62 
(ddt, J = 7.9, 6.1, 1.8 Hz, 1H), 7.38 – 7.32 (m, 3H), 7.32 – 7.25 (m, 2H), 7.16 (tdd, J = 8.1, 4.5, 1.5 
Hz, 1H), 3.01 (td, J = 7.0, 2.8 Hz, 2H), 2.82 – 2.76 (m, 2H), 2.51 – 2.38 (m, 4H), 2.05 – 1.79 (m, 5H), 
1.66 (dd, J = 14.0, 2.7 Hz, 2H). 13C NMR (CDCl3) δ 197.0 (dd, J = 6.3, 2.6 Hz), 151.1 (dd, J = 250.4, 
14.8 Hz), 150.4 (dd, J = 256.2, 13.6 Hz), 147.0, 132.8, 128.5, 128.1 (d, J = 9.9 Hz), 126.2, 125.2 (dd, 
J = 3.5, 1.3 Hz), 124.3 (dd, J = 6.6, 4.5 Hz), 121.2 (d, J = 17.4 Hz), 71.2, 57.8, 49.4, 41.4 (d, J = 6.8 
Hz), 38.5, 21.9.
4-(4-Chlorophenyl)-1-(4-(2,4-difluorophenyl)-4-oxobutyl)-4-hydroxypiperidin-1-ium 2,2,2-
trifluoroacetate (14d). General procedure C. Purification by preparative HPLC (Method C) afforded 
68 mg of a white solid (66%). LCMS (m/z): 394.3 [M+H]+, tR 3.35 min. HRMS (m/z): 
C21H22ClF2NO2: requires 394.1380 [M+H]+; found 394.1387. 1H NMR (CDCl3) δ 11.54 (s, 1H), 7.53 
(ddd, J = 8.6, 5.4, 3.3 Hz, 1H), 7.39 (d, J = 8.4 Hz, 2H), 7.31 – 7.20 (m, 3H), 7.15 (td, J = 9.5, 4.1 
Hz, 1H), 4.83 (s, 1H), 3.47 (d, J = 10.2 Hz, 2H), 3.33 (q, J = 11.3 Hz, 2H), 3.11 (td, J = 6.4, 3.2 Hz, 
4H), 2.45 (td, J = 14.0, 4.2 Hz, 2H), 2.18 (dq, J = 13.7, 6.7 Hz, 2H), 1.93 (d, J = 14.4 Hz, 2H). 13C 
NMR (CDCl3) δ 195.1, 158.7 (dd, J = 245.1, 1.9 Hz), 158.3 (dd, J = 251.3, 2.2 Hz), 144.8, 133.6, 
128.8, 126.1, 125.6 (dd, J = 15.4, 6.4 Hz), 122.1 (dd, J = 24.5, 9.6 Hz), 118.6 (dd, J = 27.2, 7.8 Hz), 
116.4 (d, J = 27.9 Hz), 68.8, 56.5, 48.9, 39.9 (d, J = 9.0 Hz), 35.4, 18.1.
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4-(4-Chlorophenyl)-1-(4-(2,5-difluorophenyl)-4-oxobutyl)-4-hydroxypiperidin-1-ium 2,2,2-
trifluoroacetate (14e). General procedure C. Purification by preparative HPLC (Method C) afforded 
60 mg of a white solid (66%). LCMS (m/z): 394.3 [M+H]+, tR 3.35 min. HRMS (m/z): 
C21H22ClF2NO2: requires 394.1380 [M+H]+; found 394.1385. 1H NMR (CDCl3) δ 11.15 (s, 1H), 7.53 
(ddd, J = 8.7, 5.4, 3.3 Hz, 1H), 7.38 (d, J = 8.3 Hz, 2H), 7.31 (d, J = 8.4 Hz, 2H), 7.23 (dq, J = 6.9, 
3.1 Hz, 1H), 7.14 (td, J = 9.6, 4.1 Hz, 1H), 3.55 (d, J = 11.4 Hz, 2H), 3.33 (q, J = 11.3 Hz, 2H), 3.21 
– 3.05 (m, 4H), 2.53 – 2.42 (m, 2H), 2.19 (t, J = 7.9 Hz, 2H), 1.9 (d, J = 14.5 Hz, 2H). 13C NMR 
(CDCl3) δ 195.1, 158.6 (dd, J = 245.1, 1.9 Hz), 158.2 (dd, J = 251.0, 2.3 Hz), 144.2, 133.8, 128.9, 
125.8, 122.0 (dd, J = 24.5, 9.8 Hz), 118.5 (dd, J = 27.5, 8.0 Hz), 116.4 (d, J = 3.1 Hz), 116.2 (d, J = 
2.8 Hz), 69.0, 56.5, 48.9, 39. 8 (d, J = 8.9 Hz), 35.3, 18.1.
4-(4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)-1-(2,6-difluorophenyl)butan-1-one (14f). A 
solution of 4-(4-chlorophenyl)-1-(3-(2-(2,6-difluorophenyl)-1,3-dioxolan-2-yl)propyl)piperidin-4-ol 
(150 mg, 342 mol) in 15 mL of 15:1 acetone:H2O was treated with pTsOH (84.7 mg, 445 mol), 
and the mixture was heated at reflux for 48 h. The mixture was concentrated under reduced pressure. 
The residue was dissolved in EtOAC (20 mL) and poured into saturated NaHCO3 (20 mL). The 
aqueous phase was extracted with EtOAc (2 × 20 mL) and the combined extracts were dried 
(Na2SO4), and concentrated under reduced pressure. The residue was purified by FCC (eluent, 98:1 
EtOAc/MeOH), affording the title compound as a beige solid (110 mg, 82%). LCMS (m/z): 394.2 
[M+H]+, tR 3.27 min. HRMS (m/z): C21H22ClF2NO2: requires 394.1418 [M+H]+; found 394.1465. 1H 
NMR (CDCl3) δ 7.45 – 7.37 (m, 2H), 7.36 (td, J = 8.4, 7.3, 5.3 Hz, 1H), 7.32 – 7.25 (m, 2H), 6.94 (t, 
J = 8.1 Hz, 2H), 2.92 (t, J = 7.1 Hz, 2H), 2.79 (dt, J = 11.7, 3.1 Hz, 2H), 2.50 – 2.37 (m, 4H), 2.07 
(td, J = 13.2, 4.5 Hz, 2H), 1.94 (p, J = 7.2 Hz, 3H), 1.69 (dd, J = 14.0, 2.7 Hz, 2H). 13C NMR (CDCl3) 
δ 197.6, 159.9 (dd, J = 253.1, 7.5 Hz), 147.1, 132.8, 132.3 (t, J = 10.4 Hz), 128.5, 126.2, 118.5 (t, J 
= 19.6 Hz), 112.4 – 112.2 (m), 112.2 – 111.9 (m), 71.12, 57.6, 49.4, 42.9, 38.5, 21.3.
4-(4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)-1-(3,4-difluorophenyl)butan-1-one (14g). 
General procedure C. Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 48 mg of 
a white solid (74%). LCMS (m/z): 364.2 [M+H]+, tR 3.51 min. HRMS (m/z): C21H22ClF2NO2: requires 
394.1380 [M+H]+; found 394.1388. 1H NMR (CDCl3) δ 7.82 (ddd, J = 10.5, 7.7, 2.1 Hz, 1H), 7.76 
(ddd, J = 8.8, 4.1, 1.8 Hz, 1H), 7.37 (d, J = 8.4 Hz, 2H), 7.28 (d, J = 8.7 Hz, 2H), 7.28 – 7.18 (m, 1H), 
2.95 (t, J = 7.0 Hz, 2H), 2.76 (d, J = 12.2 Hz, 2H), 2.49 – 2.34 (m, 4H), 2.03 – 1.90 (m, 4H), 1.80 (s, 
1H), 1.66 (dd, J = 14.2, 2.6 Hz, 2H). 13C NMR (CDCl3) δ 197.5, 153.6 (dd, J = 256.7, 13.0 Hz), 150.5 
(dd, J = 250.7, 12.9 Hz), 147.0, 134.5 (t, J = 3.8 Hz), 132.9, 128.5, 126.2, 125.1 (dd, J = 7.3, 3.6 Hz), 
117.7 – 117.6 (m), 117.5 – 117.4 (m), 71.1, 57.8, 49.4, 38.4, 36.3, 21.9.
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4-(4-Chlorophenyl)-1-(4-(3,5-difluorophenyl)-4-oxobutyl)-4-hydroxypiperidin-1-ium 2,2,2-
trifluoroacetate (14h). General procedure C. Purification by FCC (eluent 20:0.5:0.1, 
EtOAc/MeOH/NH4OH) gave 42 mg of a white solid (44%). LCMS (m/z): 394.3 [M+H]+, tR 3.44 min. 
HRMS (m/z): C21H22ClF2NO2: requires 394.1307 [M+H]+; found 394.1371. 1H NMR (Methanol-d4) 
δ 7.64 – 7.53 (m, 2H), 7.49 (d, J = 8.4 Hz, 2H), 7.36 (d, J = 8.4 Hz, 2H), 7.28 – 7.17 (m, 1H), 3.71 – 
3.54 (m, 2H), 3.44 (td, J = 12.8, 2.8 Hz, 2H), 2.34 (td, J = 14.1, 4.3 Hz, 2H), 2.27 – 2.15 (m, 2H), 
2.04 – 1.94 (m, 2H). 13C NMR (Methanol-d4) δ 197.6, 164.6 (d, J = 249.3 Hz), 164.5 (d, J = 249.3 
Hz), 147.0, 141.1 (t, J = 7.5 Hz), 134.2, 129.5, 127.4, 112.1 (d, J = 7.2 Hz), 111.9 (d, J = 7.4 Hz), 
109.3 (t, J = 26.0 Hz), 69.2, 57.5, 36.6, 36.3, 19.4.
1-(2-Chlorophenyl)-4-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)butan-1-one (14i). General 
procedure C. Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 89 mg of a white 
solid (70%). LCMS (m/z): 392.2 [M+H]+, tR 3.40 min. HRMS (m/z): C21H23Cl2NO2: requires 
392.1106 [M+H]+; found 392.1184. 1H NMR (CDCl3) δ 7.47 (dd, J = 7.5, 1.7 Hz, 1H), 7.42 – 7.34 
(m, 4H), 7.33 – 7.25 (m, 3H), 2.97 (t, J = 7.1 Hz, 2H), 2.77 (dt, J = 11.9, 3.0 Hz, 2H), 2.47 – 2.36 (m, 
4H), 2.10 – 1.98 (m, 3H), 1.93 (p, J = 7.2 Hz, 2H), 1.68 (dd, J = 14.2, 2.6 Hz, 2H). 13C NMR (CDCl3) 
δ 203.4, 147.1, 139.7, 132.8, 131.7, 130.9, 130.6, 128.9, 128.4, 126.9, 126.2, 71.1, 57.7, 49.4, 40.9, 
38.5, 21.7.
4-(4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)-1-(o-tolyl)butan-1-one (14j). General procedure 
C. Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 90 mg as a white solid 
(70%). LCMS (m/z): 372.3 [M+H]+, tR 3.47 min. HRMS (m/z): C22H26ClNO2: requires 372.1652 
[M+H]+; found 372.1626. 1H NMR (CDCl3) δ 7.66 (d, J = 7.6 Hz, 1H), 7.39 (d, J = 8.5 Hz, 2H), 7.35 
(d, J = 8.0 Hz, 1H), 7.28 (d, J = 8.6 Hz, 2H), 7.24 (d, J = 7.5 Hz, 2H), 2.92 (t, J = 7.1 Hz, 2H), 2.78 
(dt, J = 12.0, 3.1 Hz, 2H), 2.49 (s, 3H), 2.50 – 2.36 (m, 4H), 2.04 (td, J = 13.3, 4.5 Hz, 2H), 1.93 (p, 
J = 7.2 Hz, 3H), 1.68 (dd, J = 14.1, 2.6 Hz, 2H). 13C NMR (CDCl3) δ 204.4, 147.1, 138.3, 138.0, 
132.8, 132.0, 131.2, 128.6, 128.4, 126.2, 125.7, 71.2, 57.9, 49.5, 39.5, 38.6, 21.9, 21.4.
4-(4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)-1-phenylbutan-1-one (14k). General procedure 
C. Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 75mg of a white solid (75 
mg, 79%). LCMS (m/z): 358.1 [M+H]+, tR 3.21 min. HRMS (m/z): C21H24ClNO2: requires 358.1558 
[M+H]+; found 358.1579.  1H NMR (CDCl3) δ 7.98 (d, J = 8.3 Hz, 2H), 7.60 – 7.51 (m, 1H), 7.51 – 
7.42 (m, 2H), 7.36 (d, J = 8.4 Hz, 2H), 7.32 – 7.22 (m, 2H), 3.00 (t, J = 7.0 Hz, 2H), 2.79 (dt, J = 
12.0, 3.0 Hz, 2H), 2.51 – 2.37 (m, 4H), 2.07 – 1.92 (m, 5H), 1.65 (dd, J = 14.1, 2.6 Hz, 2H). 13C NMR 
(CDCl3) δ 200.1, 147.1, 137.4, 132.9, 132.8, 128.7, 128.5, 128.2, 126.2, 71.2, 58.0, 49.4, 38.5, 36.4, 
22.1.
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1-(4-Chlorophenyl)-4-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)butan-1-one (14l). General 
procedure C. Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 68 mg of the title 
compound as a yellow solid (80%). LCMS (m/z): 392.4 [M+H]+, tR 3.68 min. HRMS (m/z): 
C21H23Cl2NO2: requires 392.1106 [M+H]+; found 392.1174. 1H NMR (CDCl3) δ 7.92 (d, J = 8.6 Hz, 
2H), 7.43 (d, J = 8.6 Hz, 2H), 7.35 (d, J = 8.7 Hz, 2H), 7.28 (d, J = 8.7 Hz, 2H), 2.96 (t, J = 7.0 Hz, 
2H), 2.75 (dt, J = 12.2, 3.2 Hz, 2H), 2.50 – 2.35 (m, 4H), 2.06 – 1.90 (m, 4H), 1.73 (s, 1H), 1.65 (dd, 
J = 14.1, 2.6 Hz, 2H). 13C NMR (CDCl3) δ 198.8, 147.1, 139.4, 135.7, 132.8, 129.7, 128.9, 128.5, 
126.2, 71.2, 57.9, 49.4, 38.5, 36.4, 22.1. 
1-(4-Chloro-1,1-dimethoxybutyl)-2,3-difluorobenzene (15c). 4-Chloro-1-(2,3-
difluorophenyl)butan-1-one (450 mg, 2.06 mmol), was taken up in MeOH (15 mL) and treated with 
trimethyl orthoformate (450 mL, 4.12 mmol), p-toluenesulphonic acid monohydrate (7.83 mg, 41.2 
mmol) and stirred for 3 hr at r.t. This was diluted with sat. aq. NaHCO3 (20 mL), H2O (20 mL) and 
extracted with EtOAc (3 x 15 mL). The organic extracts were combined, washed with brine (20 mL), 
dried over MgSO4, filtered and concentrated in vacuo to afford 425 mg of the title compound as a 
light green oil (77%). LCMS (m/z): 265.8 [M+H]+, tR 3.08 min. 1H NMR (CDCl3) δ 7.35 (ddt, J = 
8.1, 6.4, 1.7 Hz, 1H), 7.14 (dddd, J = 9.9, 8.7, 7.1, 1.8 Hz, 1H), 7.06 (tdd, J = 8.1, 5.0, 1.6 Hz, 1H), 
3.42 (t, J = 6.6 Hz, 2H), 3.19 (s, 6H), 2.22 – 2.13 (m, 2H), 1.54 – 1.42 (m, 2H). 13C NMR (CDCl3) δ 
151.1 (dd, J = 247.4, 13.6 Hz), 147.9 (dd, J = 253.0, 13.5 Hz), 129.8 (d, J = 7.3 Hz), 125.1 (dd, J = 
3.7, 2.2 Hz), 123.5 (dd, J = 6.8, 4.8 Hz), 117.3 (d, J = 17.2 Hz), 101.8 (d, J = 3.2 Hz), 48.8, 44.8, 32.4 
(d, J = 3.1 Hz), 27.3.
2-(3-Chloropropyl)-2-(2,6-difluorophenyl)-1,3-dioxolane (15f). A solution of 4-chloro-1-(2,6-
difluorophenyl)butan-1-one (250 mg, 1.14 mmol), ethylene glycol (320 L, 5.72 mmol), and p-
TsOH.H2O (10.9 mg, 57.2 mol) in toluene (15 mL) was heated at reflux temperature with use of a 
Dean-Stark water trap for 16 h. The cooled reaction mixture was washed with NaOH (3  20 mL), 
followed by H2O (2  20 mL) and dried (Na2SO4). The organic layer was removed in vacuo and the 
residue purified by FCC (5:95 EtOAc/PE) to afford 249 mg of a clear oil (83%). LCMS (m/z): 263.3 
[M+H]+, tR 2.91 min. 1H NMR (CDCl3) δ 7.23 (tt, J = 8.2, 5.3 Hz, 1H), 6.85 (t, J = 8.7 Hz, 2H), 4.12 
– 4.03 (m, 2H), 3.93 – 3.84 (m, 2H), 3.56 (t, J = 6.8 Hz, 2H), 2.25 – 2.19 (m, 2H), 1.93 (dt, J = 14.1, 
6.9 Hz, 2H). 13C NMR (CDCl3) δ 160.6 (dd, J = 252.0, 7.6 Hz), 129.9 (t, J = 11.1 Hz), 117.7 (t, J = 
14.7 Hz), 112.7 – 112.6 (m), 112.5 – 112.4 (m), 109.1 (t, J = 3.5 Hz), 64.9, 45.1, 36.5 (t, J = 1.8 Hz), 
26.8.
4-(4-Chlorophenyl)-1-(4-(2,3-difluorophenyl)-4,4-dimethoxybutyl)piperidin-4-ol (16c). General 
procedure C. Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 130 mg as a 
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transparent oil (71%). LCMS (m/z): 440.1 [M+H]+, tR 2.39 min. 1H NMR (CDCl3) δ 7.40 (d, J = 8.7 
Hz, 2H), 7.38 – 7.33 (m, 1H), 7.29 (d, J = 8.6 Hz, 2H), 7.12 (dtd, J = 9.6, 7.9, 1.8 Hz, 1H), 7.04 (tdd, 
J = 8.1, 5.0, 1.4 Hz, 1H), 3.18 (s, 6H), 2.66 (d, J = 11.4 Hz, 2H), 2.38 – 2.19 (m, 4H), 2.11 – 1.97 (m, 
4H), 1.76 (s, 1H), 1.65 (dd, J = 14.1, 2.6 Hz, 2H), 1.29 – 1.16 (m, 2H). 13C NMR (CDCl3) δ 151.1 
(dd, J = 246.8, 13.8 Hz), 147.9 (dd, J = 252.8, 13.3 Hz), 146.9, 132.9, 130.1 (d, J = 7.1 Hz), 128.5, 
126.2, 125.2 (t, J = 4.9, 2.3 Hz), 123.4 (dd, J = 12.0, 5.1 Hz), 117.1 (d, J = 17.2 Hz), 102.2 (t, J = 3.1 
Hz), 71.1, 58.2, 49.4, 48.8, 38.4, 32.7 (d, J = 2.9 Hz), 21.4.
4-(4-Chlorophenyl)-1-(3-(2-(2,6-difluorophenyl)-1,3-dioxolan-2-yl)propyl)piperidin-4-ol (16f). 
General procedure C. Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 325 mg 
as a transparent oil (77%). LCMS (m/z): 438.1 [M+H]+, tR 2.39 min. 1H NMR (CDCl3) δ 7.42 (d, J = 
8.6 Hz, 2H), 7.29 (d, J = 8.6 Hz, 2H), 7.25 – 7.17 (m, 1H), 6.89 – 6.79 (m, 2H), 4.12 – 4.02 (m, 2H), 
3.93 – 3.86 (m, 2H), 2.78 (d, J = 11.3 Hz, 2H), 2.44 – 2.34 (m, 4H), 2.15 – 2.01 (m, 4H), 1.85 (s, 1H), 
1.68 (d, J = 11.5 Hz, 4H). 13C NMR (CDCl3) δ160.7 (d, J = 251.7 Hz), 160.7 (d, J = 251.9 Hz), 147.1, 
132.8, 129.7 (t, J = 11.0 Hz), 128.5, 126.2, 117.9 (t, J = 14.8 Hz), 112.6 (d, J = 7.2 Hz), 112.4 (d, J = 
7.2 Hz), 109.5 (t, J = 3.5 Hz), 71.2, 64.9, 58.5, 49.4, 38.5, 37.2, 20.9.
4-(4-Chlorophenyl)-1-(3-((4-fluorophenyl)thio)propyl)piperidin-4-ol (17a). General procedure 
C. Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 67 mg of a white solid 
(77%). LCMS (m/z): 380.1 [M+H]+, tR 3.73 min. HRMS (m/z): C20H23ClFNOS: requires 380.1276 
[M+H]+; found 380.1308. 1H NMR (CDCl3) δ 7.43 (d, J = 8.6 Hz, 2H), 7.39 – 7.31 (m, 2H), 7.34 – 
7.24 (m, 2H), 6.99 (t, J = 8.6 Hz, 2H), 2.92 (t, J = 7.3 Hz, 2H), 2.75 (dt, J = 11.8, 3.0 Hz, 2H), 2.50 
(t, J = 7.3 Hz, 2H), 2.40 (td, J = 12.0, 2.4 Hz, 2H), 2.08 (td, J = 13.2, 4.5 Hz, 2H), 1.82 (p, J = 7.3 
Hz, 2H), 1.70 (dd, J = 14.2, 2.6 Hz, 3H). 13C NMR (CDCl3) δ 161.8 (d, J = 246.1 Hz), 146.9, 132.9, 
132.3 (d, J = 8.0 Hz), 131.5 (d, J = 3.4 Hz), 128.5, 126.2, 116.1 (d, J = 21.8 Hz), 71.2, 57.4, 49.6, 
38.6, 33.2, 26.8.
4-(4-Chlorophenyl)-1-(3-(4-fluorophenoxy)propyl)piperidin-4-ol (17b). General procedure C. 
Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 77 mg of a white solid (80%). 
LCMS (m/z): 364.2 [M+H]+, tR 3.51 min. HRMS (m/z): C20H23ClFNO2: requires 380.1474 [M+H]+; 
found 364.1492. 1H NMR (CDCl3) δ 7.44 (d, J = 8.7 Hz, 2H), 7.31 (d, J = 8.6 Hz, 2H), 6.96 (dd, J = 
9.6, 7.7 Hz, 2H), 6.84 (dd, J = 9.1, 4.3 Hz, 2H), 3.98 (t, J = 6.3 Hz, 2H), 2.88 – 2.76 (m, 2H), 2.58 (t, 
J = 7.5 Hz, 2H), 2.51 – 2.39 (m, 2H), 2.11 (td, J = 13.2, 4.5 Hz, 2H), 2.03 – 1.93 (m, 2H), 1.73 (dd, 
J = 14.2, 2.7 Hz, 3H). 13C NMR (CDCl3) δ 157.3 (d, J = 238.0 Hz), 155.2 (d, J = 2.1 Hz), 147.0, 
132.9, 128.5, 126.3, 115.9 (d, J = 23.0 Hz), 115.6 (d, J = 7.8 Hz), 71.2, 67.1, 55.4, 49.6, 38.6, 27.1.
4-(4-Chlorophenyl)-1-(4-(4-fluorophenyl)-4-hydroxybutyl)piperidin-4-ol (18). General 
procedure C. Purification by FCC (20:1:0.1, EtOAc/MeOH/NH4OH) gave 60 mg of the title 
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compound as a white solid (67%). LCMS (m/z): 378.3 [M+H]+, tR 3.05 min. HRMS (m/z): 
C21H25ClFNO2: requires 378.1558 [M+H]+; found 378.1643. 1H NMR (CDCl3) δ 7.48 – 7.38 (m, 
2H), 7.36 – 7.23 (m, 4H), 6.99 (t, J = 8.7 Hz, 2H), 4.67 – 4.61 (m, 1H), 3.07 – 2.99 (m, 1H), 2.89 – 
2.79 (m, 1H), 2.64 (td, J = 12.1, 2.7 Hz, 1H), 2.58 – 2.47 (m, 3H), 2.22 (ddt, J = 18.7, 12.9, 4.7 Hz, 
2H), 2.00 – 1.88 (m, 1H), 1.81 – 1.65 (m, 6H), 1.25 (s, 1H). 13C NMR (CDCl3) δ 161.9 (d, J = 244.1 
Hz), 146.4, 141.6 (d, J = 3.1 Hz), 133.2, 128.6, 127.4 (d, J = 8.0 Hz), 126.3, 115.1 (d, J = 21.2 Hz), 
73.3, 70.9, 58.9, 50.2, 48.6, 40.2, 37.9, 37.7, 24.1.
Cyclopropyl(4-fluorophenyl)methanone (19). To a stirred solution of NaOH (1.82 g, 45.6 mmol) 
in H2O (30 mL) at room temperature was added a solution of 4-chloro-1-(4-fluorophenyl)butan-1-
one (5.00 mL, 30.4 mmol) in THF (10 mL). After addition, the reaction temperature was increased 
to 60 °C and stirred for a further 5 hours. EtOAc and H2O were added and the organic phase was 
washed with additional H2O, brine, and dried (Na2SO4) followed by concentration in vacuo to yield 
the product as a light-yellow oil (5.00 g, quantitative). LCMS: tR 2.73 min. 1H NMR (CDCl3) δ 8.08 
– 7.99 (m, 2H), 7.19 – 7.09 (m, 2H), 2.62 (tt, J = 7.8, 4.6 Hz, 1H), 1.23 (ddt, J = 6.8, 4.6, 2.2 Hz, 2H), 
1.04 (dq, J = 7.3, 3.6 Hz, 2H). 13C NMR (CDCl3) δ 199.1, 165.7 (d, J = 254.0 Hz), 134.5 (d, J = 3.0 
Hz), 130.7 (d, J = 9.2 Hz), 115.7 (d, J = 21.8 Hz), 17.2, 11.8.
Cyclopropyl(4-fluorophenyl)methanol (20). To a stirred solution of cyclopropyl(4-
fluorophenyl)methanone (5.00 g, 30.5 mmol) in MeOH (40 mL) at 0º C was added NaBH4 (1.50 g, 
39.6 mmol) portion-wise. The reaction mixture was allowed to come to room temperature and stirred 
for a further 4 hours. To the reaction mixture was added to sat. aqueous NH4Cl solution and EtOAc, 
the phases were separated, the aqueous phase was extracted twice with EtOAc, the combined organic 
phases were dried (Na2SO4), filtered, and concentrated in vacuo to afford 5.01 g of a gold oil (99%). 
LCMS (m/z): tR 2.73 min. 1H NMR (CDCl3) δ 8.08 – 7.99 (m, 1H), 7.19 – 7.09 (m, 1H), 2.62 (tt, J = 
7.8, 4.6 Hz, 1H), 1.23 (ddt, J = 6.8, 4.6, 2.2 Hz, 2H), 1.04 (dq, J = 7.3, 3.6 Hz, 2H). 13C NMR (CDCl3) 
δ 199.1, 165.7 (d, J = 254.0 Hz), 134.5 (d, J = 3.0 Hz), 130.7 (d, J = 9.2 Hz), 115.7 (d, J = 21.8 Hz), 
17.2, 11.8.
(E)-4-(4-Fluorophenyl)but-3-en-1-ol (21). To a mixture of vanadyl acetylacetonate (639 mg, 2.41 
mmol), 2,6-di-tert-butyl-p-cresol (265 mg, 1.20 mmol), and chlorobenzene (40 mL) in a round-
bottom flask was added solution of cyclopropyl(4-fluorophenyl)methanol (4.00 g, 24.1 mmol) in 
chlorobenzene (5.00 mL) and the resulting mixture was stirred at 80 °C. After 48 h, the reaction 
mixture was cooled to r.t. and filtered through a pad of Florisil. The solvent was evaporated and the 
residue was purified by FCC (eluent, 4:1 n-hexanes/EtOAc) to yield 1.41 g of a transparent oil (35%). 
LCMS: tR 2.73 min. 1H NMR (CDCl3) δ 7.35 – 7.26 (m, 2H), 6.98 (t, J = 8.7 Hz, 2H), 6.45 (d, J = 
15.9 Hz, 1H), 6.11 (dt, J = 15.8, 7.1 Hz, 1H), 3.74 (t, J = 6.3 Hz, 2H), 2.46 (qd, J = 6.4, 1.4 Hz, 2H), 
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2.04 (s, 1H). 13C NMR (CDCl3) δ 162.2 (d, J = 246.2 Hz), 133.5 (d, J = 3.2 Hz), 131.6, 127.6 (d, J = 
8.0 Hz), 126.3 (d, J = 2.3 Hz), 115.5 (d, J = 21.5 Hz), 62.1, 36.4.
(E)-4-(4-Fluorophenyl)but-3-en-1-yl methanesulfonate (22). General procedure G. Purification by 
FCC (eluent 4:1, PE/EtOAc) gave 152 mg of a transparent oil (83%). LCMS (m/z): tR 2.79 min. 1H 
NMR (CDCl3) δ 7.35 – 7.28 (m, 2H), 6.99 (t, J = 8.7 Hz, 2H), 6.48 (dt, J = 15.8, 1.5 Hz, 1H), 6.07 
(dt, J = 15.8, 7.0 Hz, 1H), 4.33 (t, J = 6.6 Hz, 2H), 3.01 (s, 3H), 2.65 (qd, J = 6.7, 1.4 Hz, 2H). 13C 
NMR (CDCl3) δ 162.4 (d, J = 246.7 Hz), 133.1 (d, J = 3.2 Hz), 132.5, 127.8 (d, J = 7.9 Hz), 123.7 
(d, J = 2.3 Hz), 115.6 (d, J = 21.6 Hz), 69.1, 37.7, 32.9.
(E)-4-(4-Chlorophenyl)-1-(4-(4-fluorophenyl)but-3-en-1-yl)piperidin-4-ol (23). General 
procedure C. Purification by FCC (20:1:0.1, EtOAc/MeOH/NH4OH) gave 80 mg of a white solid 
(82%). LCMS (m/z): 360.3 [M+H]+, tR 3.62 min. HRMS (m/z): C21H23ClFNO: requires 360.1452 
[M+H]+; found 360.1541. 1H NMR (CDCl3) δ 7.48 – 7.40 (m, 2H), 7.35 – 7.26 (m, 4H), 6.98 (t, J = 
8.7 Hz, 2H), 6.40 (d, J = 15.8 Hz, 1H), 6.12 (dt, J = 15.7, 6.9 Hz, 1H), 2.85 (dt, J = 11.9, 3.0 Hz, 2H), 
2.59 – 2.51 (m, 2H), 2.49 – 2.39 (m, 4H), 2.13 (td, J = 13.2, 4.5 Hz, 2H), 1.91 (s, 1H), 1.73 (dd, J = 
14.2, 2.6 Hz, 2H). 13C NMR (CDCl3) δ 162.1 (d, J = 245.8 Hz), 147.1, 133.9 (d, J = 3.2 Hz), 132.9, 
129.9, 128.5, 128.2 (d, J = 2.3 Hz), 127.5 (d, J = 7.8 Hz), 126.2, 115.5 (d, J = 21.5 Hz), 71.1, 58.5, 
49.5, 38.6, 30.9.
(Z)-4-(4-Fluorophenyl)but-3-en-1-ol (26). An oven-dried round-bottom flask containing a stirring 
bar was charged with Ni(COD)2 (319 mg, 10 mol%), 1,3-bis(2,6-diisopropylphenyl)imidazolinium 
chloride (492 mg, 10 mol%) and LiCl (491 mg, 11.6 mmol). The flask was fitted with a rubber 
septum, evacuated and back-filled with argon (this sequence was repeated an additional two times). 
2,3-Dihydrofuran (875 µL, 11.6 mmol) was added to the flask along with THF (15 mL). The reaction 
mixture was then cooled to -30 ºC and stirred for 2 minutes. Then, (4-fluorophenyl)magnesium 
bromide (0.8 M solution in THF; 28.9 mL, 23.1 mmol) was added via syringe. The mixture was 
stirred at this temperature for 6 hours and then diluted with EtOAc (30 mL) and a solution of aqueous 
sat. NH4Cl (20 mL). The separated organic layer was dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo. The crude material was purified by FCC (eluent 4:1 n-hexanes/EtOAc) to 
afford 600 mg of a transparent oil (31%). LCMS: tR 2.73 min. 1H NMR (CDCl3) δ 7.35 – 7.26 (m, 
2H), 6.98 (t, J = 8.7 Hz, 2H), 6.45 (d, J = 15.9 Hz, 1H), 6.11 (dt, J = 15.8, 7.1 Hz, 1H), 3.74 (t, J = 
6.3 Hz, 2H), 2.46 (qd, J = 6.4, 1.4 Hz, 2H). 13C NMR (CDCl3) δ 161.8 (d, J = 246.1 Hz), 133.3 (d, J 
= 3.4 Hz), 130.6, 130.4 (d, J = 7.8 Hz), 128.3 (d, J = 1.5 Hz), 115.2 (d, J = 21.1 Hz), 62.5, 31.9.
(Z)-4-(4-Fluorophenyl)but-3-en-1-yl methanesulfonate (27). General procedure G. Compound 
degraded after attempted FCC purification (eluent 4:1 EtOAc/PE). Therefore, the compound was used 
for the next reaction without purification.  
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(Z)-4-(4-Chlorophenyl)-1-(4-(4-fluorophenyl)but-3-en-1-yl)-4-hydroxypiperidin-1-ium 2,2,2-
trifluoroacetate (28). General procedure C. Purification by preparative HPLC (Method C) gave 65 
mg of a white solid (75%). LCMS (m/z): 360.3 [M+H]+, tR 3.65 min. HRMS (m/z): C21H23ClFNO: 
requires 360.1452 [M+H]+; found 360.1533.  1H NMR (CDCl3) δ 11.28 (s, 1H), 7.36 (d, J = 8.5 Hz, 
2H), 7.29 (d, J = 8.5 Hz, 2H), 7.20 (dd, J = 8.5, 5.4 Hz, 2H), 7.05 (t, J = 8.6 Hz, 2H), 6.59 (d, J = 
11.5 Hz, 1H), 5.89 (s, 1H), 5.50 (dt, J = 11.5, 7.1 Hz, 1H), 3.37 (d, J = 11.4 Hz, 2H), 3.23 (q, J = 11.2 
Hz, 2H), 3.05 (dq, J = 9.2, 4.4 Hz, 2H), 2.75 (q, J = 7.7 Hz, 2H), 2.41 (td, J = 14.0, 4.2 Hz, 2H), 1.87 
(d, J = 14.4 Hz, 2H). 13C NMR (CDCl3) δ 161.9 (d, J = 247.4 Hz), 144.4, 133.6, 132.2, 132.1 (d, J = 
3.6 Hz), 130.2 (d, J = 8.0 Hz), 128.8, 125.9, 124.4, 115.5 (d, J = 21.5 Hz), 68.7, 56.5, 48.9, 35.2, 23.1.
trans-2-(2-(4-Fluorophenyl)cyclopropyl)ethan-1-ol (29). A solution of (E)-4-(4-fluorophenyl)but-
3-en-1-ol (250 mg, 1.50 mmol) in DCM (30 mL), was treated with Et2Zn (0.9 M in hexanes; 8.36 
mL, 7.52 mmol). After 10 minutes, the reaction mixture was cooled to 0 °C, and treated with a 
solution of CH2I2 (607 µL, 7.52 mmol) in DCM (10 mL) drop-wise over 10 minutes and allowed to 
warm to ambient temperature. After 24 h, the reaction mixture was quenched slowly with sat. aqueous 
NH4Cl and stirred for 10 minutes. The reaction mixture was extracted with DCM (3 x 20 mL), and 
the combined organic phases were washed with sat. aqueous NaHCO3, dried (Na2SO4), filtered, and 
concentrated in vacuo to yield the desired cyclopropane as a transparent oil (265 mg, 98%). LCMS: 
tR 2.67 min. 1H NMR (CDCl3) δ 7.00 (dd, J = 8.6, 5.5 Hz, 2H), 6.93 (dd, J = 9.8, 7.6 Hz, 2H), 3.76 
(t, J = 6.5 Hz, 2H), 1.72 – 1.57 (m, 4H), 1.09 – 1.00 (m, 1H), 0.87 (dt, J = 8.5, 5.0 Hz, 1H), 0.80 (dt, 
J = 8.7, 5.2 Hz, 1H). 13C NMR (CDCl3) δ 161.1 (d, J = 243.0 Hz), 139.0 (d, J = 3.0 Hz), 127.2 (d, J 
= 7.9 Hz), 115.1 (d, J = 21.3 Hz), 62.9, 37.3, 22.2, 20.1, 15.5.
trans-2-(2-(4-Fluorophenyl)cyclopropyl)ethyl methanesulfonate (29a). General procedure G. No 
purification required post work-up, giving 366 mg of a transparent oil (95%). LCMS (m/z): 259.4 
[M+H]+, tR 2.83 min. 1H NMR (CDCl3) δ 7.04 – 6.98 (m, 2H), 6.93 (dd, J = 9.9, 7.6 Hz, 2H), 4.32 
(td, J = 6.5, 1.5 Hz, 2H), 2.96 (s, 3H), 1.83 (qd, J = 6.7, 3.3 Hz, 2H), 1.71 (dt, J = 9.2, 4.9 Hz, 1H), 
1.10 – 1.00 (m, 1H), 0.92 (dt, J = 8.5, 5.1 Hz, 1H), 0.83 (dt, J = 8.7, 5.3 Hz, 1H). 13C NMR (CDCl3) 
δ 161.2 (d, J = 243.4 Hz), 138.3 (d, J = 3.1 Hz), 127.3 (d, J = 7.7 Hz), 115.2 (d, J = 21.3 Hz), 69.8, 
37.4, 33.8, 22.3, 19.4, 15.2. 
trans-4-(4-Chlorophenyl)-1-(2-(2-(4-fluorophenyl)cyclopropyl)ethyl)piperidin-4-ol (29b). 
General procedure C. Purification by FCC (20:1:0.1, EtOAc/MeOH/NH4OH) gave 72 mg of a white 
solid (80%). LCMS (m/z): 374.3 [M+H]+, tR 3.73 min. HRMS (m/z): C22H25ClFNO: requires 
374.1609 [M+H]+; found 374.1690. 1H NMR (CDCl3) δ 7.46 – 7.39 (m, 2H), 7.33 – 7.26 (m, 2H), 
7.00 (dd, J = 8.6, 5.5 Hz, 2H), 6.97 – 6.88 (m, 2H), 2.81 (dt, J = 11.5, 3.3 Hz, 2H), 2.54 (dd, J = 8.9, 
6.9 Hz, 2H), 2.43 (ddd, J = 11.8, 9.7, 2.0 Hz, 2H), 2.10 (td, J = 13.3, 4.4 Hz, 3H), 1.71 (dd, J = 14.2, 
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2.7 Hz, 2H), 1.66 – 1.55 (m, 3H), 1.01 – 0.91 (m, 1H), 0.85 (dt, J = 8.4, 5.0 Hz, 1H), 0.77 (dt, J = 
8.6, 5.2 Hz, 1H). 13C NMR (CDCl3) δ 161.1 (d, J = 243.0 Hz), 147.1, 139.2 (d, J = 3.1 Hz), 132.8, 
128.5, 127.2 (d, J = 7.7 Hz), 126.2, 115.1 (d, J = 21.3 Hz), 71.1, 58.5, 49.7, 49.6, 38.5 (d, J = 1.5 Hz), 
32.1, 22.6, 21.6, 15.8.
cis-2-(2-(4-Fluorophenyl)cyclopropyl)ethan-1-ol (30). A solution of (Z)-4-(4-fluorophenyl)but-3-
en-1-ol (250 mg, 1.50 mmol) in DCM (30 mL), was treated with Et2Zn (0.9 M in hexanes; 8.36 mL, 
7.52 mmol). After 10 minutes, the reaction mixture was cooled to 0 °C, and treated with a solution of 
CH2I2 (607 µL, 7.52 mmol) in DCM (10 mL) drop-wise over 10 minutes and allowed to warm to 
ambient temperature. After 24 h, the reaction mixture was quenched slowly with sat. aqueous NH4Cl 
and stirred for 10 minutes. The reaction mixture was extracted with DCM (3 x 20 mL), and the 
combined organic phases were washed with sat. aqueous NaHCO3, dried (Na2SO4), and concentrated 
in vacuo to yield the desired cyclopropane as a yellow oil (271 mg, quantitative). LCMS (m/z): 181.3 
[M+H]+, tR 2.65 min. 1H NMR (CDCl3) δ 7.16 – 7.11 (m, 2H), 6.95 (t, J = 8.7 Hz, 2H), 3.56 (td, J = 
6.3, 2.5 Hz, 2H), 2.11 (td, J = 8.3, 5.8 Hz, 1H), 1.58 (s, 1H), 1.43 – 1.31 (m, 1H), 1.19 – 1.05 (m, 
2H), 1.01 (td, J = 8.2, 4.9 Hz, 1H), 0.65 (q, J = 5.3 Hz, 1H). 13C NMR (CDCl3) δ 161.4 (d, J = 243.7 
Hz), 134.8 (d, J = 3.2 Hz), 130.5 (d, J = 7.8 Hz), 114.8 (d, J = 21.1 Hz), 62.8, 31.9, 19.8, 15.4, 9.6.
cis-2-(2-(4-Fluorophenyl)cyclopropyl)ethyl methanesulfonate (30a). General procedure G. 
Purification by FCC (eluent 4:1, PE/EtOAc) gave 274 mg of a transparent oil (83%). LCMS: tR 2.83 
min. 1H NMR (CDCl3) δ 7.19 – 7.10 (m, 2H), 6.96 (t, J = 8.7 Hz, 2H), 4.20 – 4.04 (m, 2H), 2.92 (s, 
3H), 2.18 (td, J = 8.6, 6.0 Hz, 1H), 1.56 (dq, J = 13.2, 6.6 Hz, 1H), 1.31 (dt, J = 14.4, 7.2 Hz, 1H), 
1.22 – 1.15 (m, 1H), 1.05 (td, J = 8.4, 5.3 Hz, 1H), 0.69 (q, J = 5.6 Hz, 1H). 13C NMR (CDCl3) δ 
161.5 (d, J = 244.2 Hz), 134.1 (d, J = 3.1 Hz), 130.5 (d, J = 7.9 Hz), 115.1 (d, J = 21.2 Hz), 69.8, 
37.3, 28.6, 19.9, 14.7, 9.5.
cis-4-(4-Chlorophenyl)-1-(2-(2-(4-fluorophenyl)cyclopropyl)ethyl)piperidin-4-ol (30b). General 
procedure C. Purification by FCC (20:1:0.1, EtOAc/MeOH/NH4OH) gave 49 mg of a white solid 
(66%). LCMS (m/z): 374.3 [M+H]+, tR 3.73 min. HRMS (m/z): C22H25ClFNO: requires 374.1609 
[M+H]+; found 374.1687. 1H NMR (CDCl3) δ 7.44 – 7.37 (m, 2H), 7.33 – 7.26 (m, 2H), 7.21 – 7.12 
(m, 2H), 6.97 (t, J = 8.7 Hz, 2H), 2.70 – 2.59 (m, 2H), 2.51 – 2.40 (m, 1H), 2.42 – 2.29 (m, 2H), 2.25 
(td, J = 13.3, 11.7, 3.8 Hz, 1H), 2.16 – 1.98 (m, 3H), 1.86 (s, 1H), 1.65 (dq, J = 14.2, 2.8 Hz, 2H), 
1.34 (td, J = 11.9, 11.2, 5.4 Hz, 1H), 1.20 – 0.97 (m, 3H), 0.64 (q, J = 5.3 Hz, 1H). 13C NMR (CDCl3) 
δ 161.2 (d, J = 243.5 Hz), 146.9, 134.8 (d, J = 3.0 Hz), 132.7, 130.4 (d, J = 7.7 Hz), 128.4, 126.1, 
114.7 (d, J = 21.2 Hz), 70.9, 58.3, 49.6, 48.9, 38.2, 26.0, 20.1, 16.9, 9.7.
3-Chloro-1-(4-fluorophenyl)propan-1-one (33a). To a stirred suspension of AlCl3 (3.40 g, 25.5 
mmol) in DCM (100 mL) at 0 ºC was added fluorobenzene (2.00 mL, 21.2 mmol) drop-wise. After 
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30 minutes, 3-chloropropionyl chloride (2.81 mL, 25.5 mmol) was added drop-wise. The reaction 
was brought to room temperature and stirred for a further 6 hours, poured out on ice and extracted 
with DCM (2 x 30 mL). The organic fractions were collected and washed with sat. aqueous NaHCO3 
and H2O, dried (Na2SO4), filtered, and the solvent removed in vacuo. The residue was purified by 
FCC (eluent, 99:1 PE/EtOAc) to afford 3.68 g of beige crystals (93%). LCMS (m/z): 187.3 [M+H]+, 
tR 2.75 min. 1H NMR (CDCl3) δ 8.07 – 7.90 (m, 2H), 7.19 – 7.09 (m, 2H), 3.91 (t, J = 6.8 Hz, 2H), 
3.43 (t, J = 6.8 Hz, 2H). 13C NMR (CDCl3) δ 195.2, 166.1 (d, J = 255.6 Hz), 132.9 (d, J = 3.1 Hz), 
130.9 (d, J = 9.4 Hz), 116.0 (d, J = 21.9 Hz), 41.3, 38.7.
5-Chloro-1-(4-fluorophenyl)pentan-1-one (33c). To a stirred suspension of AlCl3 (2.12 g, 15.9 
mmol) in DCM (75 mL) at 0 ºC was added fluorobenzene (1.25 mL, 13.3 mmol) drop-wise. After 30 
minutes, 5-chloropentanoyl chloride (2.06 mL, 15.9 mmol) was added drop-wise. The reaction was 
brought to room temperature and stirred overnight, poured out on ice and extracted with DCM (2 x 
30 mL). The organic fractions were collected and washed with sat. aqueous NaHCO3 and H2O, dried 
(Na2SO4), filtered, and the solvent removed in vacuo. The residue was purified by FCC (eluent, 1:99 
PE/EtOAc) to afford 2.55 g of a light brown oil (90%). LCMS (m/z): 215.3 [M+H]+, tR 2.91 min. 1H 
NMR (CDCl3) δ 8.01 – 7.92 (m, 2H), 7.12 (t, J = 8.6 Hz, 2H), 3.57 (t, J = 6.0 Hz, 2H), 2.98 (t, J = 
6.5 Hz, 2H), 1.91 – 1.79 (m, 4H). 13C NMR (CDCl3) δ 198.0, 165.8 (d, J = 254.7 Hz), 133.4 (d, J = 
3.1 Hz), 130.7 (d, J = 9.4 Hz), 115.8 (d, J = 21.9 Hz), 44.8, 37.6, 32.1, 21.6.
3-(4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)propan-1-one (34a). 
General procedure C. Purification by FCC (20:1:0.1, EtOAc/MeOH/NH4OH) gave 110 mg of a white 
solid (77%). LCMS (m/z): 362.4 [M+H]+, tR 3.42 min. HRMS (m/z): C20H21ClFNO2: requires 
362.1245 [M+H]+; found 362.1357. 1H NMR (CDCl3) δ 8.01 – 7.95 (m, 2H), 7.46 – 7.39 (m, 2H), 
7.34 – 7.26 (m, 2H), 7.13 (t, J = 8.6 Hz, 2H), 3.18 (dd, J = 7.9, 6.7 Hz, 2H), 2.89 (dd, J = 8.0, 6.7 Hz, 
2H), 2.82 (dt, J = 11.6, 3.2 Hz, 2H), 2.54 (td, J = 12.0, 2.5 Hz, 2H), 2.09 (td, J = 13.2, 4.5 Hz, 2H), 
1.89 – 1.83 (s, 1H), 1.73 (dt, J = 14.0, 2.8 Hz, 2H). 13C NMR (CDCl3) δ 197.7, 165.9 (d, J = 254.8 
Hz), 146.9, 133.5 (d, J = 3.0 Hz), 132.9, 130.8 (d, J = 9.2 Hz), 128.6, 126.2, 115.9 (d, J = 21.9 Hz), 
70.9, 53.3, 49.6, 38.5, 36.4.
5-(4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)pentan-1-one (34c). General 
procedure C. Purification by FCC (20:1:0.1, EtOAc/MeOH/NH4OH) gave 115 mg of a white solid 
(75%). LCMS (m/z): 390.3 [M+H]+, tR 3.42 min. HRMS (m/z): C22H25ClFNO2: requires 390.1558 
[M+H]+; found 390.1640. 1H NMR (CDCl3) δ 8.02 – 7.92 (m, 2H), 7.45 – 7.37 (m, 2H), 7.31 – 7.24 
(m, 2H), 7.11 (t, J = 8.6 Hz, 2H), 2.96 (t, J = 7.2 Hz, 2H), 2.79 (dt, J = 11.9, 3.0 Hz, 2H), 2.50 – 2.35 
(m, 4H), 2.26 (s, 1H), 2.08 (td, J = 13.1, 4.4 Hz, 2H), 1.80 – 1.65 (m, 4H), 1.66 – 1.53 (m, 2H). 13C 
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NMR (CDCl3) δ 198.6, 165.8 (d, J = 254.6 Hz), 147.1, 133.5 (d, J = 3.0 Hz), 132.8, 130.8 (d, J = 9.3 
Hz), 128.5, 126.2, 115.8 (d, J = 21.8 Hz), 71.1, 58.5, 49.5, 38.5, 38.4, 26.6, 22.4.
1-(3-Chloropropyl)-4-fluorobenzene (35a). 3-Chloro-1-(4-fluorophenyl)propan-1-one (600 mg, 
3.22 mmol) was taken up in trifluoroacetic acid (5 mL) and the solution cooled to 0 C. To this 
solution was added dropwise triethylsilane (1.44 mL, 9.00 mmol) and the reaction stirred at 0 C for 
5 h. The solvents were removed in vacuo and the crude product was purified by FCC (eluent, n-
hexanes) to afford 437 mg of a transparent oil (79%). LCMS: tR 3.00 min. 1H NMR (CDCl3) δ 7.20 
– 7.12 (m, 2H), 7.03 – 6.94 (m, 2H), 3.52 (t, J = 6.4 Hz, 2H), 2.77 (t, J = 7.4 Hz, 2H), 2.13 – 2.01 (m, 
2H). 13C NMR (CDCl3) δ 161.6 (d, J = 243.8 Hz), 136.4 (d, J = 3.1 Hz), 130.0 (d, J = 7.9 Hz), 115.4 
(d, J = 21.1 Hz), 44.2, 34.2, 32.0.
1-(4-Chlorobutyl)-4-fluorobenzene (35b). 4-Chloro-1-(4-fluorophenyl)butan-1-one (1.25 mL, 7.66 
mmol) was taken up in trifluoroacetic acid (10 mL) and the solution cooled to 0 C. To this solution 
was added dropwise triethylsilane (3.42 mL, 21.5 mmol) and the reaction stirred at 0 C for 2 h. The 
solvents were removed in vacuo and the crude product was purified by FCC (eluent, n-hexanes) to 
afford 1.27 g of a transparent oil (89%). LCMS (m/z): 187.2 [M+H]+, tR 3.10 min. 1H NMR (CDCl3) 
δ 7.19 – 7.09 (m, 1H), 7.03 – 6.92 (m, 1H), 3.55 (t, J = 6.3 Hz, 1H), 2.63 (t, J = 7.1 Hz, 1H), 1.87 – 
1.70 (m, 2H). 13C NMR (CDCl3) δ 161.41 (d, J = 243.4 Hz), 137.55 (d, J = 3.1 Hz), 129.80 (d, J = 
7.8 Hz), 115.21 (d, J = 21.2 Hz), 44.95, 34.41, 32.10, 28.81.
1-(5-Chloropentyl)-4-fluorobenzene (35c). 5-Chloro-1-(4-fluorophenyl)pentan-1-one (600 mg, 
2.80 mmol) was taken up in trifluoroacetic acid (5 mL) and the solution cooled to 0 C. To this 
solution was added dropwise triethylsilane (1.25 mL, 7.83 mmol) and the reaction stirred at 0 C for 
5 h. The solvents were removed in vacuo and the crude product was purified by FCC (eluent, n-
hexanes) to afford 472 mg of a transparent oil (84%). LCMS: tR 3.15 min. 1H NMR (CDCl3) δ 7.13 
(dd, J = 8.4, 5.6 Hz, 2H), 6.97 (t, J = 8.7 Hz, 2H), 3.53 (t, J = 6.7 Hz, 2H), 2.60 (t, J = 7.7 Hz, 2H), 
1.81 (dd, J = 8.0, 6.7 Hz, 2H), 1.67 – 1.58 (m, 2H), 1.54 – 1.43 (m, 2H). 13C NMR (CDCl3) δ 161.3 
(d, J = 243.0 Hz), 138.0 (d, J = 3.2 Hz), 129.8 (d, J = 7.9 Hz), 115.1 (d, J = 21.0 Hz), 45.1, 35.1, 32.6, 
30.9, 26.6.
4-(4-Chlorophenyl)-1-(3-(4-fluorophenyl)propyl)piperidin-4-ol (36a). General procedure C. 
Purification by FCC (20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 105 mg of a white solid (72 mg, 70%). 
LCMS (m/z): 348.3 [M+H]+, tR 3.52 min. HRMS (m/z): C20H23ClFNO: requires 348.1452 [M+H]+; 
found 348.1532. 1H NMR (CDCl3) δ 7.47 – 7.40 (m, 2H), 7.35 – 7.27 (m, 2H), 7.18 – 7.10 (m, 2H), 
7.01 – 6.91 (m, 2H), 2.82 (dd, J = 9.1, 3.2 Hz, 2H), 2.62 (t, J = 7.7 Hz, 2H), 2.49 – 2.37 (m, 4H), 2.13 
(td, J = 13.2, 4.5 Hz, 3H), 1.84 (dq, J = 9.6, 7.7 Hz, 2H), 1.77 – 1.67 (m, 2H). 13C NMR (CDCl3) δ 
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161.2 (d, J = 243.1 Hz), 146.8, 137.6 (d, J = 3.2 Hz), 132.8, 129.7 (d, J = 7.8 Hz), 128.4, 126.1, 115.1 
(d, J = 21.1 Hz), 71.0, 57.9, 49.4, 38.4, 32.9, 28.7.
4-(4-Chlorophenyl)-1-(4-(4-fluorophenyl)butyl)piperidin-4-ol (36b). General procedure C. 
Purification by FCC (20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 150 of a white solid (77%). LCMS 
(m/z): 362.2 [M+H]+, tR 3.72 min. HRMS (m/z): C21H25ClFNO: requires 362.1712 [M+H]+; found 
362.1743. 1H NMR (CDCl3) δ 7.43 (d, J = 8.6 Hz, 2H), 7.30 (d, J = 8.6 Hz, 2H), 7.12 (dd, J = 8.4, 
5.6 Hz, 2H), 6.95 (t, J = 8.7 Hz, 2H), 2.80 (dd, J = 9.1, 3.1 Hz, 2H), 2.61 (t, J = 7.3 Hz, 2H), 2.47 – 
2.35 (m, 4H), 2.12 (td, J = 13.2, 4.4 Hz, 2H), 1.81 (s, 1H), 1.71 (dd, J = 14.1, 2.7 Hz, 2H), 1.58 (dtd, 
J = 23.0, 8.4, 3.3 Hz, 4H). 13C NMR (CDCl3) δ 161.3 (d, J = 243.1 Hz), 147.0, 138.1 (d, J = 3.3 Hz), 
132.9, 129.8 (d, J = 7.7 Hz), 128.5, 126.2, 115.1 (d, J = 21.0 Hz), 71.2, 58.8, 49.6, 38.5, 35.1, 29.7, 
26.6.
4-(4-Chlorophenyl)-1-(5-(4-fluorophenyl)pentyl)piperidin-4-ol (36c). General procedure C. 
Purification by FCC (20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 116 mg of a white solid (80%).
LCMS (m/z): 376.3 [M+H]+, tR 3.88 min. HRMS (m/z): C22H27ClFNO: requires 376.1765 
[M+H]+; found 376.1846. 1H NMR (CDCl3) δ 7.43 (d, J = 8.6 Hz, 2H), 7.30 (d, J = 8.6 Hz, 2H), 7.12 
(dd, J = 8.4, 5.6 Hz, 2H), 6.95 (t, J = 8.7 Hz, 2H), 2.82 (dt, J = 11.6, 3.2 Hz, 2H), 2.58 (t, J = 7.7 Hz, 
2H), 2.45 – 2.35 (m, 4H), 2.13 (td, J = 13.3, 4.5 Hz, 3H), 1.76 – 1.67 (m, 2H), 1.67 – 1.57 (m, 2H), 
1.55 (ddt, J = 10.9, 7.8, 3.7 Hz, 2H), 1.40 – 1.29 (m, 2H). 13C NMR (CDCl3) δ 161.3 (d, J = 243.0 
Hz), 147.0, 138.3 (d, J = 3.1 Hz), 132.9, 129.8 (d, J = 7.7 Hz), 128.5, 126.2, 115.1 (d, J = 21.0 Hz), 
71.2, 58.9, 49.6, 38.5, 35.2, 31.6, 27.3, 26.9.
3-(4-Fluorophenyl)prop-2-yn-1-ol (39a). General procedure E. Purification by FCC (eluent, 1:5 
EtOAc/n-hexanes) gave 2.45 g of a brown oil (94%). LCMS (m/z): 151.1 [M+H]+, tR 2.47 min. 1H 
NMR (CDCl3) δ 7.44 – 7.37 (m, 2H), 7.03 – 6.93 (m, 2H), 4.48 (s, 2H), 2.29 (s, 1H). 13C NMR 
(CDCl3) δ 162.7 (d, J = 249.6 Hz), 133.7 (d, J = 8.4 Hz), 118.7 (d, J = 3.5 Hz), 115.7 (d, J = 22.1 
Hz), 87.1 (d, J = 1.5 Hz), 84.7, 51.6.
4-(4-Fluorophenyl)but-3-yn-1-ol (39b). General procedure E. Purification by FCC (eluent, 1:5 
EtOAc/n-hexanes) gave 3.41 g of a brown oil that solidified upon standing (96%). LCMS (m/z): 165.3 
[M+H]+, tR 2.56 min. 1H NMR (CDCl3) δ 7.43 – 7.36 (m, 2H), 6.99 (t, J = 8.7 Hz, 2H), 3.82 (t, J = 
6.3 Hz, 2H), 2.68 (t, J = 6.3 Hz, 2H), 2.14 (s, 1H). 13C NMR (CDCl3) δ 162.4 (d, J = 248.8 Hz), 133.6 
(d, J = 8.3 Hz), 119.5 (d, J = 3.5 Hz), 115.56 (d, J = 22.0 Hz), 86.2 (d, J = 1.4 Hz), 81.4, 61.2, 23.8.
5-(4-Fluorophenyl)pent-4-yn-1-ol (39c). General procedure E. Purification by FCC (eluent, 1:5 
EtOAc/n-hexanes) gave 2.05 g of a brown oil (94%). LCMS (m/z): 179.3 [M+H]+, tR 2.65 min. 1H 
NMR (CDCl3) δ 7.40 – 7.31 (m, 2H), 7.01 – 6.92 (m, 2H), 3.81 (t, J = 6.1 Hz, 2H), 2.52 (t, J = 7.0 
Hz, 1H), 1.85 (p, J = 6.6 Hz, 2H), 1.72 (s, 1H). 13C NMR (CDCl3) δ 162.2 (d, J = 248.3 Hz), 133.5 
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(d, J = 8.3 Hz), 119.91 (d, J = 3.5 Hz), 115.55 (d, J = 22.1 Hz), 89.1 (d, J = 1.5 Hz), 80.2, 61.9, 31.5, 
16.1.
3-(4-Fluorophenyl)prop-2-yn-1-yl methanesulfonate (40a). General procedure G. Compound 
degraded after attempted FCC purification (eluent 4:1, PE/EtOAc). Therefore, the compound was 
used for the next reaction without purification.  
1-(4-Chlorobut-1-yn-1-yl)-4-fluorobenzene (40b). General procedure D. Purification by FCC 
(eluent, n-hexanes) gave 2.56 g of a yellow oil (75%). LCMS (m/z): 183.0 [M+H]+, tR 3.00 min. 1H 
NMR (CDCl3) δ 7.44 – 7.34 (m, 1H), 7.04 – 6.93 (m, 1H), 3.67 (t, J = 7.2 Hz, 1H), 2.87 (t, J = 7.2 
Hz, 1H). 13C NMR (CDCl3) δ 162.5 (d, J = 249.1 Hz), 133.7 (d, J = 8.4 Hz), 119.3 (d, J = 3.5 Hz), 
115.6 (d, J = 22.0 Hz), 85.5 (d, J = 1.5 Hz), 81.6, 42.3, 23.9.
5-(4-Fluorophenyl)pent-4-yn-1-yl methanesulfonate (40c). General procedure G. Purification by 
FCC (eluent 4:1, PE/EtOAc) gave 333 mg of a transparent oil (93%). LCMS (m/z): 257.2 [M+H]+, tR 
2.83 min. 1H NMR (CDCl3) δ 7.40 – 7.33 (m, 2H), 6.97 (t, J = 8.7 Hz, 2H), 4.40 (t, J = 6.1 Hz, 2H), 
3.03 (s, 3H), 2.56 (t, J = 6.8 Hz, 2H), 2.03 (p, J = 6.5 Hz, 2H). 13C NMR (CDCl3) δ 162.3 (d, J = 
248.7 Hz), 133.5 (d, J = 8.4 Hz), 119.5 (d, J = 3.6 Hz), 115.6 (d, J = 22.1 Hz), 87.32, 80.9, 37.4, 28.2, 
15.8.
4-(4-Chlorophenyl)-1-(3-(4-fluorophenyl)prop-2-yn-1-yl)piperidin-4-ol (41a). General procedure 
C. Purification by FCC (20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 84 mg of a yellow solid (74%). 
LCMS (m/z): 344.2 [M+H]+, tR 3.46 min. HRMS (m/z): C20H19ClFNO: requires 344.1139 [M+H]+; 
found 344.1214. 1H NMR (CDCl3) δ 7.47 – 7.37 (m, 4H), 7.31 (d, J = 8.3 Hz, 2H), 6.98 (t, J = 8.5 
Hz, 2H), 3.52 (s, 1H), 2.90 (dt, J = 11.6, 3.0 Hz, 2H), 2.71 (td, J = 12.0, 2.5 Hz, 2H), 2.18 (td, J = 
13.2, 4.6 Hz, 2H), 1.84 (s, 1H), 1.77 (dd, J = 14.2, 2.6 Hz, 2H). 13C NMR (CDCl3) δ 162.5 (d, J = 
249.1 Hz), 146.9, 133.7 (d, J = 8.3 Hz), 132.9, 128.6, 126.2, 119.2 (d, J = 3.5 Hz), 115.6 (d, J = 22.1 
Hz), 84.4 (d, J = 6.1 Hz), 70.8, 48.7, 48.0, 38.5.
4-(4-Chlorophenyl)-1-(4-(4-fluorophenyl)but-3-yn-1-yl)piperidin-4-ol (41b). General procedure 
C. Purification by FCC (20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 45 mg of a light brown solid (45 
mg, 80%). LCMS (m/z): 358.2 [M+H]+, tR 3.60 min. HRMS (m/z): C21H21ClFNO: requires 358.1400 
[M+H]+; found 358.1440. 1H NMR (CDCl3) δ 7.44 (d, J = 8.3 Hz, 2H), 7.37 (dd, J = 8.4, 5.5 Hz, 2H), 
7.31 (d, J = 8.3 Hz, 2H), 6.97 (t, J = 8.5 Hz, 2H), 2.89 – 2.80 (m, 2H), 2.75 (t, J = 7.6 Hz, 2H), 2.66 
– 2.57 (m, 2H), 2.55 (d, J = 11.9 Hz, 2H), 2.12 (td, J = 13.2, 4.5 Hz, 2H), 1.81 (s, 1H), 1.79 – 1.68 
(m, 2H). 13C NMR (CDCl3) δ 162.3 (d, J = 248.5 Hz), 146.9, 133.5 (d, J = 8.3 Hz), 132.9, 128.6, 
126.2, 119.9, 115.5 (d, J = 21.9 Hz), 88.1, 80.5, 71.1, 57.5, 49.2, 38.6, 17.9.
4-(4-Chlorophenyl)-1-(5-(4-fluorophenyl)pent-4-yn-1-yl)piperidin-4-ol (41c). General procedure 
C. Purification by FCC (20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 74 mg of a gold oil (68%). LCMS 
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(m/z): 372.3 [M+H]+, tR 3.78 min. HRMS (m/z): C22H23ClFNO: requires 372.1452 [M+H]+; found 
372.1532. 1H NMR (CDCl3) δ 7.45 – 7.38 (m, 2H), 7.39 – 7.31 (m, 2H), 7.32 – 7.25 (m, 2H), 6.96 (t, 
J = 8.7 Hz, 2H), 2.80 (dt, J = 11.9, 3.1 Hz, 2H), 2.57 – 2.48 (m, 2H), 2.49 – 2.38 (m, 4H), 2.25 (s, 
1H), 2.10 (td, J = 13.2, 4.5 Hz, 2H), 1.80 (p, J = 7.2 Hz, 2H), 1.70 (dd, J = 14.1, 2.7 Hz, 2H). 13C 
NMR (CDCl3) δ 162.1 (d, J = 248.3 Hz), 147.1, 120.0 (d, J = 3.5 Hz), 115.5 (d, J = 22.0 Hz), 89.45 
(d, J = 1.5 Hz), 79.9, 71.1, 57.8, 49.5, 38.5, 26.2, 17.6.
3-(4-Chlorophenyl)-8-(4-(4-fluorophenyl)-4-oxobutyl)-3-hydroxy-8-azabicyclo[3.2.1]octan-8-
ium 2,2,2-trifluoroacetate (42). General procedure C. Purification by preparative HPLC (Method 
C) afforded 45 mg of the title compound as a white solid (68%). LCMS (m/z): 402.3 [M+H]+, tR 3.58 
min. HRMS (m/z): C23H25ClFNO2: requires 402.1631 [M+H]+; found 402.1633. 1H NMR (CDCl3) δ 
11.34 (s, 1H), 7.99 (dd, J = 8.6, 5.4 Hz, 2H), 7.52 (d, J = 8.3 Hz, 2H), 7.33 – 7.25 (m, 2H), 7.17 (t, J 
= 8.5 Hz, 2H), 4.71 (s, 1H), 4.00 (t, J = 4.1 Hz, 2H), 3.13 (t, J = 6.1 Hz, 2H), 3.06 (dt, J = 10.5, 5.8 
Hz, 4H), 2.84 – 2.69 (m, 4H), 2.26 – 2.12 (m, 4H), 2.05 (d, J = 15.4 Hz, 2H). 13C NMR (CDCl3) δ 
197.1, 166.2 (d, J = 256.0 Hz), 145.8, 133.5, 132.7 (d, J = 3.0 Hz), 130.8 (d, J = 9.4 Hz), 128.7, 126.3, 
116.1 (d, J = 22.0 Hz), 71.9, 61.6, 50.9, 43.6, 34.9, 24.4, 18.8.
4-(4-(4-Chlorophenyl)piperazin-1-yl)-1-(4-fluorophenyl)butan-1-one (43). General procedure C. 
Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 115 mg of the title compound 
as a white solid (69%). LCMS (m/z): 361.3 [M+H]+, tR 3.41 min. HRMS (m/z): C20H22ClFN2O: 
requires 361.1405 [M+H]+; found 361.1487. 1H NMR (CDCl3) δ 8.05 – 7.93 (m, 2H), 7.20 – 7.14 
(m, 2H), 7.11 (t, J = 8.6 Hz, 2H), 6.84 – 6.79 (m, 2H), 3.09 (dd, J = 6.2, 3.8 Hz, 4H), 2.99 (t, J = 7.0 
Hz, 2H), 2.57 (t, J = 5.0 Hz, 4H), 2.45 (t, J = 7.0 Hz, 2H), 1.97 (p, J = 7.1 Hz, 2H). 13C NMR (CDCl3) 
δ 198.4, 165.7 (d, J = 254.4 Hz), 150.0, 133.7 (d, J = 3.0 Hz), 130.7 (d, J = 9.2 Hz), 128.9, 124.4, 
117.2, 115.7 (d, J = 21.8 Hz), 57.7, 53.0, 49.1, 36.2, 21.6.
4-(4-Chlorophenyl)-1,2,3,6-tetrahydropyridine (44). To concentrated hydrochloric acid (10 mL) 
in a 25 mL round-bottom flask was added 4-(4-chlorophenyl)piperidin-4-ol (500 mg, 2.36 mmol), 
and the suspension was stirred at reflux for 5 h. The solution was allowed to cool, then slowly added 
to 5 M NaOH (20 mL), and extracted with DCM (3 × 20 mL). The organic extracts were dried 
(Na2SO4) and concentrated under reduced pressure to afford the 457 mg of a white solid (quantitative 
yield). LCMS (m/z): 194.3 [M+H]+, tR 1.87 min. 1H NMR (CDCl3) δ 7.34 – 7.23 (m, 4H), 6.11 (dt, J 
= 3.5, 1.8 Hz, 1H), 3.51 (q, J = 3.0 Hz, 2H), 3.09 (t, J = 5.7 Hz, 2H), 2.41 (dddd, J = 6.9, 4.0, 2.7, 1.2 
Hz, 2H), 1.65 (s, 1H). 13C NMR (CDCl3) δ 139.9, 134.4, 132.7, 128.5, 126.2, 124.3, 45.7, 43.4, 27.9.
4-(4-(4-Chlorophenyl)-3,6-dihydropyridin-1(2H)-yl)-1-(4-fluorophenyl)butan-1-one (45). 
General procedure C. Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 49 mg of 
the title compound as a white solid (80%). LCMS (m/z): 358.2 [M+H]+, tR 3.64 min. HRMS (m/z): 
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C21H21ClFNO: requires 358.1296 [M+H]+; found 358.1379. 1H NMR (CDCl3) δ 8.04 – 7.94 (m, 2H), 
7.33 – 7.23 (m, 4H), 7.11 (t, J = 8.6 Hz, 2H), 6.04 (t, J = 1.7 Hz, 1H), 3.14 (q, J = 3.0 Hz, 2H), 3.02 
(t, J = 7.1 Hz, 2H), 2.69 (t, J = 5.7 Hz, 2H), 2.54 (t, J = 7.1 Hz, 2H), 2.49 (tt, J = 5.8, 2.5 Hz, 2H), 
2.01 (p, J = 7.1 Hz, 2H). 13C NMR (CDCl3) δ 198.6, 165.8 (d, J = 254.4 Hz), 139.4, 134.1, 133.7 (d, 
J = 3.0 Hz), 132.8, 130.8 (d, J = 9.3 Hz), 126.3, 122.6, 115.7 (d, J = 21.8 Hz), 57.5, 53.3, 50.3, 36.3, 
28.1, 21.9.
4-(6-(4-Chlorophenyl)-3-azabicyclo[4.1.0]heptan-3-yl)-1-(4-fluorophenyl)butan-1-one (46). A 
solution of 4-(4-(4-chlorophenyl)-3,6-dihydropyridin-1(2H)-yl)-1-(4-fluorophenyl)butan-1-one (110 
mg, 307 µmol) in DCM (20 mL), was treated with Et2Zn (0.9 M in hexanes; 1.71 mL, 1.54 mmol). 
After 10 minutes, the reaction mixture was cooled to 0 °C, and treated with a solution of CH2I2 (124 
µL, 1.54 mmol) in DCM (2 mL) drop-wise over and allowed to warm to ambient temperature. After 
24 h, the reaction mixture was quenched slowly with sat. aqueous NH4Cl and stirred for 10 minutes. 
The reaction mixture was extracted with DCM (3 x 20 mL), and the combined organic phases were 
washed with sat. aqueous NaHCO3, dried (Na2SO4), and concentrated in vacuo. The resulting residue 
was purified by FCC (eluent, 5% MeOH/EtOAc) to yield 82 mg of the title compound as a white 
solid (72%). LCMS (m/z): 372.2 [M+H]+, tR 3.94 min. HRMS (m/z): C22H23FNO: requires 372.1452 
[M+H]+; found 372.1517. 1H NMR (CDCl3) δ 8.05 – 7.95 (m, 2H), 7.24 – 7.17 (m, 2H), 7.18 – 7.07 
(m, 4H), 2.97 (t, J = 7.1 Hz, 2H), 2.81 (dd, J = 11.3, 5.8 Hz, 1H), 2.69 (dd, J = 11.3, 1.7 Hz, 1H), 
2.36 (t, J = 6.9 Hz, 2H), 2.26 – 2.20 (m, 2H), 2.03 (dq, J = 14.0, 7.4, 6.9 Hz, 2H), 1.92 (p, J = 7.1 Hz, 
2H), 1.37 – 1.28 (m, 1H), 0.87 (dd, J = 9.2, 4.2 Hz, 1H), 0.79 (dd, J = 5.7, 4.3 Hz, 1H). 13C NMR 
(CDCl3) δ 196.7, 166.1 (d, J = 256.1 Hz), 142.7, 132.9, 132. 7 (d, J = 3.0 Hz), 130.8 (d, J = 9.3 Hz), 
129.9, 128.9, 116.0 (d, J = 22.2 Hz), 56.3, 52.7, 48.1, 34.9, 28.7, 23.6, 18.1, 17.7, 15.1.
1-(4-Fluorophenyl)-4-(4-phenylpiperidin-1-yl)butan-1-one (47). General procedure C. 
Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 89 mg of the title compound as 
a white solid (75%). LCMS (m/z): 326.4 [M+H]+, tR 3.35 min. HRMS (m/z): C21H24FNO: requires 
326.1842 [M+H]+; found 326.1930. 1H NMR (CDCl3) δ 8.08 – 7.97 (m, 2H), 7.33 – 7.25 (m, 2H), 
7.20 (d, J = 7.3 Hz, 3H), 7.14 (t, J = 8.6 Hz, 2H), 3.07 – 2.95 (m, 4H), 2.51 – 2.41 (m, 3H), 2.10 – 
2.02 (m, 2H), 2.01 – 1.94 (m, 2H), 1.84 – 1.77 (m, 2H), 1.71 (qd, J = 12.4, 3.7 Hz, 2H). 13C NMR 
(CDCl3) δ 198.6, 165.8 (d, J = 254.4 Hz), 146.5, 133.8 (d, J = 3.0 Hz), 130.8 (d, J = 9.2 Hz), 128.5, 
126.9, 126.2, 115.7 (d, J = 21.8 Hz), 58.2, 54.4, 42.8, 36.5, 33.5, 22.1.
4-(4-(4-Chlorophenyl)piperidin-1-yl)-1-(4-fluorophenyl)butan-1-one (48). General procedure C. 
Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 59 mg of the title compound as 
a beige solid (68%). LCMS (m/z): 360.2 [M+H]+, tR 3.72 min. HRMS (m/z): C21H23ClFNO: requires 
360.1452 [M+H]+; found 360.1539. 1H NMR (CDCl3) δ 8.01 (dd, J = 8.7, 5.5 Hz, 2H), 7.26 – 7.22 
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(m, 2H), 7.16 – 7.08 (m, 4H), 3.05 – 2.94 (m, 4H), 2.52 – 2.38 (m, 3H), 2.09 – 1.90 (m, 4H), 1.76 
(dq, J = 12.6, 2.2 Hz, 2H), 1.63 (qd, J = 12.4, 3.8 Hz, 2H). 13C NMR (CDCl3) δ 198.5, 165.7 (d, J = 
254.2 Hz), 144.9, 133.8 (d, J = 3.0 Hz), 131.8, 130.8 (d, J = 9.2 Hz), 128.6, 128.3, 115.7(d, J = 21.7 
Hz), 58.2, 54.3, 42.2, 36.4, 33.5, 22.0.
tert-Butyl 4-(4-chlorophenyl)-4-hydroxypiperidine-1-carboxylate (49). To a suspension of 4-(4-
chlorophenyl)piperidin-4-ol (500 mg, 2.36 mmol) and Et3N (823 µL, 5.90 mmol) in DCM (20 mL), 
was added di-tert-butyl dicarbonate (2.06 g, 9.45 mmol) and the reaction stirred at rt for 4 h. The 
solvent was evaporated under reduced pressure and the residue was purified by FCC (eluent, 10:1 n-
hexanes/EtOAc) to afford 715 mg of a clear oil (97%). LCMS (m/z): 312.3 [M+H]+, tR 3.09 min.  1H 
NMR (CDCl3) δ 7.38 (d, J = 7.2 Hz, 2H), 7.15 (d, J = 7.3 Hz, 2H), 3.94 (br s, 2H), 3.18 (br s, 2H), 
1.89 (br s, 2H), 1.46 (s, 11H). 
tert-Butyl 4-(4-chlorophenyl)-4-methoxypiperidine-1-carboxylate (50). To a stirred suspension of 
sodium hydride (64.7 mg, 2.69 mmol) in dry DMF (15 mL) at rt was added tert-butyl 4-(4-
chlorophenyl)-4-hydroxypiperidine-1-carboxylate (700 mg, 2.24 mmol). After 30 minutes, methyl 
iodide (168 μL, 2.69 mmol) was added and the mixture was stirred overnight. The mixture was poured 
into an equal volume of H2O and extracted with EtOAc (2 × 30 mL). The EtOAc extracts were 
collected and washed with additional H2O (3 × 30 mL), dried (Na2SO4), filtered, and concentrated in 
vacuo to give an orange oil. The crude oil was purified by FCC (eluent, 10:1 n-hexanes/EtOAc) to 
afford 645 mg of a clear oil (88%). LCMS (m/z): 326.3 [M+H]+, tR 3.18 min. 1H NMR (CDCl3) δ 
8.00 (dd, J = 8.7, 5.5 Hz, 2H), 7.33 – 7.25 (m, 4H), 7.16 – 7.06 (m, 2H), 2.97 (t, J = 7.1 Hz, 2H), 2.93 
(s, 3H), 2.75 – 2.65 (m, 2H), 2.45 (t, J = 7.2 Hz, 2H), 2.38 (td, J = 11.7, 2.5 Hz, 2H), 2.03 – 1.90 (m, 
4H), 1.84 (dt, J = 13.1, 6.7 Hz, 2H). 13C NMR (CDCl3) δ 198.5, 165.7 (d, J = 254.4 Hz), 143.6, 133.8 
(d, J = 3.0 Hz), 133.0, 130.8 (d, J = 9.3 Hz), 128.6, 127.6, 115.7 (d, J = 21.8 Hz), 75.4, 49.2, 36.4, 
34.7, 22.1.
4-(4-Chlorophenyl)-4-methoxypiperidin-1-ium chloride (51). General procedure B. Concentration 
in vacuo gave 296 mg of a white solid (95%). 1H NMR (DMSO-d6) δ 9.30 (s, 2H), 7.53 – 7.45 (m, 
2H), 7.45 – 7.36 (m, 2H), 3.18 (d, J = 12.5 Hz, 12H), 3.11 – 2.96 (m, 2H), 2.89 (s, 3H), 2.20 – 2.08 
(m, 4H). 13C NMR (DMSO-d6) δ 141.9, 132.4, 128.6, 127.8, 73.4, 49.6, 39.3, 30.5.
4-(4-(4-Chlorophenyl)-4-methoxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one (52). General 
procedure C. Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 88 mg of the title 
compound as a white solid (81%). LCMS (m/z): 390.3 [M+H]+, tR 3.82 min. HRMS (m/z): 
C22H25ClFNO2: requires 390.1558 [M+H]+; found 390.1639. 1H NMR (CDCl3) δ 8.00 (dd, J = 8.7, 
5.5 Hz, 2H), 7.33 – 7.25 (m, 4H), 7.16 – 7.06 (m, 2H), 2.97 (t, J = 7.1 Hz, 2H), 2.93 (s, 3H), 2.75 – 
2.65 (m, 2H), 2.45 (t, J = 7.2 Hz, 2H), 2.38 (td, J = 11.7, 2.5 Hz, 2H), 2.03 – 1.90 (m, 4H), 1.84 (dt, 
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J = 13.1, 6.7 Hz, 2H). 13C NMR (CDCl3) δ 198.5, 165.7 (d, J = 254.4 Hz), 143.6, 133.8 (d, J = 3.0 
Hz), 133.0, 130.8 (d, J = 9.3 Hz), 128.6, 127.6, 115.7 (d, J = 21.8 Hz), 75.4, 49.2, 36.4, 34.7, 22.1.
1-(4-Chlorophenyl)-4-(4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl)butan-1-one (53). General 
procedure C. Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 75 mg of the title 
compound as a light yellow solid (71%). LCMS (m/z): 376.3 [M+H]+, tR 3.39 min. HRMS (m/z): 
C21H23ClFNO2: requires 376.1401 [M+H]+; found 376.1488. 1H NMR (CDCl3) δ 7.99 – 7.88 (m, 
2H), 7.48 – 7.36 (m, 4H), 7.01 (t, J = 8.7 Hz, 2H), 2.98 (t, J = 7.0 Hz, 2H), 2.76 (dd, J = 9.1, 6.1 Hz, 
2H), 2.51 – 2.38 (m, 4H), 2.03 – 1.92 (m, 5H), 1.69 (dd, J = 14.2, 2.6 Hz, 2H). 13C NMR (CDCl3) δ 
198.9, 161.9 (d, J = 245.2 Hz), 144.3 (d, J = 3.1 Hz), 139.4, 135.7, 129.6, 128.9, 126.4 (d, J = 7.9 
Hz), 115.0 (d, J = 21.2 Hz), 71.1, 57.9, 49.5, 38.6, 36.4, 22.1.
4-(4-Hydroxy-4-phenylpiperidin-1-yl)-1-phenylbutan-1-one (54). General procedure C. 
Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH4OH) gave 125 mg of the title compound 
as a white solid (88%). LCMS (m/z): 324.3 [M+H]+, tR 2.72 min. HRMS (m/z): C21H25NO2: requires 
324.1865 [M+H]+; found 324.1965. 1H NMR (CDCl3) δ 8.03 – 7.94 (m, 2H), 7.59 – 7.51 (m, 1H), 
7.46 (dd, J = 8.4, 6.9 Hz, 4H), 7.33 (dd, J = 8.4, 6.8 Hz, 2H), 7.27 – 7.21 (m, 1H), 3.01 (t, J = 7.0 Hz, 
2H), 2.82 (dt, J = 11.9, 3.2 Hz, 2H), 2.55 – 2.44 (m, 4H), 2.14 – 1.94 (m, 5H), 1.71 (dd, J = 14.1, 2.7 
Hz, 2H). 13C NMR (CDCl3) δ 200.1, 148.4, 137.3, 132.9, 128.7, 128.4, 128.2, 127.1, 124.6, 71.3, 
57.9, 49.5, 38.3, 36.5, 21.9.
Pharmacological Characterisation. Materials. Tag-lite labeling medium (LABMED), SNAP-
Lumi4-Tb, and the PPHT ((±)-2-(N-phenethyl-N-propyl)amino-5-hydroxytetralin hydrochloride;1-
Naphthalenol,5,6,7,8-tetrahydro-6-[(2-phenylethyl)propylamino]) derivative labelled with a red 
fluorescent probe (PPHT-red) was obtained from Cisbio Bioassays (Bagnolssur-Cèze, France). 
Ninety-six-well polypropylene plates (Corning) were purchased from Fisher Scientific UK 
(Loughborough, UK) and 384-well optiplate plates were purchased from PerkinElmer (Beaconsfield, 
UK). GppNHp used in competition assays were obtained from Sigma-Aldrich (Poole, UK). 
Cell culture. The host Chinese hamster ovary (CHO) K1 cell line was transfected with the cDNA 
encoding a SNAP-tagged human dopamine D2L receptor (Genbank ref.: NM_000795), and a stable 
dilution-cloned cell line (CHO–hD2L) was established by zeocin resistance encoded by the plasmid 
vector (pcDNA3.1zeo+, Invitrogen, Paisley UK). Cells were maintained in Dulbecco’s modified 
Eagle’s medium: Ham F12 (DMEM:F12) containing 2 mM glutamine (Sigma-Aldrich, Poole, UK) 
and supplemented with 10% fetal calf serum (Life Technologies, Paisley UK).
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Terbium labelling of SNAP-tagged D2L cells. Cell culture medium was removed from the t175 cm2 
flasks containing confluent adherent CHO–D2L cells. Twelve mL of Tag-lite labelling medium 
containing 100 nM of SNAP-Lumi4-Tb was added to the flask and incubated for 1 h at 37 °C under 
5% CO2. Cells were washed 2× in PBS (GIBCO Carlsbad, CA) to remove the excess of SNAP-
Lumi4-Tb then detached using 5 mL of GIBCO enzyme-free Hank’s-based cell dissociation buffer 
(GIBCO, Carlsbad, CA) and collected in a vial containing 5 mL of DMEM:F12 containing 2mM 
glutamine (Sigma-Aldrich) and supplemented with 10% fetal calf serum. Cells were pelleted by 
centrifugation (5 min at 1500 rpm) and the pellets were frozen to −80 °C. To prepare membranes, 
homogenisation steps were conducted at 4 °C (to avoid receptor degradation). Specifically 20 mL per 
t175-cm2 flask of wash buffer (10 mM HEPES and 10 mM EDTA, pH 7.4) was added to the pellet. 
This was homogenised using an electrical homogenizer Ultra-Turrax (Ika-Werk GmbH & Co. KG, 
Staufen, Germany) (position 6, 4 × 5-s bursts) and subsequently centrifuged at 48,000×g at 4 °C 
(Beckman Avanti J-251 Ultracentrifuge; Beckman Coulter, Fullerton, CA) for 30 min. The 
supernatant was discarded, and the pellet was re-homogenised and centrifuged as described above in 
wash buffer. The final pellet was suspended in ice-cold 10mM HEPES and 0.1mM EDTA, pH 7.4, 
at a concentration of 5–10 mg mL−1. Protein concentration was determined using the bicinchoninic 
acid assay kit (Sigma-Aldrich), using BSA as a standard and aliquots maintained at −80 °C until 
required. Prior to their use, the frozen membranes were thawed and the membranes suspended in the 
assay buffer at a membranes concentration of 0.2 mg mL−1.
Fluorescent ligand-binding assays. All fluorescent binding experiments using PPHT-red were 
conducted in white 384-well Optiplate plates, in assay binding buffer, 20 mM HEPES, 138 mM NaCl, 
6 mM MgCl2, 1 mM EGTA, 1 mM EDTA, and 0.02% pluronic acid pH 7.4, 100 µM GppNHp, and 
0.1% ascorbic acid.  GppNHp was included to remove the G protein-coupled population of receptors 
that can result in two distinct populations of binding sites in membrane preparations, since the 
Motulsky-Mahan model30 is only appropriate for ligands competing at a single site. In all cases, 
nonspecific binding was determined in the presence of 10 µM haloperidol.
Determination of PPHT-red binding kinetics. To accurately determine association rate (kon) and 
dissociation rate (koff) values, the observed rate of association (kob) was calculated using at least four 
different concentrations of PPHT-red (50-1.56 nM). The appropriate concentration of PPHT-red was 
incubated with human D2L CHO cell membranes (2 µg per well) in assay binding buffer (final assay 
volume, 40 µL). The degree of PPHT-red bound to the receptor was assessed at multiple time points 
by HTRF detection to allow construction of association kinetic curves. The kinetic parameters of 
PPHT-red and plus those of unlabelled compounds were determined using a start time of ~1sec and 
Page 66 of 78
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
67
an interval time of 20sec. The resulting data were globally fitted to the association kinetic model Eq. 
2 to derive a single best-fit estimate for kon and koff as described under data analysis. The expression 
level of the hD2LR recombinantly expressed in CHO cells was assessed, using [3H]-spiperone 
saturation binding and determined to be 1.13 ± 0.11 pmol mg−1 protein.33
Competition binding kinetics. To determine the association and dissociation rates of D2R ligands, we 
used a competition kinetic binding assay recently described to profile the kinetics of a series of D2R 
agonists31 and antipsychotic drugs.33 This approach involves the simultaneous addition of both 
fluorescent ligand and competitor to the receptor preparation, so that at t = 0 all receptors are 
unoccupied. 12.5 nM PPHT-red (a concentration which avoids ligand depletion in this assay volume), 
was added simultaneously with the unlabelled compound of varying concentrations (at t = ~1 sec) to 
CHO cell membranes derived from cells stably expressing the human D2LR (2 µg per well) in 40 µL 
of assay buffer. The degree of PPHT-red bound to the receptor was assessed at multiple time points 
by HTRF detection. 
Non-specific binding was determined as the amount of HTRF signal detected in the presence of 
haloperidol (10 µM) and was subtracted from each time point, meaning that t = 0 was always equal 
to zero. Each time point was conducted on the same 384-well plate incubated at 37 ºC with orbital 
mixing (1 s of 100 RPM per cycle). Multiple concentrations of unlabelled competitor were tested for 
determination of rate parameters. Data were globally fitted using Eq. 3 to simultaneously calculate 
kon and koff. 
Signal detection and data analysis. Signal detection was performed on a Pherastar FS (BMG Labtech, 
Offenburg, Germany) using standard HTRF settings. The terbium donor was always excited with 
three laser flashes at a wavelength of 337 nm. A kinetic TR-FRET signal was collected at 20 s 
intervals both at 665 and 620 nm, when using red acceptor. HTRF ratios were obtained by dividing 
the acceptor signal (665 nm) by the donor signal (620 nm) and multiplying this value by 10,000. All 
experiments were analysed by non-linear regression using Prism 6.0 (Graphpad Software, San Diego, 
USA). Competition displacement data were fitted to sigmoidal (variable slope) curves using a “four 
parameter logistic equation”: 
(1)𝑌 = 𝐵𝑜𝑡𝑡𝑜𝑚 + (𝑇𝑜𝑝 ― 𝐵𝑜𝑡𝑡𝑜𝑚)/(1 + 10𝑙𝑜𝑔𝐸𝐶50 ― 𝑋)𝐻𝑖𝑙𝑙𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡). 
IC50 values obtained from the inhibition curves were converted to Ki values using the method of Cheng 
and Prusoff.74 PPHT-red association data were fitted as follows to a global fitting model using 
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Graphpad Prism 6.0 to simultaneously calculate kon and koff using the following equation, where kob 
equals the observed rate of association:
 . (2)𝑘𝑜𝑏 = [𝑃𝑃𝐻𝑇 ― 𝑟𝑒𝑑] ∙ 𝑘𝑜𝑛 + 𝑘𝑜𝑓𝑓
Association and dissociation rates for unlabelled compounds were calculated using the equations 
described by Motulsky and Mahan:30 
𝐾𝐴 = 𝑘1[𝐿] + 𝑘2 𝐾𝐵 = 𝑘2[𝐼] + 𝑘4 𝑆 = (𝐾𝐴 ― 𝐾𝐵)2 + 4 ∙ 𝑘1 ∙ 𝑘3 ∙ 𝐿 ∙ 𝐼 ∙ 10
―18
𝐾𝐹
 (3)= 0.5 ∙ (𝐾𝐴 + 𝐾𝐵 + 𝑆) 𝐾𝑆 = 0.5 ∙ (𝐾𝐴 + 𝐾𝐵 ― 𝑆) 𝐷𝐼𝐹𝐹 = 𝐾𝐹 ― 𝐾𝑆 𝑄 =
.
𝐵𝑚𝑎𝑥 ∙ 𝑘1 ∙ 𝐿 ∙ 10 ―9
𝐷𝐼𝐹𝐹 𝑌 = 𝑄 × (𝑘4 ∙ 𝐷𝐼𝐹𝐹𝐾𝐹 × 𝐾𝑆 + 𝑘4 ― 𝐾𝐹𝐾𝐹 ∙ 𝑒𝑥𝑝( ― 𝐾𝐹 ∙ 𝑋) ― 𝑘4 ― 𝐾𝑆𝐾𝑆 ∙ 𝑒𝑥𝑝( ― 𝐾𝑆 ∙ 𝑋)
Where: X = Time (min), Y = Specific binding (HTRF ratio 665 nm/620 nm×10,000), k1 = kon PPHT-
red, k2 = koff PPHT-red, L = Concentration of PPHT-red used (nM), Bmax = Total binding (HTRF ratio 
665 nm/620 nm×10,000), I = Concentration of unlabelled antagonist (nM). Fixing the above 
parameters allowed the following to be calculated: k3 = Association rate of unlabelled ligand (M−1 
min−1), k4 = Dissociation rate of unlabelled ligand (min−1). Dissociation of PPHT-red was fitted to a 
one phase mono-exponential decay function to estimate the dissociation rate of PPHT-red directly. 
Specific binding was determined by subtracting the nonspecific HTRF ratio from the total HTRF ratio.
cAMP assay.  FlpIn CHO cells stably expressing the SNAP-tagged hD2LR and the CAMYEL BRET 
biosensor were plated into 96-well white-walled plates (Greiner, Kremsmünster, Austria)  at a density 
of 40,000 cells per well and grown overnight. The cells were equilibrated in Dulbecco’s phosphate 
buffered saline with 5 mM glucose at 37°C for 30 minutes before starting the experiment. 
Coelenterazine (Nanolight, Pinetop, Arizona, USA) was added at a final concentration of 5 μM at 5 
min prior to addition of agonist. For the agonist mode experiments the cells were co-stimulated with 
the analogues and 3 μM forskolin for 10 minutes before BRET readings were taken. For the antagonist 
mode experiments, a 10 μM concentration of each analogue was added prior to cells being co-
stimulated with 3 μM forskolin and an EC80 concentration (30 nM) dopamine for 10 minutes before 
BRET readings were taken.  The signals were detected at 445-505 and 505-565 nm using a Pherastar 
FS instrument (BMG LabTech, Offenburg, Germany). Net BRET was determined by subtraction of 
the vehicle control co-added with 3 μM forskolin.
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